U.S. patent application number 13/744604 was filed with the patent office on 2013-05-23 for pyridone and pyridazone analogues as gpr119 modulators.
This patent application is currently assigned to Bristol-Myers Squibb Company. The applicant listed for this patent is Bristol-Myers Squibb Company. Invention is credited to Karen A. Rossi, Dean A. Wacker, Ying Wang, Gang Wu.
Application Number | 20130131074 13/744604 |
Document ID | / |
Family ID | 41137417 |
Filed Date | 2013-05-23 |
United States Patent
Application |
20130131074 |
Kind Code |
A1 |
Wacker; Dean A. ; et
al. |
May 23, 2013 |
PYRIDONE AND PYRIDAZONE ANALOGUES AS GPR119 MODULATORS
Abstract
Novel compounds of structure Formula I: ##STR00001## or an
enantiomer, a diastereomer, or a pharmaceutically acceptable salt
thereof, wherein Z, R.sup.1, R.sup.2, R.sup.21, T.sup.1, T.sup.2,
T.sup.3 and T.sup.4 are defined herein, are provided which are
GPR119 G protein-coupled receptor modulators. GPR119 G
protein-coupled receptor modulators are useful in treating,
preventing, or slowing the progression of diseases requiring GPR119
G protein-coupled receptor modulator therapy. Thus, the disclosure
also concerns compositions comprising these novel compounds and
methods of treating diseases or conditions related to the activity
of the GPR119 G protein-coupled receptor by using any of these
novel compounds or a composition comprising any of such novel
compounds.
Inventors: |
Wacker; Dean A.; (Yardley,
PA) ; Rossi; Karen A.; (Newtown, PA) ; Wang;
Ying; (New Hope, PA) ; Wu; Gang; (Princeton,
NJ) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Bristol-Myers Squibb Company; |
Princeton |
NJ |
US |
|
|
Assignee: |
Bristol-Myers Squibb
Company
Princeton
NJ
|
Family ID: |
41137417 |
Appl. No.: |
13/744604 |
Filed: |
January 18, 2013 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
13003914 |
Jun 1, 2011 |
8372837 |
|
|
PCT/US2009/050618 |
Jul 15, 2009 |
|
|
|
13744604 |
|
|
|
|
61081058 |
Jul 16, 2008 |
|
|
|
61081060 |
Jul 16, 2008 |
|
|
|
61081069 |
Jul 16, 2008 |
|
|
|
Current U.S.
Class: |
514/252.02 ;
514/252.03; 514/275; 514/318; 544/238; 544/331; 546/194 |
Current CPC
Class: |
A61P 9/10 20180101; A61P
25/28 20180101; A61P 9/12 20180101; A61P 17/02 20180101; A61P 25/02
20180101; A61K 31/4545 20130101; A61P 27/02 20180101; C07D 401/12
20130101; A61P 19/08 20180101; A61K 45/06 20130101; A61P 13/00
20180101; A61P 3/00 20180101; A61P 3/10 20180101; C07D 403/14
20130101; A61K 31/506 20130101; A61P 3/04 20180101; A61P 25/00
20180101; A61P 35/00 20180101; A61P 3/06 20180101; A61P 13/12
20180101; C07D 413/14 20130101; C07D 403/12 20130101; A61P 9/04
20180101; A61P 19/00 20180101; A61P 31/00 20180101; A61P 9/00
20180101; C07D 401/14 20130101; A61K 31/501 20130101; A61P 7/12
20180101; A61P 27/06 20180101 |
Class at
Publication: |
514/252.02 ;
546/194; 514/318; 544/331; 514/275; 544/238; 514/252.03 |
International
Class: |
C07D 403/14 20060101
C07D403/14; A61K 31/4545 20060101 A61K031/4545; A61K 45/06 20060101
A61K045/06; C07D 403/12 20060101 C07D403/12; A61K 31/501 20060101
A61K031/501; C07D 401/12 20060101 C07D401/12; A61K 31/506 20060101
A61K031/506 |
Claims
1. A compound of Formula I: ##STR00083## or an enantiomer, a
diastereomer, or a pharmaceutically acceptable salt thereof,
wherein: Z is CH; R.sup.1 is aryl, arylalkyl or heteroaryl, any of
which may be optionally substituted with one or more R.sup.6's;
R.sup.2 is cycloalkyl, aryl, heteroaryl, heterocyclyl,
--S(O).sub.2R.sup.5, --C(.dbd.O)NR.sup.3R.sup.5, --C(.dbd.O)R.sup.5
or --C(.dbd.O)OR.sup.5, wherein the cycloalkyl, aryl, heteroaryl
and heterocyclyl may each be optionally substituted with one or
more R.sup.6's; R.sup.3 is hydrogen, alkyl, alkoxy, cycloalkyl,
aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl or
heterocyclylalkyl, wherein the heteroaryl, heteroarylalkyl,
heterocyclyl and heterocyclylalkyl may each contain 1-4 heteroatoms
selected from N, O and S; R.sup.5 is alkyl, alkenyl, aryl,
cycloalkyl, heteroaryl or heterocyclyl, each of which may be
optionally substituted with one or more R.sup.6's; R.sup.6, at each
occurrence, is independently selected from alkyl, aryl, alkenyl,
alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl,
heterocyclyl, heterocyclylalkyl, halo, --NH.sub.2, --CN,
--NO.sub.2, --C(.dbd.O)OH, --C(.dbd.O)OR.sup.10, --OCF.sub.3,
--OCHF.sub.2, --OR.sup.10, --OH, --SH, --SR.sup.10, --S(O).sub.3H,
--P(O).sub.3H.sub.2, --C(.dbd.O)NR.sup.9R.sup.9, --NR.sup.9R.sup.9,
--S(O).sub.2NR.sup.9R.sup.9, --NR.sup.9S(O).sub.2CF.sub.3,
--C(.dbd.O)NR.sup.9S(O).sub.2R.sup.9,
--S(O).sub.2NR.sup.9C(.dbd.O)OR.sup.9,
--S(O).sub.2NR.sup.9C(.dbd.O)NR.sup.9R.sup.9,
--C(.dbd.O)NR.sup.9S(O).sub.2CF.sub.3, --C(.dbd.O)R.sup.10,
--NR.sup.9C(.dbd.O)H, --NR.sup.9C(.dbd.O)R.sup.10,
--OC(.dbd.O)R.sup.10, --C(.dbd.NR.sup.14)NR.sup.9R.sup.9,
--NHC(.dbd.NR.sup.14)NR.sup.14R.sup.14, --S(.dbd.O)R.sup.10,
--S(O).sub.2R.sup.10, .dbd.O, --NR.sup.9C(.dbd.O)OR.sup.8 and
--NR.sup.9S(O.sub.2)R.sup.8, wherein the alkyl, alkenyl, alkynyl,
aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl,
heterocyclyl and heterocyclylalkyl may each be optionally
substituted with 0-5 R.sup.9a; R.sup.8, at each occurrence, is
independently selected from the group consisting of alkyl, aryl,
cycloalkyl, heteroaryl and heterocyclyl, each of which may be
optionally substituted with one or more R.sup.8a's; R.sup.8a, at
each occurrence, is independently selected from alkyl, haloalkyl,
aryl, arylalkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl,
heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo,
--NH.sub.2, --CN, --NO.sub.2, --C(.dbd.O)OH, --C(.dbd.O)OR.sup.14,
--OCF.sub.3, --OCHF.sub.2, --OR.sup.14, --OH, --SH, --SR.sup.14,
--S(O).sub.3H, --P(O).sub.3H.sub.2, --C(.dbd.O)NR.sup.14R.sup.14,
--NR.sup.14R.sup.14, --S(O).sub.2NR.sup.14R.sup.14,
--NR.sup.14S(O).sub.2CF.sub.3,
--C(.dbd.O)NR.sup.14S(O).sub.2R.sup.14,
--S(O).sub.2NR.sup.14C(.dbd.O)OR.sup.14,
--S(O).sub.2NR.sup.14C(.dbd.O)NR.sup.14R.sup.14,
--C(.dbd.O)NR.sup.14S(O).sub.2CF.sub.3, --C(.dbd.O)R.sup.14,
--NR.sup.14C(.dbd.O)H, --NR.sup.14C(.dbd.O)R.sup.14,
--OC(.dbd.O)R.sup.14, --C(.dbd.NR.sup.14)NR.sup.14R.sup.14,
--NHC(.dbd.NR.sup.14)NR.sup.14R.sup.14, --S(.dbd.O)R.sup.14,
--S(O).sub.2R.sup.14, .dbd.O, --NR.sup.14C(.dbd.O)OR.sup.14 and
--NR.sup.14S(O.sub.2)R.sup.14; R.sup.9, at each occurrence, is
independently selected from hydrogen, alkyl, alkenyl, alkynyl,
alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,
heterocyclyl and heterocyclylalkyl, wherein the alkyl, cycloalkyl,
aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and
heterocyclylalkyl may each be optionally substituted with 0-5
R.sup.8a, and the heteroaryl, heteroarylalkyl, heterocyclyl and
heterocyclylalkyl each contain 1-4 heteroatoms selected from N, O
and S; R.sup.9a, at each occurrence, is independently selected from
alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl,
cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl,
heterocyclylalkyl, halo, --NH.sub.2, --CN, --NO.sub.2,
--C(.dbd.O)OH, --C(.dbd.O)OR.sup.14, --OCF.sub.3, --OCHF.sub.2,
--OR.sup.14, --OH, --SH, --SR.sup.14, --S(O).sub.3H,
--P(O).sub.3H.sub.2, --C(.dbd.O)NR.sup.14R.sup.14,
--NR.sup.14R.sup.14, --S(O).sub.2NR.sup.14R.sup.14,
--NR.sup.14S(O).sub.2CF.sub.3,
--C(.dbd.O)NR.sup.14S(O).sub.2R.sup.10,
--S(O).sub.2NR.sup.14C(.dbd.O)OR.sup.10,
--S(O).sub.2NR.sup.14C(.dbd.O)NR.sup.14R.sup.14,
--C(.dbd.O)NR.sup.14S(O).sub.2CF.sub.3, --C(.dbd.O)R.sup.14,
--NR.sup.14C(.dbd.O)H, --NR.sup.14C(.dbd.O)R.sup.14,
--OC(.dbd.O)R.sup.14, --C(.dbd.NR.sup.14)NR.sup.14R.sup.14,
--NHC(.dbd.NR.sup.14)NR.sup.14R.sup.14, --S(.dbd.O)R.sup.14,
--S(O).sub.2R.sup.14, --NR.sup.14C(.dbd.O)OR.sup.14,
--NR.sup.14S(O.sub.2)R.sup.14, .dbd.O and arylalkyl; R.sup.10, at
each occurrence, is independently selected from alkyl, alkenyl,
alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,
heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl,
arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and
heterocyclylalkyl may each be optionally substituted with 0-3
R.sup.10a, and the heteroaryl, heteroarylalkyl, heterocyclyl and
heterocyclylalkyl each contain 1-4 heteroatoms selected from N, O
and S; R.sup.10a, at each occurrence, is independently selected
from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl,
cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl,
heterocyclylalkyl, halo, --NH.sub.2, --CN, --NO.sub.2,
--C(.dbd.O)OH, --C(.dbd.O)OR.sup.14, --OCF.sub.3, --OCHF.sub.2,
--OR.sup.14, --OH, --SH, --SR.sup.14, --S(O).sub.3H,
--P(O).sub.3H.sub.2, --C(.dbd.O)NR.sup.14R.sup.14,
--NR.sup.14R.sup.14, --S(O).sub.2NR.sup.14R.sup.14,
--NR.sup.14S(O).sub.2CF.sub.3,
--C(.dbd.O)NR.sup.14S(O).sub.2R.sup.9,
--S(O).sub.2NR.sup.14C(.dbd.O)OR.sup.9,
--S(O).sub.2NR.sup.14C(.dbd.O)NR.sup.14R.sup.14,
--C(.dbd.O)NR.sup.14S(O).sub.2CF.sub.3, --C(.dbd.O)R.sup.14,
--NR.sup.14C(.dbd.O)H, --NR.sup.14C(.dbd.O)R.sup.14,
--OC(.dbd.O)R.sup.14, --C(.dbd.NR.sup.14)NR.sup.14R.sup.14,
--NHC(.dbd.NR.sup.14)NR.sup.14R.sup.14, --S(.dbd.O)R.sup.14,
--S(O).sub.2R.sup.14, --NR.sup.14C(.dbd.O)OR.sup.14,
--NR.sup.14S(O.sub.2)R.sup.14 and arylalkyl; R.sup.14, at each
occurrence, is independently selected from hydrogen, alkyl, aryl,
cycloalkyl, heteroaryl and heterocyclyl; R.sub.21 is hydrogen,
alkyl, haloalkyl, hydroxyalkyl, aryl, cycloalkyl, halo, --CN,
--C(.dbd.O)OH, --C(.dbd.O)OR.sup.10, --OCF.sub.3, --OCHF.sub.2,
--OR.sup.10, --OH, --C(.dbd.O)NR.sup.9R.sup.9, --C(.dbd.O)R.sup.10
or --OC(.dbd.O)R.sup.10; T.sub.1 is hydrogen, halo, alkyl, aryl,
alkenyl or alkynyl, wherein the alkyl, aryl, alkenyl and alkynyl
may be optionally substituted with one or more R.sup.6's; T.sub.2
is hydrogen, alkyl, aryl, alkenyl or alkynyl, wherein the alkyl,
aryl, alkenyl and alkynyl may be optionally substituted with one or
more R.sup.6's; T.sub.3 is hydrogen, alkyl, aryl, alkenyl or
alkynyl, wherein the alkyl, aryl, alkenyl and alkynyl may be
optionally substituted with one or more R.sup.6's; and T.sub.4 is
hydrogen, halo, alkyl, aryl, alkenyl or alkynyl, wherein the alkyl,
aryl, alkenyl and alkynyl may be optionally substituted with one or
more R.sup.6's; provided that when R.sup.1 is a 5- to 6-membered
aryl or heteroaryl, T.sup.1, T.sup.2, T.sup.3, and T.sup.4 can not
all be hydrogen.
2. The compound, enantiomer, diastereomer, or a pharmaceutically
acceptable salt thereof, of claim 1, wherein the compound of
formula I is a compound of formula II(y): ##STR00084## wherein Z,
R.sub.1, R.sub.2, R.sub.21, T.sup.3 and T.sup.4 are defined as in
claim 1.
3. The compound, enantiomer, diastereomer, or a pharmaceutically
acceptable salt thereof, of claim 1, wherein the compound of
formula I is a compound of formula II(z): ##STR00085## wherein Z,
R.sub.1, R.sub.2, and R.sub.21 are defined as in claim 1.
4. The compound, enantiomer, diastereomer, or a pharmaceutically
acceptable salt thereof, of claim 1, wherein: Z is CH; R.sup.1 is
aryl, arylalkyl or heteroaryl, any of which may be optionally
substituted with one or more R.sup.6's; R.sup.2 is cycloalkyl,
aryl, heteroaryl, heterocyclyl, --S(O).sub.2R.sup.5,
--C(.dbd.O)R.sup.5 or --C(.dbd.O)OR.sup.5, wherein the cycloalkyl,
aryl, heteroaryl and heterocyclyl may each be optionally
substituted with one or more R.sup.6's; R.sup.5 is alkyl, alkenyl,
aryl, cycloalkyl, heteroaryl or heterocyclyl, each of which may be
optionally substituted with one or more R.sup.6's; R.sup.6, at each
occurrence, is independently selected from alkyl, aryl, alkenyl,
alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl,
heterocyclyl, heterocyclylalkyl, halo, --NH.sub.2, --CN,
--NO.sub.2, --C(.dbd.O)OH, --C(.dbd.O)OR.sup.10, --OCF.sub.3,
--OCHF.sub.2, --OR.sup.10, --OH, --SH, --SR.sup.10, --S(O).sub.3H,
--P(O).sub.3H.sub.2, --C(.dbd.O)NR.sup.9R.sup.9, --NR.sup.9R.sup.9,
--S(O).sub.2NR.sup.9R.sup.9, --NR.sup.9S(O).sub.2CF.sub.3,
--C(.dbd.O)NR.sup.9S(O).sub.2R.sup.9,
--S(O).sub.2NR.sup.9C(.dbd.O)OR.sup.9,
--S(O).sub.2NR.sup.9C(.dbd.O)NR.sup.9R.sup.9,
--C(.dbd.O)NR.sup.9S(O).sub.2CF.sub.3, --C(.dbd.O)R.sup.10,
--NR.sup.9C(.dbd.O)H, --NR.sup.9C(.dbd.O)R.sup.10,
--OC(.dbd.O)R.sup.10, --C(.dbd.NR.sup.14)NR.sup.9R.sup.9,
--NHC(.dbd.NR.sup.14)NR.sup.14R.sup.14, --S(.dbd.O)R.sup.10,
--S(O).sub.2R.sup.10 and .dbd.O, wherein the alkyl, alkenyl,
alkynyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl,
heteroarylalkyl, heterocyclyl and heterocyclylalkyl may each be
optionally substituted with 0-5 R.sup.9a; R.sup.8a, at each
occurrence, is independently selected from alkyl, haloalkyl, aryl,
arylalkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl,
heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo,
--NH.sub.2, --CN, --NO.sub.2, --C(.dbd.O)OH, --C(.dbd.O)OR.sup.14,
--OCF.sub.3, --OCHF.sub.2, --OR.sup.14, --OH, --SH, --SR.sup.14,
--S(O).sub.3H, --P(O).sub.3H.sub.2, --C(.dbd.O)NR.sup.14R.sup.14,
--NR.sup.14R.sup.14, --S(O).sub.2NR.sup.14R.sup.14,
--NR.sup.14S(O).sub.2CF.sub.3,
--C(.dbd.O)NR.sup.14S(O).sub.2R.sup.14,
--S(O).sub.2NR.sup.14C(.dbd.O)OR.sup.14,
--S(O).sub.2NR.sup.14C(.dbd.O)NR.sup.14R.sup.14,
--C(.dbd.O)NR.sup.14S(O).sub.2CF.sub.3, --C(.dbd.O)R.sup.14,
--NR.sup.14C(.dbd.O)H, --NR.sup.14C(.dbd.O)R.sup.14,
--OC(.dbd.O)R.sup.14, --C(.dbd.NR.sup.14)NR.sup.14R.sup.14,
--NHC(.dbd.NR.sup.14)NR.sup.14R.sup.14, --S(.dbd.O)R.sup.14,
--S(O).sub.2R.sup.14, .dbd.O, --NR.sup.14(.dbd.O)OR.sup.14 and
--NR.sup.14S(O.sub.2)R.sup.14; R.sup.9, at each occurrence, is
independently selected from hydrogen, alkyl, alkenyl, alkynyl,
alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,
heterocyclyl and heterocyclylalkyl, wherein the alkyl, cycloalkyl,
aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and
heterocyclylalkyl may each be optionally substituted with 0-5
R.sup.8a, and the heteroaryl, heteroarylalkyl, heterocyclyl and
heterocyclylalkyl each contain 1-4 heteroatoms selected from N, O
and S; R.sup.9a, at each occurrence, is independently selected from
alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl,
cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl,
heterocyclylalkyl, halo, --NH.sub.2, --CN, --NO.sub.2,
--C(.dbd.O)OH, --C(.dbd.O)OR.sup.14, --OCF.sub.3, --OCHF.sub.2,
--OR.sup.14, --OH, --SH, --SR.sup.14, --S(O).sub.3H,
--P(O).sub.3H.sub.2, --C(.dbd.O)NR.sup.14R.sup.14,
--NR.sup.14R.sup.14, --S(O).sub.2NR.sup.14R.sup.14,
--NR.sup.14S(O).sub.2CF.sub.3,
--C(.dbd.O)NR.sup.14S(O).sub.2R.sup.10,
--S(O).sub.2NR.sup.14C(.dbd.O)OR.sup.10,
--S(O).sub.2NR.sup.14C(.dbd.O)NR.sup.14R.sup.14,
--C(.dbd.O)NR.sup.14S(O).sub.2CF.sub.3, --C(.dbd.O)R.sup.14,
--NR.sup.14C(.dbd.O)H, --NR.sup.14C(.dbd.O)R.sup.14,
--OC(.dbd.O)R.sup.14, --C(.dbd.NR.sup.14)NR.sup.14R.sup.14,
--NHC(.dbd.NR.sup.14)NR.sup.14R.sup.14, --S(.dbd.O)R.sup.14,
--S(O).sub.2R.sup.14, --NR.sup.14C(.dbd.O)OR.sup.14,
--NR.sup.14S(O.sub.2)R.sup.14, .dbd.O and arylalkyl; R.sup.10, at
each occurrence, is independently selected from alkyl, alkenyl,
alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,
heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl,
arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and
heterocyclylalkyl may each be optionally substituted with 0-3
R.sup.10a, and the heteroaryl, heteroarylalkyl, heterocyclyl and
heterocyclylalkyl each contain 1-4 heteroatoms selected from N, O
and S; R.sup.10a, at each occurrence, is independently selected
from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl,
cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl,
heterocyclylalkyl, halo, --NH.sub.2, --CN, --NO.sub.2,
--C(.dbd.O)OH, --C(.dbd.O)OR.sup.14, --OCF.sub.3, --OCHF.sub.2,
--OR.sup.14, --OH, --SH, --SR.sup.14, --S(O).sub.3H,
--P(O).sub.3H.sub.2, --C(.dbd.O)NR.sup.14R.sup.14,
--NR.sup.14R.sup.14, --S(O).sub.2NR.sup.14R.sup.14,
--NR.sup.14S(O).sub.2CF.sub.3,
--C(.dbd.O)NR.sup.14S(O).sub.2R.sup.9,
--S(O).sub.2NR.sup.14C(.dbd.O)OR.sup.9,
--S(O).sub.2NR.sup.14C(.dbd.O)NR.sup.14R.sup.14,
--C(.dbd.O)NR.sup.14S(O).sub.2CF.sub.3, --C(.dbd.O)R.sup.14,
--NR.sup.14C(.dbd.O)H, --NR.sup.14C(.dbd.O)R.sup.14,
--OC(.dbd.O)R.sup.14, --C(.dbd.NR.sup.14)NR.sup.14R.sup.14,
--NHC(.dbd.NR.sup.14)NR.sup.14R.sup.14, --S(.dbd.O)R.sup.14,
--S(O).sub.2R.sup.14, --NR.sup.14C(.dbd.O)OR.sup.14,
--NR.sup.14S(O.sub.2)R.sup.14 and arylalkyl; R.sup.14, at each
occurrence, is independently selected from hydrogen, alkyl, aryl,
cycloalkyl, heteroaryl and heterocyclyl; R.sub.21 is hydrogen,
alkyl, haloalkyl, hydroxyalkyl, aryl, cycloalkyl, halo, --CN,
--C(.dbd.O)OH, --C(.dbd.O)OR.sup.10, --OCF.sub.3, --OR.sup.10,
--OH, --C(.dbd.O)NR.sup.9R.sup.9, --C(.dbd.O)R.sup.10 or
--OC(.dbd.O)R.sup.10; T.sub.1 is hydrogen, alkyl, aryl, alkenyl or
alkynyl, wherein the alkyl, aryl, alkenyl and alkynyl may be
optionally substituted with one or more R.sup.6's; T.sub.2 is
hydrogen, alkyl, aryl, alkenyl or alkynyl, wherein the alkyl, aryl,
alkenyl and alkynyl may be optionally substituted with one or more
R.sup.6's; T.sub.3 is hydrogen, alkyl, aryl, alkenyl or alkynyl,
wherein the alkyl, aryl, alkenyl and alkynyl may be optionally
substituted with one or more R.sup.6's; and T.sub.4 is hydrogen,
alkyl, aryl, alkenyl or alkynyl, wherein the alkyl, aryl, alkenyl
and alkynyl may be optionally substituted with one or more
R.sup.6's.
5. The compound, enantiomer, diastereomer, or a pharmaceutically
acceptable salt thereof, of claim 1, wherein: Z is CH; R.sup.1 is
aryl, arylalkyl or heteroaryl, any of which may be optionally
substituted with one or more R.sup.6's; R.sup.2 is cycloalkyl,
aryl, heteroaryl, heterocyclyl, --C(.dbd.O)R.sup.5 or
--C(.dbd.O)OR.sup.5, wherein the cycloalkyl, aryl, heteroaryl and
heterocyclyl may each be optionally substituted with one or more
R.sup.6's; R.sup.5 is alkyl, aryl, cycloalkyl, heteroaryl or
heterocyclyl, each of which may be optionally substituted with one
or more R.sup.6's; R.sup.6, at each occurrence, is independently
selected from alkyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl,
heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, --NH.sub.2,
--CN, --NO.sub.2, --C(.dbd.O)OH, --C(.dbd.O)OR.sup.10, --OCF.sub.3,
--OCHF.sub.2, --OR.sup.10, --OH, --SH, --SR.sup.10, --S(O).sub.3H,
--P(O).sub.3H.sub.2, --C(.dbd.O)NR.sup.9R.sup.9, --NR.sup.9R.sup.9,
--S(O).sub.2NR.sup.9R.sup.9, --NR.sup.9S(O).sub.2CF.sub.3,
--C(.dbd.O)NR.sup.9S(O).sub.2R.sup.9,
--S(O).sub.2NR.sup.9C(.dbd.O)OR.sup.9,
--S(O).sub.2NR.sup.9C(.dbd.O)NR.sup.9R.sup.9,
--C(.dbd.O)NR.sup.9S(O).sub.2CF.sub.3, --C(.dbd.O)R.sup.10,
--NR.sup.9C(.dbd.O)H, --NR.sup.9C(.dbd.O)R.sup.10,
--OC(.dbd.O)R.sup.10, --C(.dbd.NR.sup.14)NR.sup.9R.sup.9,
--NHC(.dbd.NR.sup.14)NR.sup.14R.sup.14, --S(.dbd.O)R.sup.10,
--S(O).sub.2R.sup.10 and .dbd.O, wherein the alkyl, aryl,
cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl,
heterocyclyl and heterocyclylalkyl may each be optionally
substituted with 0-5 R.sup.9a; R.sup.8a, at each occurrence, is
independently selected from alkyl, haloalkyl, aryl, arylalkyl,
cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl,
heterocyclyl, heterocyclylalkyl, halo, --NH.sub.2, --CN,
--NO.sub.2, --C(.dbd.O)OH, --C(.dbd.O)OR.sup.14, --OCF.sub.3,
--OCHF.sub.2, --OR.sup.14, --OH, --SH, --SR.sup.14, --S(O).sub.3H,
--P(O).sub.3H.sub.2, --C(.dbd.O)NR.sup.14R.sup.14,
--NR.sup.14R.sup.14, --S(O).sub.2NR.sup.14R.sup.14,
--NR.sup.14S(O).sub.2CF.sub.3,
--C(.dbd.O)NR.sup.14S(O).sub.2R.sup.14,
--S(O).sub.2NR.sup.14C(.dbd.O)OR.sup.14,
--S(O).sub.2NR.sup.14C(.dbd.O)NR.sup.14R.sup.14,
--C(.dbd.O)NR.sup.14S(O).sub.2CF.sub.3, --C(.dbd.O)R.sup.14,
--NR.sup.14C(.dbd.O)H, --NR.sup.14C(.dbd.O)R.sup.14,
--OC(.dbd.O)R.sup.14, --C(.dbd.NR.sup.14)NR.sup.14R.sup.14,
--NHC(.dbd.NR.sup.14)NR.sup.14R.sup.14, --S(.dbd.O)R.sup.14,
--S(O).sub.2R.sup.14, .dbd.O, --NR.sup.14C(.dbd.O)OR.sup.14 and
--NR.sup.14S(O.sub.2)R.sup.14; R.sup.9, at each occurrence, is
independently selected from hydrogen, alkyl, alkoxy, cycloalkyl,
aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and
heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl,
heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl may
each be optionally substituted with 0-5 R.sup.8a, and the
heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl
each contain 1-4 heteroatoms selected from N, O and S; R.sup.9a, at
each occurrence, is independently selected from alkyl, haloalkyl,
aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl,
heterocyclyl, heterocyclylalkyl, halo, --NH.sub.2, --CN,
--NO.sub.2, --C(.dbd.O)OH, --C(.dbd.O)OR.sup.14, --OCF.sub.3,
--OCHF.sub.2, --OR.sup.14, --OH, --SH, --SR.sup.14, --S(O).sub.3H,
--P(O).sub.3H.sub.2, --C(.dbd.O)NR.sup.14R.sup.14,
--NR.sup.14R.sup.14, --S(O).sub.2NR.sup.14R.sup.14,
--NR.sup.14S(O).sub.2CF.sub.3,
--C(.dbd.O)NR.sup.14S(O).sub.2R.sup.10,
--S(O).sub.2NR.sup.14C(.dbd.O)OR.sup.10,
--S(O).sub.2NR.sup.14C(.dbd.O)NR.sup.14R.sup.14,
--C(.dbd.O)NR.sup.14S(O).sub.2CF.sub.3, --C(.dbd.O)R.sup.14,
--NR.sup.14C(.dbd.O)H, --NR.sup.14C(.dbd.O)R.sup.14,
--OC(.dbd.O)R.sup.14, --C(.dbd.NR.sup.14)NR.sup.14R.sup.14,
--NHC(.dbd.NR.sup.14)NR.sup.14R.sup.14, --S(.dbd.O)R.sup.14,
--S(O).sub.2R.sup.14, --NR.sup.14C(.dbd.O)OR.sup.14,
--NR.sup.14S(O.sub.2)R.sup.14, .dbd.O and arylalkyl; R.sup.10, at
each occurrence, is independently selected from alkyl, cycloalkyl,
aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and
heterocyclylalkyl, wherein the cycloalkyl, aryl, arylalkyl,
heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl may
each be optionally substituted with 0-3 R.sup.10a, and the
heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl
each contain 1-4 heteroatoms selected from N, O and S; R.sup.10a,
at each occurrence, is independently selected from alkyl,
haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl,
heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, --NH.sub.2,
--CN, --NO.sub.2, --C(.dbd.O)OH, --C(.dbd.O)OR.sup.14, --OCF.sub.3,
--OCHF.sub.2, --OR.sup.14, --OH, --SH, --SR.sup.14, --S(O).sub.3H,
--P(O).sub.3H.sub.2, --C(.dbd.O)NR.sup.14R.sup.14,
--NR.sup.14R.sup.14, --S(O).sub.2NR.sup.14R.sup.14,
--NR.sup.14S(O).sub.2CF.sub.3,
--C(.dbd.O)NR.sup.14S(O).sub.2R.sup.9,
--S(O).sub.2NR.sup.14C(.dbd.O)OR.sup.9,
--S(O).sub.2NR.sup.14C(.dbd.O)NR.sup.14R.sup.14,
--C(.dbd.O)NR.sup.14S(O).sub.2CF.sub.3, --C(.dbd.O)R.sup.14,
--NR.sup.14C(.dbd.O)H, --NR.sup.14C(.dbd.O)R.sup.14,
--OC(.dbd.O)R.sup.14, --C(.dbd.NR.sup.14)NR.sup.14R.sup.14,
--NHC(.dbd.NR.sup.14)NR.sup.14R.sup.14, --S(.dbd.O)R.sup.14,
--S(O).sub.2R.sup.14, --NR.sup.14C(.dbd.O)OR.sup.14,
--NR.sup.14S(O.sub.2)R.sup.14 and arylalkyl; R.sup.14, at each
occurrence, is independently selected from hydrogen, alkyl, aryl,
cycloalkyl, heteroaryl and heterocyclyl; R.sub.21 is hydrogen,
alkyl, haloalkyl, hydroxyalkyl, aryl, cycloalkyl, halo, --CN,
--C(.dbd.O)OH, --C(.dbd.O)OR.sup.10, --OR.sup.10, --OH,
--C(.dbd.O)NR.sup.9R.sup.9 or --C(.dbd.O)R.sup.10; T.sub.1 is
hydrogen, alkyl or aryl, wherein the alkyl or aryl may be
optionally substituted with one or more R.sup.6's; T.sub.2 is
hydrogen, alkyl or aryl, wherein the alkyl or aryl may be
optionally substituted with one or more R.sup.6's; T.sub.3 is
hydrogen, alkyl or aryl, wherein the alkyl or aryl may be
optionally substituted with one or more R.sup.6's; and T.sub.4 is
hydrogen, alkyl or aryl, wherein the alkyl or aryl may be
optionally substituted with one or more R.sup.6's.
6. The compound, enantiomer, diastereomer, or a pharmaceutically
acceptable salt thereof, of claim 1, wherein: Z is CH; R.sup.1 is
aryl, arylalkyl or heteroaryl, any of which may be optionally
substituted with one or more R.sup.6's; R.sup.2 is aryl,
heteroaryl, heterocyclyl, --C(.dbd.O)R.sup.5 or
--C(.dbd.O)OR.sup.5, wherein the aryl, heteroaryl and heterocyclyl
may each be optionally substituted with one or more R.sup.6's;
R.sup.5 is alkyl, aryl, cycloalkyl or heteroaryl, each of which may
be optionally substituted with one or more R.sup.6's; R.sup.6, at
each occurrence, is independently selected from alkyl, aryl,
cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl,
heterocyclyl, heterocyclylalkyl, halo, --NH.sub.2, --CN,
--NO.sub.2, --C(.dbd.O)OH, --C(.dbd.O)OR.sup.10, --OCF.sub.3,
--OCHF.sub.2, --OR.sup.10, --OH, --SH, --SR.sup.10,
--C(.dbd.O)NR.sup.9R.sup.9, --NR.sup.9R.sup.9,
--S(O).sub.2NR.sup.9R.sup.9, --NR.sup.9S(O).sub.2CF.sub.3,
--C(.dbd.O)NR.sup.9S(O).sub.2R.sup.9,
--S(O).sub.2NR.sup.9C(.dbd.O)OR.sup.9,
--S(O).sub.2NR.sup.9C(.dbd.O)NR.sup.9R.sup.9,
--C(.dbd.O)NR.sup.9S(O).sub.2CF.sub.3, --C(.dbd.O)R.sup.10,
--NR.sup.9C(.dbd.O)H, --NR.sup.9C(.dbd.O)R.sup.10,
--OC(.dbd.O)R.sup.10, --C(.dbd.NR.sup.14)NR.sup.9R.sup.9,
--NHC(.dbd.NR.sup.14)NR.sup.14R.sup.14, --S(.dbd.O)R.sup.10,
--S(O).sub.2R.sup.10 and .dbd.O, wherein the alkyl, aryl,
cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl,
heterocyclyl and heterocyclylalkyl may each be optionally
substituted with 0-5 R.sup.9a; R.sup.8a, at each occurrence, is
independently selected from alkyl, haloalkyl, aryl, arylalkyl,
cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl,
heterocyclyl, heterocyclylalkyl, halo, --NH.sub.2, --CN,
--NO.sub.2, --C(.dbd.O)OH, --C(.dbd.O)OR.sup.14, --OCF.sub.3,
--OCHF.sub.2, --OR.sup.14, --OH, --SH, --SR.sup.14,
--C(.dbd.O)NR.sup.14R.sup.14, --NR.sup.14R.sup.14,
--S(O).sub.2NR.sup.14R.sup.14, --NR.sup.14S(O).sub.2CF.sub.3,
--C(.dbd.O)NR.sup.14S(O).sub.2R.sup.14,
--S(O).sub.2NR.sup.14C(.dbd.O)OR.sup.14,
--S(O).sub.2NR.sup.14C(.dbd.O)NR.sup.14R.sup.14,
--C(.dbd.O)NR.sup.14S(O).sub.2CF.sub.3, --C(.dbd.O)R.sup.14,
--NR.sup.14C(.dbd.O)H, --NR.sup.14C(.dbd.O)R.sup.14,
--OC(.dbd.O)R.sup.14, --C(.dbd.NR.sup.14)NR.sup.14R.sup.14,
--NHC(.dbd.NR.sup.14)NR.sup.14R.sup.14, --S(.dbd.O)R.sup.14,
--S(O).sub.2R.sup.14, .dbd.O, --NR.sup.14C(.dbd.O)OR.sup.14 and
--NR.sup.14S(O.sub.2)R.sup.14; R.sup.9, at each occurrence, is
independently selected from hydrogen, alkyl, cycloalkyl, aryl,
arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and
heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl,
heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl may
each be optionally substituted with 0-5 R.sup.8a, and the
heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl
each contain 1-4 heteroatoms selected from N, O and S; R.sup.9a, at
each occurrence, is independently selected from alkyl, haloalkyl,
aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl,
heterocyclyl, heterocyclylalkyl, halo, --NH.sub.2, --CN,
--NO.sub.2, --C(.dbd.O)OH, --C(.dbd.O)OR.sup.14, --OCF.sub.3,
--OCHF.sub.2, --OR.sup.14, --OH, --SH, --SR.sup.14,
--C(.dbd.O)NR.sup.14R.sup.14, --NR.sup.14R.sup.14,
--S(O).sub.2NR.sup.14R.sup.14, --NR.sup.14S(O).sub.2CF.sub.3,
--C(.dbd.O)NR.sup.14S(O).sub.2R.sup.10,
--S(O).sub.2NR.sup.14C(.dbd.O)OR.sup.10,
--S(O).sub.2NR.sup.14C(.dbd.O)NR.sup.14R.sup.14,
--C(.dbd.O)NR.sup.14S(O).sub.2CF.sub.3, --C(.dbd.O)R.sup.14,
--NR.sup.14C(.dbd.O)H, --NR.sup.14C(.dbd.O)R.sup.14,
--OC(.dbd.O)R.sup.14, --C(.dbd.NR.sup.14)NR.sup.14R.sup.14,
--NHC(.dbd.NR.sup.14)NR.sup.14R.sup.14, --S(.dbd.O)R.sup.14,
--S(O).sub.2R.sup.14, --NR.sup.14C(.dbd.O)OR.sup.14,
--NR.sup.14S(O.sub.2)R.sup.14, .dbd.O and arylalkyl; R.sup.10, at
each occurrence, is independently selected from alkyl, cycloalkyl,
aryl, arylalkyl, heteroaryl, heteroarylalkyl and heterocyclyl,
wherein the cycloalkyl, aryl, arylalkyl, heteroaryl,
heteroarylalkyl and heterocyclyl may each be optionally substituted
with 0-3 R.sup.10a, and the heteroaryl, heteroarylalkyl and
heterocyclyl each contain 1-4 heteroatoms selected from N, O and S;
R.sup.10a, at each occurrence, is independently selected from
alkyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl,
heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, --NH.sub.2,
--CN, --NO.sub.2, --C(.dbd.O)OH, --C(.dbd.O)OR.sup.14, --OCF.sub.3,
--OCHF.sub.2, --OR.sup.14, --OH, --SH, --SR.sup.14,
--C(.dbd.O)NR.sup.14R.sup.14, --NR.sup.14R.sup.14,
--S(O).sub.2NR.sup.14R.sup.14, --NR.sup.14S(O).sub.2CF.sub.3,
--C(.dbd.O)NR.sup.14S(O).sub.2R.sup.9,
--S(O).sub.2NR.sup.14C(.dbd.O)OR.sup.9,
--S(O).sub.2NR.sup.14C(.dbd.O)NR.sup.14R.sup.14,
--C(.dbd.O)NR.sup.14S(O).sub.2CF.sub.3, --C(.dbd.O)R.sup.14,
--NR.sup.14C(.dbd.O)H, --NR.sup.14C(.dbd.O)R.sup.14,
--OC(.dbd.O)R.sup.14, --C(.dbd.NR.sup.14)NR.sup.14R.sup.14,
--NHC(.dbd.NR.sup.14)NR.sup.14R.sup.14, --S(.dbd.O)R.sup.14,
--S(O).sub.2R.sup.14, --NR.sup.14C(.dbd.O)OR.sup.14,
--NR.sup.14S(O.sub.2)R.sup.14 and arylalkyl; R.sup.14, at each
occurrence, is independently selected from hydrogen, alkyl, aryl,
cycloalkyl and heteroaryl; R.sub.21 is hydrogen, alkyl, haloalkyl,
hydroxyalkyl, aryl, cycloalkyl, halo, --CN, --C(.dbd.O)OH,
--C(.dbd.O)OR.sup.10, --OR.sup.10, --C(.dbd.O)NR.sup.9R.sup.9 or
--C(.dbd.O)R.sup.10; T.sub.1 is hydrogen or alkyl, wherein the
alkyl may be optionally substituted with one or more R.sup.6's;
T.sub.2 is hydrogen or alkyl, wherein the alkyl may be optionally
substituted with one or more R.sup.6's; T.sub.3 is hydrogen, alkyl
or aryl, wherein the alkyl or aryl may be optionally substituted
with one or more R.sup.6's; and T.sub.4 is hydrogen or alkyl,
wherein the alkyl may be optionally substituted with one or more
R.sup.6's.
7. The compound, enantiomer, diastereomer, or a pharmaceutically
acceptable salt thereof, of claim 1, wherein: Z is CH; R.sup.1 is
aryl, arylalkyl or heteroaryl, any of which may be optionally
substituted with one or more R.sup.6's; R.sup.2 is aryl,
heteroaryl, --C(.dbd.O)R.sup.5 or --C(.dbd.O)OR.sup.5, wherein the
aryl and heteroaryl may each be optionally substituted with one or
more R.sup.6's; R.sup.5 is alkyl, aryl or heteroaryl, each of which
may be optionally substituted with one or more R.sup.6's; R.sup.6,
at each occurrence, is independently selected from alkyl, aryl,
cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl,
heterocyclyl, heterocyclylalkyl, halo, --NH.sub.2, --CN,
--NO.sub.2, --C(.dbd.O)OH, --C(.dbd.O)OR.sup.10, --OCF.sub.3,
--OCHF.sub.2, --OR.sup.10, --OH, --SH, --SR.sup.10,
--C(.dbd.O)NR.sup.9R.sup.9, --NR.sup.9R.sup.9,
--S(O).sub.2NR.sup.9R.sup.9, --NR.sup.9S(O).sub.2CF.sub.3,
--C(.dbd.O)NR.sup.9S(O).sub.2R.sup.9,
--S(O).sub.2NR.sup.9C(.dbd.O)OR.sup.9,
--S(O).sub.2NR.sup.9C(.dbd.O)NR.sup.9R.sup.9,
--C(.dbd.O)NR.sup.9S(O).sub.2CF.sub.3, --C(.dbd.O)R.sup.10,
--NR.sup.9C(.dbd.O)H, --NR.sup.9C(.dbd.O)R.sup.10,
--OC(.dbd.O)R.sup.10, --S(.dbd.O)R.sup.10, --S(O).sub.2R.sup.10 and
.dbd.O, wherein the alkyl, aryl, cycloalkyl, cycloalkylalkyl,
heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl may
each be optionally substituted with 0-5 R.sup.9a; R.sup.8a, at each
occurrence, is independently selected from alkyl, haloalkyl, aryl,
arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl,
heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, --NH.sub.2,
--CN, --NO.sub.2, --C(.dbd.O)OH, --C(.dbd.O)OR.sup.14, --OCF.sub.3,
--OCHF.sub.2, --OR.sup.14, --OH, --SH, --SR.sup.14,
--C(.dbd.O)NR.sup.14R.sup.14, --NR.sup.14R.sup.14,
--S(O).sub.2NR.sup.14R.sup.14, --NR.sup.14S(O).sub.2CF.sub.3,
--C(.dbd.O)NR.sup.14S(O).sub.2R.sup.14,
--S(O).sub.2NR.sup.14C(.dbd.O)OR.sup.14,
--S(O).sub.2NR.sup.14C(.dbd.O)NR.sup.14R.sup.14,
--C(.dbd.O)NR.sup.14S(O).sub.2CF.sub.3, --C(.dbd.O)R.sup.14,
--NR.sup.14C(.dbd.O)H, --NR.sup.14C(.dbd.O)R.sup.14,
--OC(.dbd.O)R.sup.14, --S(.dbd.O)R.sup.14, --S(O).sub.2R.sup.14,
.dbd.O, --NR.sup.14C(.dbd.O)OR.sup.14 and
--NR.sup.14S(O.sub.2)R.sup.14; R.sup.9, at each occurrence, is
independently selected from hydrogen, alkyl, cycloalkyl, aryl,
arylalkyl, heteroaryl, heteroarylalkyl and heterocyclyl, wherein
the alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl
and heterocyclyl may each be optionally substituted with 0-5
R.sup.8a, and the heteroaryl, heteroarylalkyl and heterocyclyl each
contain 1-4 heteroatoms selected from N, O and S; R.sup.9a, at each
occurrence, is independently selected from alkyl, haloalkyl, aryl,
cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl,
heterocyclyl, heterocyclylalkyl, halo, --NH.sub.2, --CN,
--NO.sub.2, --C(.dbd.O)OH, --C(.dbd.O)OR.sup.14, --OCF.sub.3,
--OCHF.sub.2, --OR.sup.14, --OH, --SH, --SR.sup.14,
--C(.dbd.O)NR.sup.14R.sup.14, --NR.sup.14R.sup.14,
--S(O).sub.2NR.sup.14R.sup.14, --NR.sup.14S(O).sub.2CF.sub.3,
--C(.dbd.O)NR.sup.14S(O).sub.2R.sup.10,
--S(O).sub.2NR.sup.14C(.dbd.O)OR.sup.10,
--S(O).sub.2NR.sup.14C(.dbd.O)NR.sup.14R.sup.14,
--C(.dbd.O)NR.sup.14S(O).sub.2CF.sub.3, --C(.dbd.O)R.sup.14,
--NR.sup.14C(.dbd.O)H, --NR.sup.14C(.dbd.O)R.sup.14,
--OC(.dbd.O)R.sup.14, --S(.dbd.O)R.sup.14, --S(O).sub.2R.sup.14,
--NR.sup.14C(.dbd.O)OR.sup.14, --NR.sup.14S(O.sub.2)R.sup.14,
.dbd.O and arylalkyl; R.sup.10, at each occurrence, is
independently selected from alkyl, cycloalkyl, aryl, arylalkyl,
heteroaryl and heterocyclyl, wherein the cycloalkyl, aryl,
arylalkyl, heteroaryl and heterocyclyl may each be optionally
substituted with 0-3 R.sup.10a, and the heteroaryl and heterocyclyl
each contain 1-4 heteroatoms selected from N, O and S; R.sup.10a,
at each occurrence, is independently selected from alkyl,
haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl,
heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, --NH.sub.2,
--CN, --NO.sub.2, --C(.dbd.O)OH, --C(.dbd.O)OR.sup.14, --OCF.sub.3,
--OCHF.sub.2, --OR.sup.14, --OH, --SH, --SR.sup.14,
--C(.dbd.O)NR.sup.14R.sup.14, --NR.sup.14R.sup.14,
--S(O).sub.2NR.sup.14R.sup.14, --NR.sup.14S(O).sub.2CF.sub.3,
--C(.dbd.O)NR.sup.14S(O).sub.2R.sup.9,
--S(O).sub.2NR.sup.14C(.dbd.O)OR.sup.9,
--S(O).sub.2NR.sup.14C(.dbd.O)NR.sup.14R.sup.14,
--C(.dbd.O)NR.sup.14S(O).sub.2CF.sub.3, --C(.dbd.O)R.sup.14,
--NR.sup.14C(.dbd.O)H, --NR.sup.14C(.dbd.O)R.sup.14,
--OC(.dbd.O)R.sup.14, --S(.dbd.O)R.sup.14, --S(O).sub.2R.sup.14,
--NR.sup.14C(.dbd.O)OR.sup.14, --NR.sup.14S(O.sub.2)R.sup.14 and
arylalkyl; R.sup.14, at each occurrence, is independently selected
from hydrogen, alkyl, aryl, cycloalkyl and heteroaryl; R.sub.21 is
hydrogen, alkyl, haloalkyl, hydroxyalkyl, aryl, halo, --CN,
--C(.dbd.O)OH, --C(.dbd.O)OR.sup.10, --OR.sup.10,
--C(.dbd.O)NR.sup.9R.sup.9 or --C(.dbd.O)R.sup.10; T.sub.1 and
T.sub.2 are hydrogen; T.sub.3 is hydrogen, alkyl or aryl, wherein
the alkyl or aryl may be optionally substituted with one or more
R.sup.6's; and T.sub.4 is hydrogen, alkyl or aryl, wherein the
alkyl or aryl may be optionally substituted with one or more
R.sup.6's.
8. The compound, enantiomer, diastereomer, or a pharmaceutically
acceptable salt thereof, of claim 1, wherein: Z is CH; R.sup.1 is
aryl, arylalkyl or heteroaryl, any of which may be optionally
substituted with one or more R.sup.6's; R.sup.2 is aryl, heteroaryl
or --C(.dbd.O)OR.sup.5, wherein the aryl and heteroaryl may each be
optionally substituted with one or more R.sup.6's; R.sup.5 is
alkyl, aryl or heteroaryl, each of which may be optionally
substituted with one or more R.sup.6's; R.sup.6, at each
occurrence, is independently selected from alkyl, aryl, cycloalkyl,
cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl,
heterocyclylalkyl, halo, --NH.sub.2, --CN, --NO.sub.2,
--C(.dbd.O)OH, --C(.dbd.O)OR.sup.10, --OCF.sub.3, --OCHF.sub.2,
--OR.sup.10, --OH, --SH, --SR.sup.10, --C(.dbd.O)NR.sup.9R.sup.9,
--NR.sup.9R.sup.9, --S(O).sub.2NR.sup.9R.sup.9,
--NR.sup.9S(O).sub.2CF.sub.3, --C(.dbd.O)NR.sup.9S(O).sub.2R.sup.9,
--S(O).sub.2NR.sup.9C(.dbd.O)OR.sup.9, --C(.dbd.O)R.sup.10,
--NR.sup.9C(.dbd.O)H, --NR.sup.9C(.dbd.O)R.sup.10,
--OC(.dbd.O)R.sup.10, --S(.dbd.O)R.sup.10, --S(O).sub.2R.sup.10 and
.dbd.O, wherein the alkyl, aryl, cycloalkyl, cycloalkylalkyl,
heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl may
each be optionally substituted with 0-5 R.sup.9a; R.sup.8a, at each
occurrence, is independently selected from alkyl, haloalkyl, aryl,
arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl,
heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, --NH.sub.2,
--CN, --NO.sub.2, --C(.dbd.O)OH, --C(.dbd.O)OR.sup.14, --OCF.sub.3,
--OCHF.sub.2, --OR.sup.14, --OH, --SH, --SR.sup.14,
--C(.dbd.O)NR.sup.14R.sup.14, --NR.sup.14R.sup.14,
--S(O).sub.2NR.sup.14R.sup.14, --NR.sup.14S(O).sub.2CF.sub.3,
--C(.dbd.O)NR.sup.14S(O).sub.2R.sup.14,
--S(O).sub.2NR.sup.14C(.dbd.O)OR.sup.14, --C(.dbd.O)R.sup.14,
--NR.sup.14C(.dbd.O)H, --NR.sup.14C(.dbd.O)R.sup.14,
--OC(.dbd.O)R.sup.14, --S(.dbd.O)R.sup.14, --S(O).sub.2R.sup.14,
.dbd.O, --NR.sup.14C(.dbd.O)OR.sup.14 and
--NR.sup.14S(O.sub.2)R.sup.14; R.sup.9, at each occurrence, is
independently selected from hydrogen, alkyl, cycloalkyl, aryl,
arylalkyl, heteroaryl and heterocyclyl, wherein the alkyl,
cycloalkyl, aryl, arylalkyl, heteroaryl, and heterocyclyl may each
be optionally substituted with 0-5 R.sup.8a, and the heteroaryl and
heterocyclyl each contain 1-4 heteroatoms selected from N, O and S;
R.sup.9a, at each occurrence, is independently selected from alkyl,
haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl,
heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, --NH.sub.2,
--CN, --NO.sub.2, --C(.dbd.O)OH, --C(.dbd.O)OR.sup.14, --OCF.sub.3,
--OCHF.sub.2, --OR.sup.14, --OH, --SH, --SR.sup.14,
--C(.dbd.O)NR.sup.14R.sup.14, --NR.sup.14R.sup.14,
--S(O).sub.2NR.sup.14R.sup.14, --NR.sup.14S(O).sub.2CF.sub.3,
--C(.dbd.O)NR.sup.14S(O).sub.2R.sup.10,
--S(O).sub.2NR.sup.14C(.dbd.O)OR.sup.10, --C(.dbd.O)R.sup.14,
--NR.sup.14C(.dbd.O)H, --NR.sup.14C(.dbd.O)R.sup.14,
--OC(.dbd.O)R.sup.14, --S(.dbd.O)R.sup.14, --S(O).sub.2R.sup.14,
--NR.sup.14C(.dbd.O)OR.sup.14, --NR.sup.14S(O.sub.2)R.sup.14,
.dbd.O and arylalkyl; R.sup.10, at each occurrence, is
independently selected from alkyl, cycloalkyl, aryl, heteroaryl and
heterocyclyl, wherein the cycloalkyl, aryl, heteroaryl and
heterocyclyl may each be optionally substituted with 0-3 R.sup.10a,
and the heteroaryl and heterocyclyl each contain 1-4 heteroatoms
selected from N, O and S; R.sup.10a, at each occurrence, is
independently selected from alkyl, haloalkyl, aryl, cycloalkyl,
cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl,
heterocyclylalkyl, halo, --NH.sub.2, --CN, --NO.sub.2,
--C(.dbd.O)OH, --C(.dbd.O)OR.sup.14, --OCF.sub.3, --OCHF.sub.2,
--OR.sup.14, --OH, --SH, --SR.sup.14, --C(.dbd.O)NR.sup.14R.sup.14,
--NR.sup.14R.sup.14, --S(O).sub.2NR.sup.14R.sup.14,
--NR.sup.14S(O).sub.2CF.sub.3,
--C(.dbd.O)NR.sup.14S(O).sub.2R.sup.9,
--S(O).sub.2NR.sup.14C(.dbd.O)OR.sup.9, --C(.dbd.O)R.sup.14,
--NR.sup.14C(.dbd.O)H, --NR.sup.14C(.dbd.O)R.sup.14,
--OC(.dbd.O)R.sup.14, --S(.dbd.O)R.sup.14, --S(O).sub.2R.sup.14,
--NR.sup.14C(.dbd.O)OR.sup.14, --NR.sup.14S(O.sub.2)R.sup.14 and
arylalkyl; R.sup.14, at each occurrence, is independently selected
from hydrogen, alkyl, aryl, cycloalkyl and heteroaryl; R.sub.21 is
hydrogen, alkyl, haloalkyl, hydroxyalkyl, aryl, halo, --CN,
--C(.dbd.O)OR.sup.10, --OR.sup.10, --C(.dbd.O)NR.sup.9R.sup.9 or
--C(.dbd.O)R.sup.10; T.sub.1, T.sub.2 and T.sub.4 are hydrogen; and
T.sub.3 is hydrogen, alkyl or aryl, wherein the alkyl or aryl may
be optionally substituted with one or more R.sup.6's.
9. The compound, enantiomer, diastereomer, or a pharmaceutically
acceptable salt thereof, of claim 1, wherein: Z is CH; R.sup.1 is
aryl, arylalkyl or heteroaryl, any of which may be optionally
substituted with one or more R.sup.6's; R.sup.2 is heteroaryl or
--C(.dbd.O)OR.sup.5, wherein the heteroaryl may be optionally
substituted with one or more R.sup.6's; R.sup.5 is alkyl, aryl or
heteroaryl, each of which may be optionally substituted with one or
more R.sup.6's; R.sup.6, at each occurrence, is independently
selected from alkyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl,
heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, --NH.sub.2,
--CN, --NO.sub.2, --C(.dbd.O)OH, --C(.dbd.O)OR.sup.10, --OCF.sub.3,
--OCHF.sub.2, --OR.sup.10, --OH, --SH, --SR.sup.10,
--C(.dbd.O)NR.sup.9R.sup.9, --NR.sup.9R.sup.9,
--S(O).sub.2NR.sup.9R.sup.9, --NR.sup.9S(O).sub.2CF.sub.3,
--C(.dbd.O)R.sup.10, --NR.sup.9C(.dbd.O)H,
--NR.sup.9C(.dbd.O)R.sup.10, --OC(.dbd.O)R.sup.10,
--S(.dbd.O)R.sup.10, --S(O).sub.2R.sup.10 and .dbd.O, wherein the
alkyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl,
heteroarylalkyl, heterocyclyl and heterocyclylalkyl may each be
optionally substituted with 0-5 R.sup.9a; R.sup.8a, at each
occurrence, is independently selected from alkyl, haloalkyl, aryl,
arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl,
heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, --NH.sub.2,
--CN, --NO.sub.2, --C(.dbd.O)OH, --C(.dbd.O)OR.sup.14, --OCF.sub.3,
--OCHF.sub.2, --OR.sup.14, --OH, --SH, --SR.sup.14,
--C(.dbd.O)NR.sup.14R.sup.14, --NR.sup.14R.sup.14,
--S(O).sub.2NR.sup.14R.sup.14, --NR.sup.14S(O).sub.2CF.sub.3,
--C(.dbd.O)R.sup.14, --NR.sup.14C(.dbd.O)H,
--NR.sup.14C(.dbd.O)R.sup.14, --OC(.dbd.O)R.sup.14,
--S(.dbd.O)R.sup.14, --S(O).sub.2R.sup.14, .dbd.O,
--NR.sup.14C(.dbd.O)OR.sup.14 and --NR.sup.14S(O.sub.2)R.sup.14;
R.sup.9, at each occurrence, is independently selected from
hydrogen, alkyl, cycloalkyl, aryl, heteroaryl and heterocyclyl,
wherein the alkyl, cycloalkyl, aryl, heteroaryl and heterocyclyl
may each be optionally substituted with 0-5 R.sup.8a, and the
heteroaryl and heterocyclyl each contain 1-4 heteroatoms selected
from N, O and S; R.sup.9a, at each occurrence, is independently
selected from alkyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl,
heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo,
--NH.sub.2, --CN, --NO.sub.2, --C(.dbd.O)OH, --C(.dbd.O)OR.sup.14,
--OCF.sub.3, --OCHF.sub.2, --OR.sup.14, --OH, --SH, --SR.sup.14,
--C(.dbd.O)NR.sup.14R.sup.14, --NR.sup.14R.sup.14,
--S(O).sub.2NR.sup.14R.sup.14, --NR.sup.14S(O).sub.2CF.sub.3,
--C(.dbd.O)R.sup.14, --NR.sup.14C(.dbd.O)H,
--NR.sup.14C(.dbd.O)R.sup.14, --OC(.dbd.O)R.sup.14,
--S(.dbd.O)R.sup.14, --S(O).sub.2R.sup.14,
--NR.sup.14C(.dbd.O)OR.sup.14, --NR.sup.14S(O.sub.2)R.sup.14,
.dbd.O and arylalkyl; R.sup.10, at each occurrence, is
independently selected from alkyl, cycloalkyl, aryl and heteroaryl,
wherein the cycloalkyl, aryl and heteroaryl may each be optionally
substituted with 0-3 R.sup.10a, and the heteroaryl contains 1-4
heteroatoms selected from N, O and S; R.sup.10a, at each
occurrence, is independently selected from alkyl, haloalkyl, aryl,
cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl,
heterocyclyl, heterocyclylalkyl, halo, --NH.sub.2, --CN,
--NO.sub.2, --C(.dbd.O)OH, --C(.dbd.O)OR.sup.14, --OCF.sub.3,
--OCHF.sub.2, --OR.sup.14, --OH, --SH, --SR.sup.14,
--C(.dbd.O)NR.sup.14R.sup.14, --NR.sup.14R.sup.14,
--S(O).sub.2NR.sup.14R.sup.14, --NR.sup.14S(O).sub.2CF.sub.3,
--C(.dbd.O)R.sup.14, --NR.sup.14C(.dbd.O)H,
--NR.sup.14C(.dbd.O)R.sup.14, --OC(.dbd.O)R.sup.14,
--S(.dbd.O)R.sup.14, --S(O).sub.2R.sup.14,
--NR.sup.14C(.dbd.O)OR.sup.14, --NR.sup.14S(O.sub.2)R.sup.14 and
arylalkyl; R.sup.14, at each occurrence, is independently selected
from hydrogen, alkyl, aryl, cycloalkyl and heteroaryl; R.sub.21 is
hydrogen, alkyl, haloalkyl, hydroxyalkyl, aryl, halo, --CN,
--C(.dbd.O)OR.sup.10, --C(.dbd.O)NR.sup.9R.sup.9 or
--C(.dbd.O)R.sup.10; T.sub.1, T.sub.2 and T.sub.4 are hydrogen; and
T.sub.3 is hydrogen or alkyl, wherein the alkyl may be optionally
substituted with one or more R.sup.6's.
10. The compound, enantiomer, diastereomer, or a pharmaceutically
acceptable salt thereof, of claim 1, wherein: Z is CH; R.sup.1 is
aryl or heteroaryl, any of which may be optionally substituted with
one or more R.sup.6's; R.sup.2 is heteroaryl or
--C(.dbd.O)OR.sup.5, wherein the heteroaryl may be optionally
substituted with one or more R.sup.6's; R.sup.5 is alkyl, aryl or
heteroaryl, each of which may be optionally substituted with one or
more R.sup.6's; R.sup.6, at each occurrence, is independently
selected from alkyl, aryl, cycloalkyl, heteroaryl, heterocyclyl,
halo, --NH.sub.2, --CN, --NO.sub.2, --C(.dbd.O)OH,
--C(.dbd.O)OR.sup.10, --OCF.sub.3, --OCHF.sub.2, --OR.sup.10, --OH,
--SH, --SR.sup.10, --C(.dbd.O)NR.sup.9R.sup.9, --NR.sup.9R.sup.9,
--S(O).sub.2NR.sup.9R.sup.9, --NR.sup.9S(O).sub.2CF.sub.3,
--C(.dbd.O)R.sup.10, --NR.sup.9C(.dbd.O)H,
--NR.sup.9C(.dbd.O)R.sup.10, --OC(.dbd.O)R.sup.10,
--S(.dbd.O)R.sup.10, --S(O).sub.2R.sup.10 and .dbd.O, wherein the
alkyl, aryl, cycloalkyl, heteroaryl, and heterocyclyl may each be
optionally substituted with 0-5 R.sup.9a; R.sup.8a, at each
occurrence, is independently selected from alkyl, haloalkyl, aryl,
arylalkyl, cycloalkyl, heteroaryl, heterocyclyl, halo, --NH.sub.2,
--CN, --NO.sub.2, --C(.dbd.O)OH, --C(.dbd.O)OR.sup.14, --OCF.sub.3,
--OCHF.sub.2, --OR.sup.14, --OH, --SH, --SR.sup.14,
--C(.dbd.O)NR.sup.14R.sup.14, --NR.sup.14R.sup.14,
--S(O).sub.2NR.sup.14R.sup.14, --NR.sup.14S(O).sub.2CF.sub.3,
--C(.dbd.O)R.sup.14, --NR.sup.14C(.dbd.O)H,
--NR.sup.14C(.dbd.O)R.sup.14, --OC(.dbd.O)R.sup.14,
--S(.dbd.O)R.sup.14, --S(O).sub.2R.sup.14, .dbd.O,
--NR.sup.14C(.dbd.O)OR.sup.14 and --NR.sup.14S(O.sub.2)R.sup.14;
R.sup.9, at each occurrence, is independently selected from
hydrogen, alkyl, cycloalkyl, aryl and heteroaryl, wherein the
alkyl, cycloalkyl, aryl and heteroaryl, may each be optionally
substituted with 0-5 R.sup.8a, and the heteroaryl contains 1-4
heteroatoms selected from N, O and S; R.sup.9a, at each occurrence,
is independently selected from alkyl, haloalkyl, aryl, cycloalkyl,
heteroaryl, heterocyclyl, halo, --NH.sub.2, --CN, --NO.sub.2,
--C(.dbd.O)OH, --C(.dbd.O)OR.sup.14, --OCF.sub.3, --OCHF.sub.2,
--OR.sup.14, --OH, --SH, --SR.sup.14, --C(.dbd.O)NR.sup.14R.sup.14,
--NR.sup.14R.sup.14, --S(O).sub.2NR.sup.14R.sup.14,
--NR.sup.14S(O).sub.2CF.sub.3, --C(.dbd.O)R.sup.14,
--NR.sup.14C(.dbd.O)H, --NR.sup.14C(.dbd.O)R.sup.14,
--OC(.dbd.O)R.sup.14, --S(.dbd.O)R.sup.14, --S(O).sub.2R.sup.14,
--NR.sup.14C(.dbd.O)OR.sup.14, --NR.sup.14S(O.sub.2)R.sup.14,
.dbd.O and arylalkyl; R.sup.10, at each occurrence, is
independently selected from alkyl, cycloalkyl, aryl and heteroaryl,
wherein the cycloalkyl, aryl and heteroaryl may each be optionally
substituted with 0-3 R.sup.10a, and the heteroaryl contains 1-4
heteroatoms selected from N, O and S; R.sup.10a, at each
occurrence, is independently selected from alkyl, haloalkyl, aryl,
cycloalkyl, heteroaryl, heterocyclyl, halo, --NH.sub.2, --CN,
--NO.sub.2, --C(.dbd.O)OH, --C(.dbd.O)OR.sup.14, --OCF.sub.3,
--OCHF.sub.2, --OR.sup.14, --OH, --SH, --SR.sup.14,
--C(.dbd.O)NR.sup.14R.sup.14, --NR.sup.14R.sup.14,
--S(O).sub.2NR.sup.14R.sup.14, --NR.sup.14S(O).sub.2CF.sub.3,
--C(.dbd.O)R.sup.14, --NR.sup.14C(.dbd.O)H,
--NR.sup.14C(.dbd.O)R.sup.14, --OC(.dbd.O)R.sup.14,
--S(.dbd.O)R.sup.14, --S(O).sub.2R.sup.14,
--NR.sup.14C(.dbd.O)OR.sup.14, --NR.sup.14S(O.sub.2)R.sup.14 and
arylalkyl; R.sup.14, at each occurrence, is independently selected
from hydrogen, alkyl, aryl, cycloalkyl and heteroaryl; R.sub.21 is
hydrogen, alkyl, haloalkyl, hydroxyalkyl, aryl, halo, --CN,
--C(.dbd.O)OR.sup.10 or --C(.dbd.O)NR.sup.9R.sup.9; T.sub.1,
T.sub.2 and T.sub.4 are hydrogen; and T.sub.3 is hydrogen or
alkyl.
11. The compound of claim 1, wherein the compound is selected from
the group consisting of: ##STR00086##
12. A pharmaceutical composition comprised of a therapeutically
effective amount of a compound of claim 1, or an enantiomer, a
diastereomer, or a pharmaceutically acceptable salt thereof, and
optionally a pharmaceutically acceptable carrier.
13. The pharmaceutical composition of claim 12, further comprising
a therapeutically effective amount of one or more other
therapeutically active agents.
14. A method of modulating the activity of the GPR119G
protein-coupled receptor comprising administering to a mammalian
patient in need thereof a therapeutically effective amount of at
least one compound of claim 1, or an enantiomer, a diastereomer, or
a pharmaceutically acceptable salt thereof, and optionally an
additional therapeutic agent.
15. A method for preventing, inhibiting, or treating the
progression or onset of diseases or disorders associated with the
activity of the GPR119G protein-coupled receptor comprising
administering to a mammalian patient in need of prevention,
inhibition, or treatment a therapeutically effective amount of at
least one compound of claim 1, or an enantiomer, a diastereomer, or
a pharmaceutically acceptable salt thereof, and optionally an
additional therapeutic agent wherein: (a) the diseases or disorders
are selected from the group consisting of diabetes, hyperglycemia,
impaired glucose tolerance, insulin resistance, hyperinsulinemia,
retinopathy, neuropathy, nephropathy, delayed wound healing,
atherosclerosis and its sequelae, abnormal heart function,
myocardial ischemia, stroke, Metabolic Syndrome, hypertension,
obesity, dislipidemia, dyslipidemia, hyperlipidemia,
hypertriglyceridemia, hypercholesterolemia, low HDL, high LDL,
non-cardiac ischemia, infection, cancer, vascular restenosis,
pancreatitis, neurodegenerative disease, lipid disorders, cognitive
impairment and dementia, bone disease, HIV protease associated
lipodystrophy and glaucoma; and (b) the additional therapeutic
agent is selected from the group consisting of anti-diabetic
agents, anti-hyperglycemic agents, anti-hyperinsulinemic agents,
anti-retinopathic agents, anti-neuropathic agents,
anti-nephropathic agents, anti-atherosclerotic agents,
anti-ischemic agents, anti-hypertensive agents, anti-obesity
agents, anti-dyslipidemic agents, anti-dyslipidemic agents,
anti-hyperlipidemic agents, anti-hypertriglyceridemic agents,
anti-hypercholesterolemic agents, anti-restenotic agents,
anti-pancreatic agents, lipid lowering agents, appetite
suppressants, treatments for heart failure, treatments for
peripheral arterial disease and anti-inflammatory agents.
16. A pharmaceutical composition comprised of a therapeutically
effective amount of a compound of claim 11, or an enantiomer, a
diastereomer, or a pharmaceutically acceptable salt thereof, and
optionally a pharmaceutically acceptable carrier.
17. The pharmaceutical composition of claim 16, further comprising
a therapeutically effective amount of one or more other
therapeutically active agents.
18. A method of modulating the activity of the GPR119G
protein-coupled receptor comprising administering to a mammalian
patient in need thereof a therapeutically effective amount of at
least one compound of claim 11, or an enantiomer, a diastereomer,
or a pharmaceutically acceptable salt thereof, and optionally an
additional therapeutic agent.
19. A method for preventing, inhibiting, or treating the
progression or onset of diseases or disorders associated with the
activity of the GPR119G protein-coupled receptor comprising
administering to a mammalian patient in need of prevention,
inhibition, or treatment a therapeutically effective amount of at
least one compound of claim 11, or an enantiomer, a diastereomer,
or a pharmaceutically acceptable salt thereof, and optionally an
additional therapeutic agent wherein: (a) the diseases or disorders
are selected from the group consisting of diabetes, hyperglycemia,
impaired glucose tolerance, insulin resistance, hyperinsulinemia,
retinopathy, neuropathy, nephropathy, delayed wound healing,
atherosclerosis and its sequelae, abnormal heart function,
myocardial ischemia, stroke, Metabolic Syndrome, hypertension,
obesity, dislipidemia, dyslipidemia, hyperlipidemia,
hypertriglyceridemia, hypercholesterolemia, low HDL, high LDL,
non-cardiac ischemia, infection, cancer, vascular restenosis,
pancreatitis, neurodegenerative disease, lipid disorders, cognitive
impairment and dementia, bone disease, HIV protease associated
lipodystrophy and glaucoma; and (b) the additional therapeutic
agent is selected from the group consisting of anti-diabetic
agents, anti-hyperglycemic agents, anti-hyperinsulinemic agents,
anti-retinopathic agents, anti-neuropathic agents,
anti-nephropathic agents, anti-atherosclerotic agents,
anti-ischemic agents, anti-hypertensive agents, anti-obesity
agents, anti-dyslipidemic agents, anti-dyslipidemic agents,
anti-hyperlipidemic agents, anti-hypertriglyceridemic agents,
anti-hypercholesterolemic agents, anti-restenotic agents,
anti-pancreatic agents, lipid lowering agents, appetite
suppressants, treatments for heart failure, treatments for
peripheral arterial disease and anti-inflammatory agents.
Description
CROSS REFERENCES TO RELATED APPLICATIONS
[0001] This application is a divisional of U.S. patent application
Ser. No. 13/003,914, now allowed, which is a 35 U.S.C. 371
application of International Application No. PCT/US2009/050618,
filed on Jul. 15, 2009, which claims the benefit of U.S.
Provisional Application Ser. Nos. 61/081,058, 61/081,060, and
61/081,069, all filed on Jul. 16, 2008. The entirety of each of
these applications is incorporated herein by reference.
FIELD OF THE INVENTION
[0002] The present invention provides novel pyridone and pyridazone
compounds and analogues, which are modulators of the GPR119G
protein-coupled receptor, compositions containing them, and methods
of using them, for example, for the prevention and/or treatment of
diseases or disorders associated with the activity of the GPR119G
protein-coupled receptor, e.g., diabetes and obesity.
BACKGROUND OF THE INVENTION
[0003] Diabetes mellitus is a serious disease afflicting over 100
million people worldwide. In the United States, there are more than
12 million diabetics, with 600,000 new cases diagnosed each year.
Diabetes mellitus is a diagnostic term for a group of disorders
characterized by abnormal glucose homeostasis resulting in elevated
blood sugar. There are many types of diabetes, but the two most
common are Type 1 (also referred to as insulin-dependent diabetes
mellitus or IDDM) and Type 2 (also referred to as
non-insulin-dependent diabetes mellitus or NIDDM).
[0004] The etiology of the different types of diabetes is not the
same; however, everyone with diabetes has two things in common:
overproduction of glucose by the liver and little or no ability to
move glucose out of the blood into the cells where it becomes the
body's primary fuel.
[0005] People who do not have diabetes rely on insulin, a hormone
made in the pancreas, to move glucose from the blood into the cells
of the body. However, people who have diabetes either do not
produce insulin or cannot efficiently use the insulin they produce;
therefore, they cannot move glucose into their cells. Glucose
accumulates in the blood creating a condition called hyperglycemia,
and over time, can cause serious health problems.
[0006] Diabetes is a syndrome with interrelated metabolic,
vascular, and neuropathic components. The metabolic syndrome,
generally characterized by hyperglycemia, comprises alterations in
carbohydrate, fat and protein metabolism caused by absent or
markedly reduced insulin secretion and/or ineffective insulin
action. The vascular syndrome consists of abnormalities in the
blood vessels leading to cardiovascular, retinal and renal
complications. Abnormalities in the peripheral and autonomic
nervous systems are also part of the diabetic syndrome.
[0007] Diabetes has also been implicated in the development of
kidney disease, eye diseases and nervous-system problems. Kidney
disease, also called nephropathy, occurs when the kidney's "filter
mechanism" is damaged and protein leaks into urine in excessive
amounts and eventually the kidney fails. Diabetes is also a leading
cause of damage to the retina at the back of the eye and increases
risk of cataracts and glaucoma. Finally, diabetes is associated
with nerve damage, especially in the legs and feet, which
interferes with the ability to sense pain and contributes to
serious infections. Taken together, diabetes complications are one
of the nation's leading causes of death.
[0008] Many people with NIDDM have sedentary lifestyles and are
obese; they weigh approximately 20% more than the recommended
weight for their height and build. Furthermore, obesity is
characterized by hyperinsulinemia and insulin resistance, a feature
shared with NIDDM, hypertension and atherosclerosis.
[0009] Obesity, which is the result of an imbalance between caloric
intake and energy expenditure, is highly correlated with insulin
resistance and diabetes in experimental animals and human. However,
the molecular mechanisms that are involved in obesity-diabetes
syndromes are not clear. During early development of obesity,
increased insulin secretion balances insulin resistance and
protects patients from hyperglycemia (Le Stunff et al., Diabetes,
43:696-702 (1989)). However, over time, .beta.-cell function
deteriorates and non-insulin-dependent diabetes develops in about
20% of the obese population (Pederson, P., Diab. Metab. Rev.,
5:505-509 (1989)) and (Brancati, F. L. et al., Arch. Intern. Med.,
159:957-963 (1999)). Given its high prevalence in modern societies,
obesity has thus become the leading risk factor for NIDDM (Hill, J.
O. et al., Science, 280:1371-1374 (1998)). However, the factors
which predispose a fraction of patients to alteration of insulin
secretion in response to fat accumulation remain unknown. The most
common diseases with obesity are cardiovascular disease
(particularly hypertension), diabetes (obesity aggravates the
development of diabetes), gall bladder disease (particularly
cancer) and diseases of reproduction. Research has shown that even
a modest reduction in body weight can correspond to a significant
reduction in the risk of developing coronary heart disease.
[0010] Obesity considerably increases the risk of developing
cardiovascular diseases as well. Coronary insufficiency,
atheromatous disease, and cardiac insufficiency are at the
forefront of the cardiovascular complication induced by obesity. It
is estimated that if the entire population had an ideal weight, the
risk of coronary insufficiency would decrease by 25% and the risk
of cardiac insufficiency and of cerebral vascular accidents by 35%.
The incidence of coronary diseases is doubled in subjects less than
50 years of age who are 30% overweight. The diabetes patient faces
a 30% reduced lifespan. After age 45, people with diabetes are
about three times more likely than people without diabetes to have
significant heart disease and up to five times more likely to have
a stroke. These findings emphasize the inter-relations between
risks factors for NIDDM, obesity and coronary heart disease as well
as the potential value of an integrated approach involving the
treatment of both obesity and diabetes (Perry, I. J. et al., BMJ,
310:560-564 (1995)).
[0011] Type 2 diabetes results from the progressive loss of
pancreatic .beta.-cell function in the presence of insulin
resistance, leading to an overall reduction in insulin output
(Prentki, M. et al., "Islet failure in type 2 diabetes", J. Clin.
Invest., 116:1802-1812 (2006)). .beta.-cells are the cell type that
store and release insulin in response to an elevation in plasma
glucose or in response to hormonal signals from the gut following
the ingestion of food. Evidence suggests that in type 2 diabetics
the rate of .beta.-cell cell death (apoptosis) exceeds that of new
.beta.-cell development, yielding an overall loss in .beta.-cell
number (Butler, A. E. et al., ".beta.-cell deficit and increased
.beta.-cell apoptosis in humans with type 2 diabetes", Diabetes,
52:102-110 (2003)). .beta.-cell apoptosis may arise from persistent
elevations in plasma glucose levels (glucotoxicity) and/or plasma
lipid levels (lipotoxicity).
[0012] G-protein coupled receptors (GPCRs) expressed on
.beta.-cells are known to modulate the release of insulin in
response to changes in plasma glucose levels (Ahren, B., "Autonomic
regulation of islet hormone secretion--Implications for health and
disease", Diabetologia, 43:393-410 (2003)). Those GPCRs
specifically coupled to the elevation of cAMP via the G.sub.s alpha
subunit of G-protein, have been shown to enhance glucose-stimulated
insulin release from .beta.-cells. Cyclic AMP-stimulating GPCRs on
.beta.-cells include the GLP-1, GIP, .beta.2-adrenergic receptors
and GPR119. Increasing cAMP concentration in .beta.-cells is known
to lead to the activation of PKA which is thought to prevent the
opening of potassium channels on the surface of the .beta.-cell.
The reduction in K.sup.+ efflux depolarizes the .beta.-cell leading
to an influx of Ca.sup.++ which promotes the release of
insulin.
[0013] GPR119 (e.g., human GPR119, GENBANK.RTM. Accession No.
AAP72125 and alleles thereof; e.g., mouse GPR119, GENBANK.RTM.
Accession No. AY288423 and alleles thereof) is a GPCR located at
chromosome position Xp26.1 (Fredricksson, R. et al., "Seven
evolutionarily conserved human rhodopsin G protein-coupled
receptors lacking close relatives", FEBS Lett., 554:381-388
(2003)). The receptor is coupled to Gs, and when stimulated,
produces an elevation in cAMP in a variety of cell types including
.beta.-cell-derived insulinomas (Soga, T. et al.,
"Lysophosphatidylcholine enhances glucose-dependent insulin
secretion via an orphan G-protein-coupled receptor", Biochem.
Biophys. Res. Comm., 326:744-751 (2005), international patent
applications WO 04/065380, WO 04/076413, WO 05/007647, WO
05/007658, WO 05/121121, WO 06/083491 and EP 1338651). The receptor
has been shown to be localized to the .beta.-cells of the pancreas
in a number of species as well as in specific cell types of the
gastrointestinal tract. Activation of GPR119, with agonist ligands
such as lysophosphatidylcholine, produce a glucose dependent
increase in insulin secretion from primary mouse islets and various
insulinoma cell lines such as NIT-1 and HIT-T15 (Soga, T. et al.,
"Lysophosphatidylcholine enhances glucose-dependent insulin
secretion via an orphan G-protein-coupled receptor", Biochem.
Biophys. Res. Comm., 326:744-751 (2005); Chu, Z. L. et al., "A role
for .beta.-cell-expressed GPR119 in glycemic control by enhancing
glucose-dependent insulin release", Endocrinology,
doi:10.1210/en.2006-1608 (2007)).
[0014] When activators of GPR119 are administered to either normal
mice or mice that are prone to diabetes due to genetic mutation,
prior to an oral glucose tolerance test, improvements in glucose
tolerance are observed. A short-lived increase in plasma
glucagon-like peptide-1 and plasma insulin levels are also observed
in these treated animals (Chu, Z. L. et al., "A role for
.beta.-cell-expressed GPR119 in glycemic control by enhancing
glucose-dependent insulin release", Endocrinology,
doi:10.1210/en.2006-1608 (2007)). In addition to effects on plasma
glucose levels, GPR119 activators have also been demonstrated to
produce reductions in acute food intake and to reduce body weight
in rats following chronic administration (Overton, H. A. et al.,
"Deorphanization of a G protein-coupled receptor for
oleoylethanolamide qand its use in the discovery of small-molecule
hypophagic agents", Cell Metabolism, 3:167-175 (2006), and
international patent applications WO 05/007647 and WO
05/007658).
SUMMARY OF THE INVENTION
[0015] In accordance with the present invention, compounds are
provided that have the general structure of Formula I:
##STR00002##
or an enantiomer, a diastereomer, or a pharmaceutically acceptable
salt thereof, wherein Z, R.sup.1, R.sup.2, R.sup.21, T.sup.1,
T.sup.2, T.sup.3 and T.sup.4 are defined below.
[0016] Compounds of the present invention modulate the activity of
G protein-coupled receptors. Preferably, compounds of the present
invention modulate the activity of the GPR119G protein-coupled
receptor ("GPR119"). Consequently, the compounds of the present
invention may be used in the treatment of multiple diseases or
disorders associated with GPR119, such as diabetes and related
conditions, microvascular complications associated with diabetes,
the macrovascular complications associated with diabetes,
cardiovascular diseases, Metabolic Syndrome and its component
conditions, obesity and other maladies. Examples of diseases or
disorders associated with the modulation of the GPR119G
protein-coupled receptor that can be prevented, modulated, or
treated according to the present invention include, but are not
limited to, diabetes, hyperglycemia, impaired glucose tolerance,
insulin resistance, hyperinsulinemia, retinopathy, neuropathy,
nephropathy, delayed wound healing, atherosclerosis and its
sequelae, abnormal heart function, myocardial ischemia, stroke,
Metabolic Syndrome, hypertension, obesity, dislipidemia,
dyslipidemia, hyperlipidemia, hypertriglyceridemia,
hypercholesterolemia, low HDL, high LDL, non-cardiac ischemia,
infection, cancer, vascular restenosis, pancreatitis,
neurodegenerative disease, lipid disorders, cognitive impairment
and dementia, bone disease, HIV protease associated lipodystrophy
and glaucoma.
[0017] In addition, the present invention relates to a formulated
product wherein the selected formulation is made by using a
compound of Formula I as the only active ingredient or by combining
(a) a compound of Formula I (using any of the compound embodiments
listed herein) and (b) an additional active ingredient, for
example, dipeptidyl peptidase-IV (DPP4) inhibitor (for example a
member selected from saxagliptin, sitagliptin, vildagliptin and
alogliptin).
[0018] Therefore, in another aspect the present invention provides
for compounds of Formula I, pharmaceutical compositions containing
such compounds, and for methods of using such compounds. In
particular, the present invention provides a pharmaceutical
composition comprising a therapeutically effective amount of a
compound of Formula I, alone or in combination with a
pharmaceutically acceptable carrier.
[0019] Further, in another aspect the present invention provides a
method for preventing, modulating, or treating the progression or
onset of diseases or disorders associated with the activity of the
GPR119G protein-coupled receptor, such as defined above and
hereinafter, wherein a therapeutically effective amount of a
compound of Formula I is administered to a mammalian, i.e., human,
patient in need of treatment.
[0020] The compounds of the invention can be used alone, in
combination with other compounds of the present invention, or in
combination with one or more other agent(s).
[0021] Further, the present invention provides a method for
preventing, modulating, or treating the diseases as defined above
and hereinafter, wherein a therapeutically effective amount of a
combination of a compound of Formula I and another compound of
Formula I and/or at least one other type of therapeutic agent, is
administered to a mammalian, i.e., human, patient in need of
treatment.
DETAILED DESCRIPTION OF THE INVENTION
[0022] In the first aspect of the present invention, compounds of
Formula I are provided:
##STR00003##
[0023] In the first embodiment of the first aspect, the present
invention provides a compound of Formula I, or an enantiomer, a
diastereomer, or a pharmaceutically acceptable salt thereof,
wherein:
[0024] Z is CH or N;
[0025] R.sup.1 is aryl, arylalkyl or heteroaryl, any of which may
be optionally substituted with one or more R.sup.6's;
[0026] R.sup.2 is cycloalkyl, aryl, heteroaryl, heterocyclyl,
--S(O).sub.2R.sup.5, --C(.dbd.O)NR.sup.3R.sup.5, --C(.dbd.O)R.sup.5
or --C(.dbd.O)OR.sup.5, wherein the cycloalkyl, aryl, heteroaryl
and heterocyclyl may each be optionally substituted with one or
more R.sup.6's;
[0027] R.sup.3 is hydrogen, alkyl, alkoxy, cycloalkyl, aryl,
arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl or
heterocyclylalkyl, wherein the heteroaryl, heteroarylalkyl,
heterocyclyl and heterocyclylalkyl may each contain 1-4 heteroatoms
selected from N, O and S;
[0028] R.sup.5 is alkyl, alkenyl, aryl, cycloalkyl, heteroaryl or
heterocyclyl, each of which may be optionally substituted with one
or more R.sup.6's;
[0029] R.sup.6, at each occurrence, is independently selected from
alkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl,
heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo,
--NH.sub.2, --CN, --NO.sub.2, --C(.dbd.O)OH, --C(.dbd.O)OR.sup.10,
--OCF.sub.3, --OCHF.sub.2, --OR.sup.10, --OH, --SH, --SR.sup.10,
--S(O).sub.3H, --P(O).sub.3H.sub.2, --C(.dbd.O)NR.sup.9R.sup.9,
--NR.sup.9R.sup.9, --S(O).sub.2NR.sup.9R.sup.9,
--NR.sup.9S(O).sub.2CF.sub.3, --C(.dbd.O)NR.sup.9S(O).sub.2R.sup.9,
--S(O).sub.2NR.sup.9C(.dbd.O)OR.sup.9,
--S(O).sub.2NR.sup.9C(.dbd.O)NR.sup.9R.sup.9,
--C(.dbd.O)NR.sup.9S(O).sub.2CF.sub.3, --C(.dbd.O)R.sup.10,
--NR.sup.9C(.dbd.O)H, --NR.sup.9C(.dbd.O)R.sup.10,
--OC(.dbd.O)R.sup.10, --C(.dbd.NR.sup.14)NR.sup.9R.sup.9,
--NHC(.dbd.NR.sup.14)NR.sup.14R.sup.14, --S(.dbd.O)R.sup.10,
--S(O).sub.2R.sup.10, .dbd.O, --NR.sup.9C(.dbd.O)OR.sup.8 and
--NR.sup.9S(O.sub.2)R.sup.8, wherein the alkyl, alkenyl, alkynyl,
aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl,
heterocyclyl and heterocyclylalkyl may each be optionally
substituted with 0-5 R.sup.9a;
[0030] R.sup.8, at each occurrence, is independently selected from
the group consisting of alkyl, aryl, cycloalkyl, heteroaryl and
heterocyclyl, each of which may be optionally substituted with one
or more R.sup.8a's;
[0031] R.sup.8a, at each occurrence, is independently selected from
alkyl, haloalkyl, aryl, arylalkyl, alkenyl, alkynyl, cycloalkyl,
cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl,
heterocyclylalkyl, halo, --NH.sub.2, --CN, --NO.sub.2,
--C(.dbd.O)OH, --C(.dbd.O)OR.sup.14, --OCF.sub.3, --OCHF.sub.2,
--OR.sup.14, --OH, --SH, --SR.sup.14, --S(O).sub.3H,
--P(O).sub.3H.sub.2, --C(.dbd.O)NR.sup.14R.sup.14,
--NR.sup.14R.sup.14, --S(O).sub.2NR.sup.14R.sup.14,
--NR.sup.14S(O).sub.2CF.sub.3,
--C(.dbd.O)NR.sup.14S(O).sub.2R.sup.14,
--S(O).sub.2NR.sup.14C(.dbd.O)OR.sup.14,
--S(O).sub.2NR.sup.14C(.dbd.O)NR.sup.14R.sup.14,
--C(.dbd.O)NR.sup.14S(O).sub.2CF.sub.3, --C(.dbd.O)R.sup.14,
--NR.sup.14C(.dbd.O)H, --NR.sup.14C(.dbd.O)R.sup.14,
--OC(.dbd.O)R.sup.14, --C(.dbd.NR.sup.14)NR.sup.14R.sup.14,
--NHC(.dbd.NR.sup.14)NR.sup.14R.sup.14, --S(.dbd.O)R.sup.14,
--S(O).sub.2R.sup.14, .dbd.O, --NR.sup.14(.dbd.O)OR.sup.14 and
--NR.sup.14S(O.sub.2)R.sup.14;
[0032] R.sup.9, at each occurrence, is independently selected from
hydrogen, alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, aryl,
arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and
heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl,
heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl may
each be optionally substituted with 0-5 R.sup.8a, and the
heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl
each contain 1-4 heteroatoms selected from N, O and S;
[0033] R.sup.9a, at each occurrence, is independently selected from
alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl,
cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl,
heterocyclylalkyl, halo, --NH.sub.2, --CN, --NO.sub.2,
--C(.dbd.O)OH, --C(.dbd.O)OR.sup.14, --OCF.sub.3, --OCHF.sub.2,
--OR.sup.14, --OH, --SH, --SR.sup.14, --S(O).sub.3H,
--P(O).sub.3H.sub.2, --C(.dbd.O)NR.sup.14R.sup.14,
--NR.sup.14R.sup.14,
--S(O).sub.2NR.sup.14R.sup.14, --NR.sup.14S(O).sub.2CF.sub.3,
--C(.dbd.O)NR.sup.14S(O).sub.2R.sup.10,
--S(O).sub.2NR.sup.14C(.dbd.O)OR.sup.10,
--S(O).sub.2NR.sup.14C(.dbd.O)NR.sup.14R.sup.14,
--C(.dbd.O)NR.sup.14S(O).sub.2CF.sub.3, --C(.dbd.O)R.sup.14,
--NR.sup.14C(.dbd.O)H, --NR.sup.14C(.dbd.O)R.sup.14,
--OC(.dbd.O)R.sup.14, --C(.dbd.NR.sup.14)NR.sup.14R.sup.14,
--NHC(.dbd.NR.sup.14)NR.sup.14R.sup.14, --S(.dbd.O)R.sup.14,
--S(O).sub.2R.sup.14, --NR.sup.14C(.dbd.O)OR.sup.14,
--NR.sup.14S(O.sub.2)R.sup.14, .dbd.O and arylalkyl;
[0034] R.sup.10, at each occurrence, is independently selected from
alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl,
heteroarylalkyl, heterocyclyl and heterocyclylalkyl, wherein the
cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,
heterocyclyl and heterocyclylalkyl may each be optionally
substituted with 0-3 R.sup.10a, and the heteroaryl,
heteroarylalkyl, heterocyclyl and heterocyclylalkyl each contain
1-4 heteroatoms selected from N, O and S;
[0035] R.sup.10a, at each occurrence, is independently selected
from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl,
cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl,
heterocyclylalkyl, halo, --NH.sub.2, --CN, --NO.sub.2,
--C(.dbd.O)OH, --C(.dbd.O)OR.sup.14, --OCF.sub.3, --OCHF.sub.2,
--OR.sup.14, --OH, --SH, --SR.sup.14, --S(O).sub.3H,
--P(O).sub.3H.sub.2, --C(.dbd.O)NR.sup.14R.sup.14,
--NR.sup.14R.sup.14,
--S(O).sub.2NR.sup.14R.sup.14, --NR.sup.14S(O).sub.2CF.sub.3,
--C(.dbd.O)NR.sup.14S(O).sub.2R.sup.9,
--S(O).sub.2NR.sup.14C(.dbd.O)OR.sup.9,
--S(O).sub.2NR.sup.14C(.dbd.O)NR.sup.14R.sup.14,
--C(.dbd.O)NR.sup.14S(O).sub.2CF.sub.3, --C(.dbd.O)R.sup.14,
--NR.sup.14C(.dbd.O)H, --NR.sup.14C(.dbd.O)R.sup.14,
--OC(.dbd.O)R.sup.14, --C(.dbd.NR.sup.14)NR.sup.14R.sup.14,
--NHC(.dbd.NR.sup.14)NR.sup.14R.sup.14, --S(.dbd.O)R.sup.14,
--S(O).sub.2R.sup.14, --NR.sup.14C(.dbd.O)OR.sup.14,
--NR.sup.14S(O.sub.2)R.sup.14 and arylalkyl;
[0036] R.sup.14, at each occurrence, is independently selected from
hydrogen, alkyl, aryl, cycloalkyl, heteroaryl and heterocyclyl;
[0037] R.sub.21 is hydrogen, alkyl, haloalkyl, hydroxyalkyl, aryl,
cycloalkyl, halo, --CN, --C(.dbd.O)OH, --C(.dbd.O)OR.sup.10,
--OCF.sub.3, --OCHF.sub.2, --OR.sup.10, --OH,
--C(.dbd.O)NR.sup.9R.sup.9, --C(.dbd.O)R.sup.10 or
--OC(.dbd.O)R.sup.10;
[0038] T.sub.1 is hydrogen, halo, alkyl, aryl, alkenyl or alkynyl,
wherein the alkyl, aryl, alkenyl and alkynyl may be optionally
substituted with one or more R.sup.6's;
[0039] T.sub.2 is hydrogen, alkyl, aryl, alkenyl or alkynyl,
wherein the alkyl, aryl, alkenyl and alkynyl may be optionally
substituted with one or more R.sup.6's;
[0040] T.sub.3 is hydrogen, alkyl, aryl, alkenyl or alkynyl,
wherein the alkyl, aryl, alkenyl and alkynyl may be optionally
substituted with one or more R.sup.6's; and
[0041] T.sub.4 is hydrogen, halo, alkyl, aryl, alkenyl or alkynyl,
wherein the alkyl, aryl, alkenyl and alkynyl may be optionally
substituted with one or more R.sup.6's;
[0042] provided that when Z is CH and R.sup.1 is a 5- to 6-membered
aryl or heteroaryl, T.sup.1, T.sup.2, T.sup.3, and T.sup.4 can not
all be hydrogen.
[0043] The terms "Formula I" and all embodiments thereof shall
include enantiomers, diastereomers, solvates and salts thereof
(particularly enantiomers, diastereomers and pharmaceutically
acceptable salts thereof).
[0044] In a second embodiment of the first aspect, the present
invention provides a compound of Formula I, or an enantiomer, a
diastereomer, or a pharmaceutically acceptable salt thereof,
wherein R.sup.1 is a 5- or 6-membered aryl, a 5- or 6-membered
arylalkyl or a 5- to 10-membered heteroaryl, any of which may be
optionally substituted with one or more R.sup.6's.
[0045] In a third embodiment of the first aspect, the present
invention provides a compound of Formula I, or an enantiomer, a
diastereomer, or a pharmaceutically acceptable salt thereof,
wherein R.sup.1 is a 5- or 6-membered aryl or a 5- to 10-membered
heteroaryl, both of which may be optionally substituted with one or
more R.sup.6's.
[0046] In a fourth embodiment of the first aspect, the present
invention provides a compound of Formula I, or an enantiomer, a
diastereomer, or a pharmaceutically acceptable salt thereof,
wherein R.sup.1 is 9-membered bicyclic heteroaryl, which may be
optionally substituted with one or more R.sup.6's.
[0047] In a fifth embodiment of the first aspect, the present
invention provides a compound of Formula I, or an enantiomer, a
diastereomer, or a pharmaceutically acceptable salt thereof,
wherein the compound of formula I is a compound of formula
II(y):
##STR00004##
wherein Z, R.sub.1, R.sub.2, R.sub.21, T.sup.3 and T.sup.4 are
defined as set forth above.
[0048] In a sixth embodiment of the first aspect, the present
invention provides a compound of Formula I, or an enantiomer, a
diastereomer, or a pharmaceutically acceptable salt thereof,
wherein the compound of formula I is a compound of formula
II(z):
##STR00005##
wherein Z, R.sub.1, R.sub.2, and R.sub.21 are defined as set forth
above.
[0049] In a seventh embodiment of the first aspect, the present
invention provides a compound of Formula I, or an enantiomer, a
diastereomer, or a pharmaceutically acceptable salt thereof,
wherein:
[0050] Z is CH or N;
[0051] R.sup.1 is aryl, arylalkyl or heteroaryl, any of which may
be optionally substituted with one or more R.sup.6's;
[0052] R.sup.2 is cycloalkyl, aryl, heteroaryl, heterocyclyl,
--S(O).sub.2R.sup.5, --C(.dbd.O)R.sup.5 or --C(.dbd.O)OR.sup.5,
wherein the cycloalkyl, aryl, heteroaryl and heterocyclyl may each
be optionally substituted with one or more R.sup.6's;
[0053] R.sup.5 is alkyl, alkenyl, aryl, cycloalkyl, heteroaryl or
heterocyclyl, each of which may be optionally substituted with one
or more R.sup.6's;
[0054] R.sup.6, at each occurrence, is independently selected from
alkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl,
heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo,
--NH.sub.2, --CN, --NO.sub.2, --C(.dbd.O)OH, --C(.dbd.O)OR.sup.10,
--OCF.sub.3, --OCHF.sub.2, --OR.sup.10, --OH, --SH, --SR.sup.10,
--S(O).sub.3H, --P(O).sub.3H.sub.2, --C(.dbd.O)NR.sup.9R.sup.9,
--NR.sup.9R.sup.9, --S(O).sub.2NR.sup.9R.sup.9,
--NR.sup.9S(O).sub.2CF.sub.3, --C(.dbd.O)NR.sup.9S(O).sub.2R.sup.9,
--S(O).sub.2NR.sup.9C(.dbd.O)OR.sup.9,
--S(O).sub.2NR.sup.9C(.dbd.O)NR.sup.9R.sup.9,
--C(.dbd.O)NR.sup.9S(O).sub.2CF.sub.3, --C(.dbd.O)R.sup.10,
--NR.sup.9C(.dbd.O)H, --NR.sup.9C(.dbd.O)R.sup.10,
--OC(.dbd.O)R.sup.10, --C(.dbd.NR.sup.14)NR.sup.9R.sup.9,
--NHC(.dbd.NR.sup.14)NR.sup.14R.sup.14, --S(.dbd.O)R.sup.10,
--S(O).sub.2R.sup.10 and .dbd.O, wherein the alkyl, alkenyl,
alkynyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl,
heteroarylalkyl, heterocyclyl and heterocyclylalkyl may each be
optionally substituted with 0-5 R.sup.9a;
[0055] R.sup.8a, at each occurrence, is independently selected from
alkyl, haloalkyl, aryl, arylalkyl, alkenyl, alkynyl, cycloalkyl,
cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl,
heterocyclylalkyl, halo, --NH.sub.2, --CN, --NO.sub.2,
--C(.dbd.O)OH, --C(.dbd.O)OR.sup.14, --OCF.sub.3, --OCHF.sub.2,
--OR.sup.14, --OH, --SH, --SR.sup.14, --S(O).sub.3H,
--P(O).sub.3H.sub.2, --C(.dbd.O)NR.sup.14R.sup.14,
--NR.sup.14R.sup.14, --S(O).sub.2NR.sup.14R.sup.14,
--NR.sup.14S(O).sub.2CF.sub.3,
--C(.dbd.O)NR.sup.14S(O).sub.2R.sup.14,
--S(O).sub.2NR.sup.14C(.dbd.O)OR.sup.14,
--S(O).sub.2NR.sup.14C(.dbd.O)NR.sup.14R.sup.14,
--C(.dbd.O)NR.sup.14S(O).sub.2CF.sub.3, --C(.dbd.O)R.sup.14,
--NR.sup.14C(.dbd.O)H, --NR.sup.14C(.dbd.O)R.sup.14,
--OC(.dbd.O)R.sup.14, --C(.dbd.NR.sup.14)NR.sup.14R.sup.14,
--NHC(.dbd.NR.sup.14)NR.sup.14R.sup.14, --S(.dbd.O)R.sup.14,
--S(O).sub.2R.sup.14, .dbd.O, --NR.sup.14C(.dbd.O)OR.sup.14 and
--NR.sup.14S(O.sub.2)R.sup.14;
[0056] R.sup.9, at each occurrence, is independently selected from
hydrogen, alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, aryl,
arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and
heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl,
heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl may
each be optionally substituted with 0-5 R.sup.8a, and the
heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl
each contain 1-4 heteroatoms selected from N, O and S;
[0057] R.sup.9a, at each occurrence, is independently selected from
alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl,
cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl,
heterocyclylalkyl, halo, --NH.sub.2, --CN, --NO.sub.2,
--C(.dbd.O)OH, --C(.dbd.O)OR.sup.14, --OCF.sub.3, --OCHF.sub.2,
--OR.sup.14, --OH, --SH, --SR.sup.14, --S(O).sub.3H,
--P(O).sub.3H.sub.2, --C(.dbd.O)NR.sup.14R.sup.14,
--NR.sup.14R.sup.14,
--S(O).sub.2NR.sup.14R.sup.14, --NR.sup.14S(O).sub.2CF.sub.3,
--C(.dbd.O)NR.sup.14S(O).sub.2R.sup.10,
--S(O).sub.2NR.sup.14C(.dbd.O)OR.sup.10,
--S(O).sub.2NR.sup.14C(.dbd.O)NR.sup.14R.sup.14,
--C(.dbd.O)NR.sup.14S(O).sub.2CF.sub.3, --C(.dbd.O)R.sup.14,
--NR.sup.14C(.dbd.O)H, --NR.sup.14C(.dbd.O)R.sup.14,
--OC(.dbd.O)R.sup.14, --C(.dbd.NR.sup.14)NR.sup.14R.sup.14,
--NHC(.dbd.NR.sup.14)NR.sup.14R.sup.14, --S(.dbd.O)R.sup.14,
--S(O).sub.2R.sup.14, --NR.sup.14C(.dbd.O)OR.sup.14,
--NR.sup.14S(O.sub.2)R.sup.14, .dbd.O and arylalkyl;
[0058] R.sup.10, at each occurrence, is independently selected from
alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl,
heteroarylalkyl, heterocyclyl and heterocyclylalkyl, wherein the
cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,
heterocyclyl and heterocyclylalkyl may each be optionally
substituted with 0-3 R.sup.10a, and the heteroaryl,
heteroarylalkyl, heterocyclyl and heterocyclylalkyl each contain
1-4 heteroatoms selected from N, O and S;
[0059] R.sup.10a, at each occurrence, is independently selected
from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl,
cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl,
heterocyclylalkyl, halo, --NH.sub.2, --CN, --NO.sub.2,
--C(.dbd.O)OH, --C(.dbd.O)OR.sup.14, --OCF.sub.3, --OCHF.sub.2,
--OR.sup.14, --OH, --SH, --SR.sup.14, --S(O).sub.3H,
--P(O).sub.3H.sub.2, --C(.dbd.O)NR.sup.14R.sup.14,
--NR.sup.14R.sup.14,
--S(O).sub.2NR.sup.14R.sup.14, --NR.sup.14S(O).sub.2CF.sub.3,
--C(.dbd.O)NR.sup.14S(O).sub.2R.sup.9,
--S(O).sub.2NR.sup.14C(.dbd.O)OR.sup.9,
--S(O).sub.2NR.sup.14C(.dbd.O)NR.sup.14R.sup.14,
--C(.dbd.O)NR.sup.14S(O).sub.2CF.sub.3, --C(.dbd.O)R.sup.14,
--NR.sup.14C(.dbd.O)H, --NR.sup.14C(.dbd.O)R.sup.14,
--OC(.dbd.O)R.sup.14, --C(.dbd.NR.sup.14)NR.sup.14R.sup.14,
--NHC(.dbd.NR.sup.14)NR.sup.14R.sup.14, --S(.dbd.O)R.sup.14,
--S(O).sub.2R.sup.14, --NR.sup.14C(.dbd.O)OR.sup.14,
--NR.sup.14S(O.sub.2)R.sup.14 and arylalkyl;
[0060] R.sup.14, at each occurrence, is independently selected from
hydrogen, alkyl, aryl, cycloalkyl, heteroaryl and heterocyclyl;
[0061] R.sub.21 is hydrogen, alkyl, haloalkyl, hydroxyalkyl, aryl,
cycloalkyl, halo, --CN, --C(.dbd.O)OH, --C(.dbd.O)OR.sup.10,
--OCF.sub.3, --OR.sup.10, --OH, --C(.dbd.O)NR.sup.9R.sup.9,
--C(.dbd.O)R.sup.10 or --OC(.dbd.O)R.sup.10,
[0062] T.sub.1 is hydrogen, alkyl, aryl, alkenyl or alkynyl,
wherein the alkyl, aryl, alkenyl and alkynyl may be optionally
substituted with one or more R.sup.6's;
[0063] T.sub.2 is hydrogen, alkyl, aryl, alkenyl or alkynyl,
wherein the alkyl, aryl, alkenyl and alkynyl may be optionally
substituted with one or more R.sup.6's;
[0064] T.sub.3 is hydrogen, alkyl, aryl, alkenyl or alkynyl,
wherein the alkyl, aryl, alkenyl and alkynyl may be optionally
substituted with one or more R.sup.6's; and
[0065] T.sub.4 is hydrogen, alkyl, aryl, alkenyl or alkynyl,
wherein the alkyl, aryl, alkenyl and alkynyl may be optionally
substituted with one or more R.sup.6's.
[0066] In an eighth embodiment of the first aspect, the present
invention provides a compound of Formula I, or an enantiomer, a
diastereomer, or a pharmaceutically acceptable salt thereof,
wherein:
[0067] Z is CH or N;
[0068] R.sup.1 is aryl, arylalkyl or heteroaryl, any of which may
be optionally substituted with one or more R.sup.6's;
[0069] R.sup.2 is cycloalkyl, aryl, heteroaryl, heterocyclyl,
--C(.dbd.O)R.sup.5 or --C(.dbd.O)OR.sup.5, wherein the cycloalkyl,
aryl, heteroaryl and heterocyclyl may each be optionally
substituted with one or more R.sup.6's;
[0070] R.sup.5 is alkyl, aryl, cycloalkyl, heteroaryl or
heterocyclyl, each of which may be optionally substituted with one
or more R.sup.6's;
[0071] R.sup.6, at each occurrence, is independently selected from
alkyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl,
heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, --NH.sub.2,
--CN, --NO.sub.2, --C(.dbd.O)OH, --C(.dbd.O)OR.sup.10, --OCF.sub.3,
--OCHF.sub.2, --OR.sup.10, --OH, --SH, --SR.sup.10, --S(O).sub.3H,
--P(O).sub.3H.sub.2, --C(.dbd.O)NR.sup.9R.sup.9, --NR.sup.9R.sup.9,
--S(O).sub.2NR.sup.9R.sup.9, --NR.sup.9S(O).sub.2CF.sub.3,
--C(.dbd.O)NR.sup.9S(O).sub.2R.sup.9,
--S(O).sub.2NR.sup.9C(.dbd.O)OR.sup.9,
--S(O).sub.2NR.sup.9C(.dbd.O)NR.sup.9R.sup.9,
--C(.dbd.O)NR.sup.9S(O).sub.2CF.sub.3, --C(.dbd.O)R.sup.10,
--NR.sup.9C(.dbd.O)H, --NR.sup.9C(.dbd.O)R.sup.10,
--OC(.dbd.O)R.sup.10, --C(.dbd.NR.sup.14)NR.sup.9R.sup.9,
--NHC(.dbd.NR.sup.14)NR.sup.14R.sup.14, --S(.dbd.O)R.sup.10,
--S(O).sub.2R.sup.10 and .dbd.O, wherein the alkyl, aryl,
cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl,
heterocyclyl and heterocyclylalkyl may each be optionally
substituted with 0-5 R.sup.9a;
[0072] R.sup.8a, at each occurrence, is independently selected from
alkyl, haloalkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl,
heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo,
--NH.sub.2, --CN, --NO.sub.2, --C(.dbd.O)OH, --C(.dbd.O)OR.sup.14,
--OCF.sub.3, --OCHF.sub.2, --OR.sup.14, --OH, --SH, --SR.sup.14,
--S(O).sub.3H, --P(O).sub.3H.sub.2, --C(.dbd.O)NR.sup.14R.sup.14,
--NR.sup.14R.sup.14, --S(O).sub.2NR.sup.14R.sup.14,
--NR.sup.14S(O).sub.2CF.sub.3,
--C(.dbd.O)NR.sup.14S(O).sub.2R.sup.14,
--S(O).sub.2NR.sup.14C(.dbd.O)OR.sup.14,
--S(O).sub.2NR.sup.14C(.dbd.O)NR.sup.14R.sup.14,
--C(.dbd.O)NR.sup.14S(O).sub.2CF.sub.3, --C(.dbd.O)R.sup.14,
--NR.sup.14C(.dbd.O)OR.sup.14, --NR.sup.14C(.dbd.O)R.sup.14,
--OC(.dbd.O)R.sup.14, --C(.dbd.NR.sup.14)NR.sup.14R.sup.14,
--NHC(.dbd.NR.sup.14)NR.sup.14R.sup.14, --S(.dbd.O)R.sup.14,
--S(O).sub.2R.sup.14, .dbd.O, --NR.sup.14C(.dbd.O)OR.sup.14 and
--NR.sup.14S(O.sub.2)R.sup.14;
[0073] R.sup.9, at each occurrence, is independently selected from
hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl,
heteroarylalkyl, heterocyclyl and heterocyclylalkyl, wherein the
alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,
heterocyclyl and heterocyclylalkyl may each be optionally
substituted with 0-5 R.sup.8a, and the heteroaryl, heteroarylalkyl,
heterocyclyl and heterocyclylalkyl each contain 1-4 heteroatoms
selected from N, O and S;
[0074] R.sup.9a, at each occurrence, is independently selected from
alkyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl,
heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, --NH.sub.2,
--CN, --NO.sub.2, --C(.dbd.O)OH, --C(.dbd.O)OR.sup.14, --OCF.sub.3,
--OCHF.sub.2, --OR.sup.14, --OH, --SH, --SR.sup.14, --S(O).sub.3H,
--P(O).sub.3H.sub.2, --C(.dbd.O)NR.sup.14R.sup.14,
--NR.sup.14R.sup.14, --S(O).sub.2NR.sup.14R.sup.14,
--NR.sup.14S(O).sub.2CF.sub.3,
--C(.dbd.O)NR.sup.14S(O).sub.2R.sup.10,
--S(O).sub.2NR.sup.14C(.dbd.O)OR.sup.10,
--S(O).sub.2NR.sup.14C(.dbd.O)NR.sup.14R.sup.14,
--C(.dbd.O)NR.sup.14S(O).sub.2CF.sub.3, --C(.dbd.O)R.sup.14,
--NR.sup.14C(.dbd.O)H, --NR.sup.14C(.dbd.O)R.sup.14,
--OC(.dbd.O)R.sup.14, --C(.dbd.NR.sup.14)NR.sup.14R.sup.14,
--NHC(.dbd.NR.sup.14)NR.sup.14R.sup.14, --S(.dbd.O)R.sup.14,
--S(O).sub.2R.sup.14, --NR.sup.14C(.dbd.O)OR.sup.14,
--NR.sup.14S(O.sub.2)R.sup.14, .dbd.O and arylalkyl;
[0075] R.sup.10, at each occurrence, is independently selected from
alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,
heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl,
arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and
heterocyclylalkyl may each be optionally substituted with 0-3
R.sup.10a, and the heteroaryl, heteroarylalkyl, heterocyclyl and
heterocyclylalkyl each contain 1-4 heteroatoms selected from N, O
and S;
[0076] R.sup.10a, at each occurrence, is independently selected
from alkyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl,
heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo,
--NH.sub.2, --CN, --NO.sub.2, --C(.dbd.O)OH, --C(.dbd.O)OR.sup.14,
--OCF.sub.3, --OCHF.sub.2, --OR.sup.14, --OH, --SH, --SR.sup.14,
--S(O).sub.3H, --P(O).sub.3H.sub.2, --C(.dbd.O)NR.sup.14R.sup.14,
--NR.sup.14R.sup.14, --S(O).sub.2NR.sup.14R.sup.14,
--NR.sup.14S(O).sub.2CF.sub.3,
--C(.dbd.O)NR.sup.14S(O).sub.2R.sup.9,
--S(O).sub.2NR.sup.14C(.dbd.O)OR.sup.9,
--S(O).sub.2NR.sup.14C(.dbd.O)NR.sup.14R.sup.14,
--C(.dbd.O)NR.sup.14S(O).sub.2CF.sub.3, --C(.dbd.O)R.sup.14,
--NR.sup.14C(.dbd.O)OR.sup.14, --NR.sup.14C(.dbd.O)R.sup.14,
--OC(.dbd.O)R.sup.14, --C(.dbd.NR.sup.14)NR.sup.14R.sup.14,
--NHC(.dbd.NR.sup.14)NR.sup.14R.sup.14, --S(.dbd.O)R.sup.14,
--S(O).sub.2R.sup.14, --NR.sup.14C(.dbd.O)OR.sup.14,
--NR.sup.14S(O.sub.2)R.sup.14 and arylalkyl;
[0077] R.sup.14, at each occurrence, is independently selected from
hydrogen, alkyl, aryl, cycloalkyl, heteroaryl and heterocyclyl;
[0078] R.sub.21 is hydrogen, alkyl, haloalkyl, hydroxyalkyl, aryl,
cycloalkyl, halo, --CN, --C(.dbd.O)OH, --C(.dbd.O)OR.sup.10,
--OCF.sub.3, --OR.sup.10, --OH, --C(.dbd.O)NR.sup.9R.sup.9 or
--C(.dbd.O)R.sup.10;
[0079] T.sub.1 is hydrogen, alkyl or aryl, wherein the alkyl or
aryl may be optionally substituted with one or more R.sup.6's;
[0080] T.sub.2 is hydrogen, alkyl or aryl, wherein the alkyl or
aryl may be optionally substituted with one or more R.sup.6's;
[0081] T.sub.3 is hydrogen, alkyl or aryl, wherein the alkyl or
aryl may be optionally substituted with one or more R.sup.6's;
and
[0082] T.sub.4 is hydrogen, alkyl or aryl, wherein the alkyl or
aryl may be optionally substituted with one or more R.sup.6's.
[0083] In a ninth embodiment of the first aspect, the present
invention provides a compound of Formula I, or an enantiomer, a
diastereomer, or a pharmaceutically acceptable salt thereof,
wherein:
[0084] Z is CH or N;
[0085] R.sup.1 is aryl, arylalkyl or heteroaryl, any of which may
be optionally substituted with one or more R.sup.6's;
[0086] R.sup.2 is aryl, heteroaryl, heterocyclyl,
--C(.dbd.O)R.sup.5 or --C(.dbd.O)OR.sup.5, wherein the aryl,
heteroaryl and heterocyclyl may each be optionally substituted with
one or more R.sup.6's;
[0087] R.sup.5 is alkyl, aryl, cycloalkyl or heteroaryl, each of
which may be optionally substituted with one or more R.sup.6's;
[0088] R.sup.6, at each occurrence, is independently selected from
alkyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl,
heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, --NH.sub.2,
--CN, --NO.sub.2, --C(.dbd.O)OH, --C(.dbd.O)OR.sup.10, --OCF.sub.3,
--OCHF.sub.2, --OR.sup.10, --OH, --SH, --SR.sup.10,
--C(.dbd.O)NR.sup.9R.sup.9, --NR.sup.9R.sup.9,
--S(O).sub.2NR.sup.9R.sup.9, --NR.sup.9S(O).sub.2CF.sub.3,
--C(.dbd.O)NR.sup.9S(O).sub.2R.sup.9,
--S(O).sub.2NR.sup.9C(.dbd.O)OR.sup.9,
--S(O).sub.2NR.sup.9C(.dbd.O)NR.sup.9R.sup.9,
--C(.dbd.O)NR.sup.9S(O).sub.2CF.sub.3, --C(.dbd.O)R.sup.10,
--NR.sup.9C(.dbd.O)H, --NR.sup.9C(.dbd.O)R.sup.10,
--OC(.dbd.O)R.sup.10, --C(.dbd.NR.sup.14)NR.sup.9R.sup.9,
--NHC(.dbd.NR.sup.14)NR.sup.14R.sup.14, --S(.dbd.O)R.sup.10,
--S(O).sub.2R.sup.10 and .dbd.O, wherein the alkyl, aryl,
cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl,
heterocyclyl and heterocyclylalkyl may each be optionally
substituted with 0-5 R.sup.9a;
[0089] R.sup.8a, at each occurrence, is independently selected from
alkyl, haloalkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl,
heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo,
--NH.sub.2, --CN, --NO.sub.2, --C(.dbd.O)OH, --C(.dbd.O)OR.sup.14,
--OCF.sub.3, --OCHF.sub.2, --OR.sup.14, --OH, --SH, --SR.sup.14,
--C(.dbd.O)NR.sup.14R.sup.14, --NR.sup.14R.sup.14,
--S(O).sub.2NR.sup.14R.sup.14, --NR.sup.14S(O).sub.2CF.sub.3,
--C(.dbd.O)NR.sup.14S(O).sub.2R.sup.14,
--S(O).sub.2NR.sup.14C(.dbd.O)OR.sup.14,
--S(O).sub.2NR.sup.14C(.dbd.O)NR.sup.14R.sup.14,
--C(.dbd.O)NR.sup.14S(O).sub.2CF.sub.3, --C(.dbd.O)R.sup.14,
--NR.sup.14C(.dbd.O)H, --NR.sup.14C(.dbd.O)R.sup.14,
--OC(.dbd.O)R.sup.14, --C(.dbd.NR.sup.14)NR.sup.14R.sup.14,
--NHC(.dbd.NR.sup.14)NR.sup.14R.sup.14, --S(.dbd.O)R.sup.14,
--S(O).sub.2R.sup.14, .dbd.O, --NR.sup.14C(.dbd.O)OR.sup.14 and
--NR.sup.14S(O.sub.2)R.sup.14;
[0090] R.sup.9, at each occurrence, is independently selected from
hydrogen, alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl,
heteroarylalkyl, heterocyclyl and heterocyclylalkyl, wherein the
alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,
heterocyclyl and heterocyclylalkyl may each be optionally
substituted with 0-5 R.sup.8a, and the heteroaryl, heteroarylalkyl,
heterocyclyl and heterocyclylalkyl each contain 1-4 heteroatoms
selected from N, O and S;
[0091] R.sup.9a, at each occurrence, is independently selected from
alkyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl,
heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, --NH.sub.2,
--CN, --NO.sub.2, --C(.dbd.O)OH, --C(.dbd.O)OR.sup.14, --OCF.sub.3,
--OCHF.sub.2, --OR.sup.14, --OH, --SH, --SR.sup.14,
--C(.dbd.O)NR.sup.14R.sup.14, --NR.sup.14R.sup.14,
--S(O).sub.2NR.sup.14R.sup.14, --NR.sup.14S(O).sub.2CF.sub.3,
--C(.dbd.O)NR.sup.14S(O).sub.2R.sup.10,
--S(O).sub.2NR.sup.14C(.dbd.O)OR.sup.10,
--S(O).sub.2NR.sup.14C(.dbd.O)NR.sup.14R.sup.14,
--C(.dbd.O)NR.sup.14S(O).sub.2CF.sub.3, --C(.dbd.O)R.sup.14,
--NR.sup.14C(.dbd.O)H, --NR.sup.14C(.dbd.O)R.sup.14,
--OC(.dbd.O)R.sup.14, --C(.dbd.NR.sup.14)NR.sup.14R.sup.14,
--NHC(.dbd.NR.sup.14)NR.sup.14R.sup.14, --S(.dbd.O)R.sup.14,
--S(O).sub.2R.sup.14, --NR.sup.14C(.dbd.O)OR.sup.14,
--NR.sup.14S(O.sub.2)R.sup.14, .dbd.O and arylalkyl;
[0092] R.sup.10, at each occurrence, is independently selected from
alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl and
heterocyclyl, wherein the cycloalkyl, aryl, arylalkyl, heteroaryl,
heteroarylalkyl and heterocyclyl may each be optionally substituted
with 0-3 R.sup.10a, and the heteroaryl, heteroarylalkyl and
heterocyclyl each contain 1-4 heteroatoms selected from N, O and
S;
[0093] R.sup.10a, at each occurrence, is independently selected
from alkyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl,
heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo,
--NH.sub.2, --CN, --NO.sub.2, --C(.dbd.O)OH, --C(.dbd.O)OR.sup.14,
--OCF.sub.3, --OCHF.sub.2, --OR.sup.14, --OH, --SH, --SR.sup.14,
--C(.dbd.O)NR.sup.14R.sup.14, --NR.sup.14R.sup.14,
--S(O).sub.2NR.sup.14R.sup.14, --NR.sup.14S(O).sub.2CF.sub.3,
--C(.dbd.O)NR.sup.14S(O).sub.2R.sup.9,
--S(O).sub.2NR.sup.14C(.dbd.O)OR.sup.9,
--S(O).sub.2NR.sup.14C(.dbd.O)NR.sup.14R.sup.14,
--C(.dbd.O)NR.sup.14S(O).sub.2CF.sub.3--C(.dbd.O)R.sup.14,
--NR.sup.14C(.dbd.O)H, --NR.sup.14C(.dbd.O)R.sup.14,
--OC(.dbd.O)R.sup.14, --C(.dbd.NR.sup.14)NR.sup.14R.sup.14,
--NHC(.dbd.NR.sup.14)NR.sup.14R.sup.14, --S(.dbd.O)R.sup.14,
--S(O).sub.2R.sup.14, --NR.sup.14C(.dbd.O)OR.sup.14,
--NR.sup.14S(O.sub.2)R.sup.14 and arylalkyl;
[0094] R.sup.14, at each occurrence, is independently selected from
hydrogen, alkyl, aryl, cycloalkyl and heteroaryl;
[0095] R.sub.21 is hydrogen, alkyl, haloalkyl, hydroxyalkyl, aryl,
cycloalkyl, halo, --CN, --C(.dbd.O)OH, --C(.dbd.O)OR.sup.10,
--OR.sup.10, --C(.dbd.O)NR.sup.9R.sup.9 or --C(.dbd.O)R.sup.10;
[0096] T.sub.1 is hydrogen or alkyl, wherein the alkyl may be
optionally substituted with one or more R.sup.6's;
[0097] T.sub.2 is hydrogen or alkyl, wherein the alkyl may be
optionally substituted with one or more R.sup.6's;
[0098] T.sub.3 is hydrogen, alkyl or aryl, wherein the alkyl or
aryl may be optionally substituted with one or more R.sup.6's;
and
[0099] T.sub.4 is hydrogen or alkyl, wherein the alkyl may be
optionally substituted with one or more R.sup.6's.
[0100] In a tenth embodiment of the first aspect, the present
invention provides a compound of Formula I, or an enantiomer, a
diastereomer, or a pharmaceutically acceptable salt thereof,
wherein:
[0101] Z is CH or N;
[0102] R.sup.1 is aryl, arylalkyl or heteroaryl, any of which may
be optionally substituted with one or more R.sup.6's;
[0103] R.sup.2 is aryl, heteroaryl, --C(.dbd.O)R.sup.5 or
--C(.dbd.O)OR.sup.5, wherein the aryl and heteroaryl may each be
optionally substituted with one or more R.sup.6's;
[0104] R.sup.5 is alkyl, aryl or heteroaryl, each of which may be
optionally substituted with one or more R.sup.6's;
[0105] R.sup.6, at each occurrence, is independently selected from
alkyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl,
heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, --NH.sub.2,
--CN, --NO.sub.2, --C(.dbd.O)OH, --C(.dbd.O)OR.sup.10, --OCF.sub.3,
--OCHF.sub.2, --OR.sup.10, --OH, --SH, --SR.sup.10,
--C(.dbd.O)NR.sup.9R.sup.9, --NR.sup.9R.sup.9,
--S(O).sub.2NR.sup.9R.sup.9, --NR.sup.9S(O).sub.2CF.sub.3,
--C(.dbd.O)NR.sup.9S(O).sub.2R.sup.9,
--S(O).sub.2NR.sup.9C(.dbd.O)OR.sup.9,
--S(O).sub.2NR.sup.9C(.dbd.O)NR.sup.9R.sup.9,
--C(.dbd.O)NR.sup.9S(O).sub.2CF.sub.3, --C(.dbd.O)R.sup.10,
--NR.sup.9C(.dbd.O)H, --NR.sup.9C(.dbd.O)R.sup.10,
--OC(.dbd.O)R.sup.10, --S(.dbd.O)R.sup.10, --S(O).sub.2R.sup.10 and
.dbd.O, wherein the alkyl, aryl, cycloalkyl, cycloalkylalkyl,
heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl may
each be optionally substituted with 0-5 R.sup.9a;
[0106] R.sup.8a, at each occurrence, is independently selected from
alkyl, haloalkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl,
heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo,
--NH.sub.2, --CN, --NO.sub.2, --C(.dbd.O)OH, --C(.dbd.O)OR.sup.14,
--OCF.sub.3, --OCHF.sub.2, --OR.sup.14, --OH, --SH, --SR.sup.14,
--C(.dbd.O)NR.sup.14R.sup.14, --NR.sup.14R.sup.14,
--S(O).sub.2NR.sup.14R.sup.14, --NR.sup.14S(O).sub.2CF.sub.3,
--C(.dbd.O)NR.sup.14S(O).sub.2R.sup.14,
--S(O).sub.2NR.sup.14C(.dbd.O)OR.sup.14,
--S(O).sub.2NR.sup.14C(.dbd.O)NR.sup.14R.sup.14,
--C(.dbd.O)NR.sup.14S(O).sub.2CF.sub.3, --C(.dbd.O)R.sup.14,
--NR.sup.14C(.dbd.O)H, --NR.sup.14C(.dbd.O)R.sup.14,
--OC(.dbd.O)R.sup.14, --S(.dbd.O)R.sup.14, --S(O).sub.2R.sup.14,
.dbd.O, --NR.sup.14C(.dbd.O)OR.sup.14 and
--NR.sup.14S(O.sub.2)R.sup.14;
[0107] R.sup.9, at each occurrence, is independently selected from
hydrogen, alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl,
heteroarylalkyl and heterocyclyl, wherein the alkyl, cycloalkyl,
aryl, arylalkyl, heteroaryl, heteroarylalkyl and heterocyclyl may
each be optionally substituted with 0-5 R.sup.8a, and the
heteroaryl, heteroarylalkyl and heterocyclyl each contain 1-4
heteroatoms selected from N, O and S;
[0108] R.sup.9a, at each occurrence, is independently selected from
alkyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl,
heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, --NH.sub.2,
--CN, --NO.sub.2, --C(.dbd.O)OH, --C(.dbd.O)OR.sup.14, --OCF.sub.3,
--OCHF.sub.2, --OR.sup.14, --OH, --SH, --SR.sup.14,
--C(.dbd.O)NR.sup.14R.sup.14, --NR.sup.14R.sup.14,
--S(O).sub.2NR.sup.14R.sup.14, --NR.sup.14S(O).sub.2CF.sub.3,
--C(.dbd.O)NR.sup.14S(O).sub.2R.sup.10,
--S(O).sub.2NR.sup.14C(.dbd.O)OR.sup.10,
--S(O).sub.2NR.sup.14C(.dbd.O)NR.sup.14R.sup.14,
--C(.dbd.O)NR.sup.14S(O).sub.2CF.sub.3, --C(.dbd.O)R.sup.14,
--NR.sup.14C(.dbd.O)H, --NR.sup.14C(.dbd.O)R.sup.14,
--OC(.dbd.O)R.sup.14, --S(.dbd.O)R.sup.14, --S(O).sub.2R.sup.14,
--NR.sup.14C(.dbd.O)OR.sup.14, --NR.sup.14S(O.sub.2)R.sup.14,
.dbd.O and arylalkyl;
[0109] R.sup.10, at each occurrence, is independently selected from
alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl and heterocyclyl,
wherein the cycloalkyl, aryl, arylalkyl, heteroaryl and
heterocyclyl may each be optionally substituted with 0-3 R.sup.10a,
and the heteroaryl and heterocyclyl each contain 1-4 heteroatoms
selected from N, O and S;
[0110] R.sup.10a, at each occurrence, is independently selected
from alkyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl,
heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo,
--NH.sub.2, --CN, --NO.sub.2, --C(.dbd.O)OH, --C(.dbd.O)OR.sup.14,
--OCF.sub.3, --OCHF.sub.2, --OR.sup.14, --OH, --SH, --SR.sup.14,
--C(.dbd.O)NR.sup.14R.sup.14, --NR.sup.14R.sup.14,
--S(O).sub.2NR.sup.14R.sup.14, --NR.sup.14S(O).sub.2CF.sub.3,
--C(.dbd.O)NR.sup.14S(O).sub.2R.sup.9,
--S(O).sub.2NR.sup.14C(.dbd.O)OR.sup.9,
--S(O).sub.2NR.sup.14C(.dbd.O)NR.sup.14R.sup.14,
--C(.dbd.O)NR.sup.14S(O).sub.2CF.sub.3, --C(.dbd.O)R.sup.14,
--NR.sup.14C(.dbd.O)H, --NR.sup.14C(.dbd.O)R.sup.14,
--OC(.dbd.O)R.sup.14, --S(.dbd.O)R.sup.14, --S(O).sub.2R.sup.14,
--NR.sup.14C(.dbd.O)OR.sup.14, --NR.sup.14S(O.sub.2)R.sup.14 and
arylalkyl;
[0111] R.sup.14, at each occurrence, is independently selected from
hydrogen, alkyl, aryl, cycloalkyl and heteroaryl;
[0112] R.sub.21 is hydrogen, alkyl, haloalkyl, hydroxyalkyl, aryl,
halo, --CN, --C(.dbd.O)OH, --C(.dbd.O)OR.sup.10, --OR.sup.10,
--C(.dbd.O)NR.sup.9R.sup.9 or --C(.dbd.O)R.sup.10;
[0113] T.sub.1 and T.sub.2 are hydrogen;
[0114] T.sub.3 is hydrogen, alkyl or aryl, wherein the alkyl or
aryl may be optionally substituted with one or more R.sup.6's;
and
[0115] T.sub.4 is hydrogen, alkyl or aryl, wherein the alkyl or
aryl may be optionally substituted with one or more R.sup.6's.
[0116] In an eleventh embodiment of the first aspect, the present
invention provides a compound of Formula I, or an enantiomer, a
diastereomer, or a pharmaceutically acceptable salt thereof,
wherein:
[0117] Z is CH or N;
[0118] R.sup.1 is aryl, arylalkyl or heteroaryl, any of which may
be optionally substituted with one or more R.sup.6's;
[0119] R.sup.2 is aryl, heteroaryl or --C(.dbd.O)OR.sup.5, wherein
the aryl and heteroaryl may each be optionally substituted with one
or more R.sup.6's;
[0120] R.sup.5 is alkyl, aryl or heteroaryl, each of which may be
optionally substituted with one or more R.sup.6's;
[0121] R.sup.6, at each occurrence, is independently selected from
alkyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl,
heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, --NH.sub.2,
--CN, --NO.sub.2, --C(.dbd.O)OH, --C(.dbd.O)OR.sup.10, --OCF.sub.3,
--OCHF.sub.2, --OR.sup.10, --OH, --SH, --SR.sup.10,
--C(.dbd.O)NR.sup.9R.sup.9, --NR.sup.9R.sup.9,
--S(O).sub.2NR.sup.9R.sup.9, --NR.sup.9S(O).sub.2CF.sub.3,
--C(.dbd.O)NR.sup.9S(O).sub.2R.sup.9,
--S(O).sub.2NR.sup.9C(.dbd.O)OR.sup.9, --C(.dbd.O)R.sup.10,
--NR.sup.9C(.dbd.O)H, --NR.sup.9C(.dbd.O)R.sup.10,
--OC(.dbd.O)R.sup.10, --S(.dbd.O)R.sup.10, --S(O).sub.2R.sup.10 and
.dbd.O, wherein the alkyl, aryl, cycloalkyl, cycloalkylalkyl,
heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl may
each be optionally substituted with 0-5 R.sup.9a;
[0122] R.sup.8a, at each occurrence, is independently selected from
alkyl, haloalkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl,
heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo,
--NH.sub.2, --CN, --NO.sub.2, --C(.dbd.O)OH, --C(.dbd.O)OR.sup.14,
--OCF.sub.3, --OCHF.sub.2, --OR.sup.14, --OH, --SH, --SR.sup.14,
--C(.dbd.O)NR.sup.14R.sup.14, --NR.sup.14R.sup.14,
--S(O).sub.2NR.sup.14R.sup.14, --NR.sup.14S(O).sub.2CF.sub.3,
--C(.dbd.O)NR.sup.14S(O).sub.2R.sup.14,
--S(O).sub.2NR.sup.14C(.dbd.O)OR.sup.14, --C(.dbd.O)R.sup.14,
--NR.sup.14C(.dbd.O)H, --NR.sup.14C(.dbd.O)R.sup.14,
--OC(.dbd.O)R.sup.14, --S(.dbd.O)R.sup.14, --S(O).sub.2R.sup.14,
.dbd.O, --NR.sup.14C(.dbd.O)OR.sup.14 and
--NR.sup.14S(O.sub.2)R.sup.14;
[0123] R.sup.9, at each occurrence, is independently selected from
hydrogen, alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl and
heterocyclyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl,
heteroaryl, and heterocyclyl may each be optionally substituted
with 0-5 R.sup.8a, and the heteroaryl and heterocyclyl each contain
1-4 heteroatoms selected from N, O and S;
[0124] R.sup.9a, at each occurrence, is independently selected from
alkyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl,
heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, --NH.sub.2,
--CN, --NO.sub.2, --C(.dbd.O)OH, --C(.dbd.O)OR.sup.14, --OCF.sub.3,
--OCHF.sub.2, --OR.sup.14, --OH, --SH, --SR.sup.14,
--C(.dbd.O)NR.sup.14R.sup.14, --NR.sup.14R.sup.14,
--S(O).sub.2NR.sup.14R.sup.14, --NR.sup.14S(O).sub.2CF.sub.3,
--C(.dbd.O)NR.sup.14S(O).sub.2R.sup.10,
--S(O).sub.2NR.sup.14C(.dbd.O)OR.sup.10, --C(.dbd.O)R.sup.14,
--NR.sup.14C(.dbd.O)H, --NR.sup.14C(.dbd.O)R.sup.14,
--OC(.dbd.O)R.sup.14, --S(.dbd.O)R.sup.14, --S(O).sub.2R.sup.14,
--NR.sup.14C(.dbd.O)OR.sup.14, --NR.sup.14S(O.sub.2)R.sup.14,
.dbd.O and arylalkyl;
[0125] R.sup.10, at each occurrence, is independently selected from
alkyl, cycloalkyl, aryl, heteroaryl and heterocyclyl, wherein the
cycloalkyl, aryl, heteroaryl and heterocyclyl may each be
optionally substituted with 0-3 R.sup.10a, and the heteroaryl and
heterocyclyl each contain 1-4 heteroatoms selected from N, O and
S;
[0126] R.sup.10a, at each occurrence, is independently selected
from alkyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl,
heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo,
--NH.sub.2, --CN, --NO.sub.2, --C(.dbd.O)OH, --C(.dbd.O)OR.sup.14,
--OCF.sub.3, --OCHF.sub.2, --OR.sup.14, --OH, --SH, --SR.sup.14,
--C(.dbd.O)NR.sup.14R.sup.14, --NR.sup.14R.sup.14,
--S(O).sub.2NR.sup.14R.sup.14, --NR.sup.14S(O).sub.2CF.sub.3,
--C(.dbd.O)NR.sup.14S(O).sub.2R.sup.9,
--S(O).sub.2NR.sup.14C(.dbd.O)OR.sup.9, --C(.dbd.O)R.sup.14,
--NR.sup.14C(.dbd.O)H, --NR.sup.14C(.dbd.O)R.sup.14,
--OC(.dbd.O)R.sup.14, --S(.dbd.O)R.sup.14, --S(O).sub.2R.sup.14,
--NR.sup.14C(.dbd.O)OR.sup.14, --NR.sup.14S(O.sub.2)R.sup.14 and
arylalkyl;
[0127] R.sup.14, at each occurrence, is independently selected from
hydrogen, alkyl, aryl, cycloalkyl and heteroaryl;
[0128] R.sub.21 is hydrogen, alkyl, haloalkyl, hydroxyalkyl, aryl,
halo, --CN, --C(.dbd.O)OR.sup.10, --OR.sup.10,
--C(.dbd.O)NR.sup.9R.sup.9 or --C(.dbd.O)R.sup.10;
[0129] T.sub.1, T.sub.2 and T.sub.4 are hydrogen; and
[0130] T.sub.3 is hydrogen, alkyl or aryl, wherein the alkyl or
aryl may be optionally substituted with one or more R.sup.6's.
[0131] In a twelfth embodiment of the first aspect, the present
invention provides a compound of Formula I, or an enantiomer, a
diastereomer, or a pharmaceutically acceptable salt thereof,
wherein:
[0132] Z is CH or N;
[0133] R.sup.1 is aryl, arylalkyl or heteroaryl, any of which may
be optionally substituted with one or more R.sup.6's;
[0134] R.sup.2 is heteroaryl or --C(.dbd.O)OR.sup.5, wherein the
heteroaryl may be optionally substituted with one or more
R.sup.6's;
[0135] R.sup.5 is alkyl, aryl or heteroaryl, each of which may be
optionally substituted with one or more R.sup.6's;
[0136] R.sup.6, at each occurrence, is independently selected from
alkyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl,
heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, --NH.sub.2,
--CN, --NO.sub.2, --C(.dbd.O)OH, --C(.dbd.O)OR.sup.10, --OCF.sub.3,
--OCHF.sub.2, --OR.sup.10, --OH, --SH, --SR.sup.10,
--C(.dbd.O)NR.sup.9R.sup.9, --NR.sup.9R.sup.9,
--S(O).sub.2NR.sup.9R.sup.9, --NR.sup.9S(O).sub.2CF.sub.3,
--C(.dbd.O)R.sup.10, --NR.sup.9C(.dbd.O)H,
--NR.sup.9C(.dbd.O)R.sup.10, --OC(.dbd.O)R.sup.10,
--S(.dbd.O)R.sup.10, --S(O).sub.2R.sup.10 and .dbd.O, wherein the
alkyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl,
heteroarylalkyl, heterocyclyl and heterocyclylalkyl may each be
optionally substituted with 0-5 R.sup.9a;
[0137] R.sup.8a, at each occurrence, is independently selected from
alkyl, haloalkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl,
heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo,
--NH.sub.2, --CN, --NO.sub.2, --C(.dbd.O)OH, --C(.dbd.O)OR.sup.14,
--OCF.sub.3, --OCHF.sub.2, --OR.sup.14, --OH, --SH, --SR.sup.14,
--C(.dbd.O)NR.sup.14R.sup.14, --NR.sup.14R.sup.14,
--S(O).sub.2NR.sup.14R.sup.14, --NR.sup.14S(O).sub.2CF.sub.3,
--C(.dbd.O)R.sup.14, --NR.sup.14C(.dbd.O)H,
--NR.sup.14C(.dbd.O)R.sup.14, --OC(.dbd.O)R.sup.14,
--S(.dbd.O)R.sup.14, --S(O).sub.2R.sup.14, .dbd.O,
--NR.sup.14C(.dbd.O)OR.sup.14 and
--NR.sup.14S(O.sub.2)R.sup.14;
[0138] R.sup.9, at each occurrence, is independently selected from
hydrogen, alkyl, cycloalkyl, aryl, heteroaryl and heterocyclyl,
wherein the alkyl, cycloalkyl, aryl, heteroaryl and heterocyclyl
may each be optionally substituted with 0-5 R.sup.8a, and the
heteroaryl and heterocyclyl each contain 1-4 heteroatoms selected
from N, O and S;
[0139] R.sup.9a, at each occurrence, is independently selected from
alkyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl,
heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, --NH.sub.2,
--CN, --NO.sub.2, --C(.dbd.O)OH, --C(.dbd.O)OR.sup.14, --OCF.sub.3,
--OCHF.sub.2, --OR.sup.14, --OH, --SH, --SR.sup.14,
--C(.dbd.O)NR.sup.14R.sup.14, --NR.sup.14R.sup.14,
--S(O).sub.2NR.sup.14R.sup.14, --NR.sup.14S(O).sub.2CF.sub.3,
--C(.dbd.O)R.sup.14, --NR.sup.14C(.dbd.O)H,
--NR.sup.14C(.dbd.O)R.sup.14, --OC(.dbd.O)R.sup.14,
--S(.dbd.O)R.sup.14, --S(O).sub.2R.sup.14,
--NR.sup.14C(.dbd.O)OR.sup.14, --NR.sup.14S(O.sub.2)R.sup.14,
.dbd.O and arylalkyl;
[0140] R.sup.10, at each occurrence, is independently selected from
alkyl, cycloalkyl, aryl and heteroaryl, wherein the cycloalkyl,
aryl and heteroaryl may each be optionally substituted with 0-3
R.sup.10a, and the heteroaryl contains 1-4 heteroatoms selected
from N, O and S;
[0141] R.sup.10a, at each occurrence, is independently selected
from alkyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl,
heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo,
--NH.sub.2, --CN, --NO.sub.2, --C(.dbd.O)OH, --C(.dbd.O)OR.sup.14,
--OCF.sub.3, --OCHF.sub.2, --OR.sup.14, --OH, --SH, --SR.sup.14,
--C(.dbd.O)NR.sup.14R.sup.14, --NR.sup.14R.sup.14,
--S(O).sub.2NR.sup.14R.sup.14, --NR.sup.14S(O).sub.2CF.sub.3,
--C(.dbd.O)R.sup.14, --NR.sup.14C(.dbd.O)H,
--NR.sup.14C(.dbd.O)R.sup.14, --OC(.dbd.O)R.sup.14,
--S(.dbd.O)R.sup.14, --S(O).sub.2R.sup.14,
--NR.sup.14C(.dbd.O)OR.sup.14, --NR.sup.14S(O.sub.2)R.sup.14 and
arylalkyl;
[0142] R.sup.14, at each occurrence, is independently selected from
hydrogen, alkyl, aryl, cycloalkyl and heteroaryl;
[0143] R.sub.21 is hydrogen, alkyl, haloalkyl, hydroxyalkyl, aryl,
halo, --CN, --C(.dbd.O)OR.sup.10, --C(.dbd.O)NR.sup.9R.sup.9 or
--C(.dbd.O)R.sup.10;
[0144] T.sub.1, T.sub.2 and T.sub.4 are hydrogen; and
[0145] T.sub.3 is hydrogen or alkyl, wherein the alkyl may be
optionally substituted with one or more R.sup.6's.
[0146] In a thirteenth embodiment of the first aspect, the present
invention provides a compound of Formula I, or an enantiomer, a
diastereomer, or a pharmaceutically acceptable salt thereof,
wherein:
[0147] Z is CH or N;
[0148] R.sup.1 is aryl or heteroaryl, any of which may be
optionally substituted with one or more R.sup.6's;
[0149] R.sup.2 is heteroaryl or --C(.dbd.O)OR.sup.5, wherein the
heteroaryl may be optionally substituted with one or more
R.sup.6's;
[0150] R.sup.5 is alkyl, aryl or heteroaryl, each of which may be
optionally substituted with one or more R.sup.6's;
[0151] R.sup.6, at each occurrence, is independently selected from
alkyl, aryl, cycloalkyl, heteroaryl, heterocyclyl, halo,
--NH.sub.2, --CN, --NO.sub.2, --C(.dbd.O)OH, --C(.dbd.O)OR.sup.10,
--OCF.sub.3, --OCHF.sub.2, --OR.sup.10, --OH, --SH,
--C(.dbd.O)NR.sup.9R.sup.9, --NR.sup.9R.sup.9,
--S(O).sub.2NR.sup.9R.sup.9, --NR.sup.9S(O).sub.2CF.sub.3,
--C(.dbd.O)R.sup.10, --NR.sup.9C(.dbd.O)H,
--NR.sup.9C(.dbd.O)R.sup.10, --OC(.dbd.O)R.sup.10,
--S(.dbd.O)R.sup.10, --S(O).sub.2R.sup.10 and .dbd.O, wherein the
alkyl, aryl, cycloalkyl, heteroaryl, and heterocyclyl may each be
optionally substituted with 0-5 R.sup.9a;
[0152] R.sup.8a, at each occurrence, is independently selected from
alkyl, haloalkyl, aryl, arylalkyl, cycloalkyl, heteroaryl,
heterocyclyl, halo, --NH.sub.2, --CN, --NO.sub.2, --C(.dbd.O)OH,
--C(.dbd.O)OR.sup.14, --OCF.sub.3, --OCHF.sub.2, --OR.sup.14, --OH,
--SH, --SR.sup.14, --C(.dbd.O)NR.sup.14R.sup.14,
--NR.sup.14R.sup.14, --S(O).sub.2NR.sup.14R.sup.14,
--NR.sup.14S(O).sub.2CF.sub.3, --C(.dbd.O)R.sup.14,
--NR.sup.14C(.dbd.O)H, --NR.sup.14C(.dbd.O)R.sup.14,
--OC(.dbd.O)R.sup.14, --S(.dbd.O)R.sup.14, --S(O).sub.2R.sup.14,
.dbd.O, --NR.sup.14C(.dbd.O)OR.sup.14 and
--NR.sup.14S(O.sub.2)R.sup.14l
[0153] R.sup.9, at each occurrence, is independently selected from
hydrogen, alkyl, cycloalkyl, aryl and heteroaryl, wherein the
alkyl, cycloalkyl, aryl and heteroaryl, may each be optionally
substituted with 0-5 R.sup.8a, and the heteroaryl contains 1-4
heteroatoms selected from N, O and S;
[0154] R.sup.9a, at each occurrence, is independently selected from
alkyl, haloalkyl, aryl, cycloalkyl, heteroaryl, heterocyclyl, halo,
--NH.sub.2, --CN, --NO.sub.2, --C(.dbd.O)OH, --C(.dbd.O)OR.sup.14,
--OCF.sub.3, --OCHF.sub.2, --OR.sup.14, --OH, --SH, --SR.sup.14,
--C(.dbd.O)NR.sup.14R.sup.14, --NR.sup.14R.sup.14,
--S(O).sub.2NR.sup.14R.sup.14, --NR.sup.14S(O).sub.2CF.sub.3,
--C(.dbd.O)R.sup.14, --NR.sup.14C(.dbd.O)H,
--NR.sup.14C(.dbd.O)R.sup.14, --OC(.dbd.O)R.sup.14,
--S(.dbd.O)R.sup.14, --S(O).sub.2R.sup.14,
--NR.sup.14C(.dbd.O)OR.sup.14, --NR.sup.14S(O.sub.2)R.sup.14,
.dbd.O and arylalkyl;
[0155] R.sup.10, at each occurrence, is independently selected from
alkyl, cycloalkyl, aryl and heteroaryl, wherein the cycloalkyl,
aryl and heteroaryl may each be optionally substituted with 0-3
R.sup.10a, and the heteroaryl contains 1-4 heteroatoms selected
from N, O and S;
[0156] R.sup.10a, at each occurrence, is independently selected
from alkyl, haloalkyl, aryl, cycloalkyl, heteroaryl, heterocyclyl,
halo, --NH.sub.2, --CN, --NO.sub.2, --C(.dbd.O)OH,
--C(.dbd.O)OR.sup.14, --OCF.sub.3, --OCHF.sub.2, --OR.sup.14, --OH,
--SH, --SR.sup.14, --C(.dbd.O)NR.sup.14R.sup.14,
--NR.sup.14R.sup.14, --S(O).sub.2NR.sup.14R.sup.14,
--NR.sup.14S(O).sub.2CF.sub.3, --C(.dbd.O)R.sup.14,
--NR.sup.14C(.dbd.O)H, --NR.sup.14C(.dbd.O)R.sup.14,
--OC(.dbd.O)R.sup.14, --S(.dbd.O)R.sup.14, --S(O).sub.2R.sup.14,
--NR.sup.14C(.dbd.O)OR.sup.14, --NR.sup.14S(O.sub.2)R.sup.14 and
arylalkyl;
[0157] R.sup.14, at each occurrence, is independently selected from
hydrogen, alkyl, aryl, cycloalkyl and heteroaryl;
[0158] R.sub.21 is hydrogen, alkyl, haloalkyl, hydroxyalkyl, aryl,
halo, --CN, --C(.dbd.O)OR.sup.10 or --C(.dbd.O)NR.sup.9R.sup.9;
[0159] T.sub.1, T.sub.2 and T.sub.4 are hydrogen; and
[0160] T.sub.3 is hydrogen or alkyl.
[0161] In a fourteenth embodiment of the first aspect, the present
invention provides a compound of Formula I, or an enantiomer, a
diastereomer, or a pharmaceutically acceptable salt thereof,
wherein:
[0162] Z is CH or N;
[0163] R.sup.1 is a 5- or 6-membered aryl, a 5- or 6-membered
arylalkyl or a 5- to 10-membered heteroaryl, any of which may be
optionally substituted with one or more R.sup.6's;
[0164] R.sup.2 is a 5- to 10-membered heteroaryl or
--C(.dbd.O)OR.sup.5, wherein the heteroaryl may be optionally
substituted with one or more R.sup.6's;
[0165] R.sup.5 is alkyl or aryl, each of which may be optionally
substituted with one or more R.sup.6's;
[0166] R.sup.6, at each occurrence, is independently selected from
alkyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl,
heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, --NH.sub.2,
--CN, --NO.sub.2, --C(.dbd.O)OH, --C(.dbd.O)OR.sup.10, --OCF.sub.3,
--OCHF.sub.2, --OR.sup.10, --OH, --SH, --SR.sup.10,
--C(.dbd.O)NR.sup.9R.sup.9, --NR.sup.9R.sup.9,
--S(O).sub.2NR.sup.9R.sup.9, --NR.sup.9S(O).sub.2CF.sub.3,
--C(.dbd.O)R.sup.10, --NR.sup.9C(.dbd.O)H,
--NR.sup.9C(.dbd.O)R.sup.10, --OC(.dbd.O)R.sup.10,
--S(.dbd.O)R.sup.10, --S(O).sub.2R.sup.10 and .dbd.O, wherein the
alkyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl,
heteroarylalkyl, heterocyclyl and heterocyclylalkyl may each be
optionally substituted with 0-5 R.sup.9a;
[0167] R.sup.8a, at each occurrence, is independently selected from
alkyl, haloalkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl,
heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo,
--NH.sub.2, --CN, --NO.sub.2, --C(.dbd.O)OH, --C(.dbd.O)OR.sup.14,
--OCF.sub.3, --OCHF.sub.2, --OR.sup.14, --OH, --SH, --SR.sup.14,
--C(.dbd.O)NR.sup.14R.sup.14, --NR.sup.14R.sup.14,
--S(O).sub.2NR.sup.14R.sup.14, --NR.sup.14S(O).sub.2CF.sub.3,
--C(.dbd.O)R.sup.14, --NR.sup.14C(.dbd.O)H,
--NR.sup.14C(.dbd.O)R.sup.14, --OC(.dbd.O)R.sup.14,
--S(.dbd.O)R.sup.14, --S(O).sub.2R.sup.14, .dbd.O,
--NR.sup.14C(.dbd.O)OR.sup.14 and
--NR.sup.14S(O.sub.2)R.sup.14;
[0168] R.sup.9, at each occurrence, is independently selected from
hydrogen, alkyl, cycloalkyl, aryl, heteroaryl and heterocyclyl,
wherein the alkyl, cycloalkyl, aryl, heteroaryl and heterocyclyl
may each be optionally substituted with 0-5 R.sup.8a, and the
heteroaryl and heterocyclyl each contain 1-4 heteroatoms selected
from N, O and S;
[0169] R.sup.9a, at each occurrence, is independently selected from
alkyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl,
heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, --NH.sub.2,
--CN, --NO.sub.2, --C(.dbd.O)OH, --C(.dbd.O)OR.sup.14, --OCF.sub.3,
--OCHF.sub.2, --OR.sup.14, --OH, --SH, --SR.sup.14,
--C(.dbd.O)NR.sup.14R.sup.14, --NR.sup.14R.sup.14,
--S(O).sub.2NR.sup.14R.sup.14, --NR.sup.14S(O).sub.2CF.sub.3,
--C(.dbd.O)R.sup.14, --NR.sup.14C(.dbd.O)H,
--NR.sup.14C(.dbd.O)R.sup.14, --OC(.dbd.O)R.sup.14,
--S(.dbd.O)R.sup.14, --S(O).sub.2R.sup.14,
--NR.sup.14C(.dbd.O)OR.sup.14, --NR.sup.14S(O.sub.2)R.sup.14,
.dbd.O and arylalkyl;
[0170] R.sup.10, at each occurrence, is independently selected from
alkyl, cycloalkyl, aryl and heteroaryl, wherein the cycloalkyl,
aryl and heteroaryl may each be optionally substituted with 0-3
R.sup.10a, and the heteroaryl contains 1-4 heteroatoms selected
from N, O and S;
[0171] R.sup.10a, at each occurrence, is independently selected
from alkyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl,
heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo,
--NH.sub.2, --CN, --NO.sub.2, --C(.dbd.O)OH, --C(.dbd.O)OR.sup.14,
--OCF.sub.3, --OCHF.sub.2, --OR.sup.14, --OH, --SH, --SR.sup.14,
--C(.dbd.O)NR.sup.14R.sup.14, --NR.sup.14R.sup.14,
--S(O).sub.2NR.sup.14R.sup.14, --NR.sup.14S(O).sub.2CF.sub.3,
--C(.dbd.O)R.sup.14, --NR.sup.14C(.dbd.O)H,
--NR.sup.14C(.dbd.O)R.sup.14, --OC(.dbd.O)R.sup.14,
--S(.dbd.O)R.sup.14, --S(O).sub.2R.sup.14,
--NR.sup.14C(.dbd.O)OR.sup.14, --NR.sup.14S(O.sub.2)R.sup.14 and
arylalkyl;
[0172] R.sup.14, at each occurrence, is independently selected from
hydrogen, alkyl, aryl, cycloalkyl and heteroaryl;
[0173] R.sub.21 is hydrogen, alkyl, haloalkyl, hydroxyalkyl, aryl,
halo, --CN, --C(.dbd.O)OR.sup.10, --C(.dbd.O)NR.sup.9R.sup.9 or
--C(.dbd.O)R.sup.10;
[0174] T.sub.1, T.sub.2 and T.sub.4 are hydrogen; and
[0175] T.sub.3 is hydrogen or alkyl.
[0176] In a fifteenth embodiment of the first aspect, the present
invention provides a compound of Formula I, or an enantiomer, a
diastereomer, or a pharmaceutically acceptable salt thereof,
wherein:
[0177] Z is CH or N;
[0178] R.sup.1 is a 5- or 6-membered aryl, a 5- or 6-membered
arylalkyl or a 5- to 10-membered heteroaryl, any of which may be
optionally substituted with one or more R.sup.6's;
[0179] R.sup.2 is a 5- to 6-membered heteroaryl or
--C(.dbd.O)OR.sup.5, wherein the heteroaryl may be optionally
substituted with one or more R.sup.6's;
[0180] R.sup.5 is alkyl, which may be optionally substituted with
one or more R.sup.6's;
[0181] R.sup.6, at each occurrence, is independently selected from
alkyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl,
heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, --NH.sub.2,
--CN, --NO.sub.2, --C(.dbd.O)OH, --C(.dbd.O)OR.sup.10, --OCF.sub.3,
--OCHF.sub.2, --OR.sup.10, --OH, --SH, --SR.sup.10,
--C(.dbd.O)NR.sup.9R.sup.9, --NR.sup.9R.sup.9,
--S(O).sub.2NR.sup.9R.sup.9, --NR.sup.9S(O).sub.2CF.sub.3,
--C(.dbd.O)R.sup.10, --NR.sup.9C(.dbd.O)H,
--NR.sup.9C(.dbd.O)R.sup.10, --OC(.dbd.O)R.sup.10,
--S(.dbd.O)R.sup.10, --S(O).sub.2R.sup.10 and .dbd.O, wherein the
alkyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl,
heteroarylalkyl, heterocyclyl and heterocyclylalkyl may each be
optionally substituted with 0-5 R.sup.9a;
[0182] R.sup.8a, at each occurrence, is independently selected from
alkyl, haloalkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl,
heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo,
--NH.sub.2, --CN, --NO.sub.2, --C(.dbd.O)OH, --C(.dbd.O)OR.sup.14,
--OCF.sub.3, --OCHF.sub.2, --OR.sup.14, --OH, --SH, --SR.sup.14,
--C(.dbd.O)NR.sup.14R.sup.14, --NR.sup.14R.sup.14,
--S(O).sub.2NR.sup.14R.sup.14, --NR.sup.14S(O).sub.2CF.sub.3,
--C(.dbd.O)R.sup.14, --NR.sup.14C(.dbd.O)H,
--NR.sup.14C(.dbd.O)R.sup.14, --OC(.dbd.O)R.sup.14,
--S(.dbd.O)R.sup.14, --S(O).sub.2R.sup.14, .dbd.O,
--NR.sup.14C(.dbd.O)OR.sup.14 and
--NR.sup.14S(O.sub.2)R.sup.14;
[0183] R.sup.9, at each occurrence, is independently selected from
hydrogen, alkyl, cycloalkyl, aryl, heteroaryl and heterocyclyl,
wherein the alkyl, cycloalkyl, aryl, heteroaryl and heterocyclyl
may each be optionally substituted with 0-5 R.sup.8a, and the
heteroaryl and heterocyclyl each contain 1-4 heteroatoms selected
from N, O and S;
[0184] R.sup.9a, at each occurrence, is independently selected from
alkyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl,
heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, --NH.sub.2,
--CN, --NO.sub.2, --C(.dbd.O)OH, --C(.dbd.O)OR.sup.14, --OCF.sub.3,
--OCHF.sub.2, --OR.sup.14, --OH, --SH, --SR.sup.14,
--C(.dbd.O)NR.sup.14R.sup.14, --NR.sup.14R.sup.14,
--S(O).sub.2NR.sup.14R.sup.14, --NR.sup.14S(O).sub.2CF.sub.3,
--C(.dbd.O)R.sup.14, --NR.sup.14C(.dbd.O)H,
--NR.sup.14C(.dbd.O)R.sup.14, --OC(.dbd.O)R.sup.14,
--S(.dbd.O)R.sup.14, --S(O).sub.2R.sup.14,
--NR.sup.14C(.dbd.O)OR.sup.14, --NR.sup.14S(O.sub.2)R.sup.14,
.dbd.O and arylalkyl;
[0185] R.sup.10, at each occurrence, is independently selected from
alkyl, cycloalkyl, aryl and heteroaryl, wherein the cycloalkyl,
aryl and heteroaryl may each be optionally substituted with 0-3
R.sup.10a, and the heteroaryl contains 1-4 heteroatoms selected
from N, O and S;
[0186] R.sup.10a, at each occurrence, is independently selected
from alkyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl,
heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo,
--NH.sub.2, --CN, --NO.sub.2, --C(.dbd.O)OH, --C(.dbd.O)OR.sup.14,
--OCF.sub.3, --OCHF.sub.2, --OR.sup.14, --OH, --SH, --SR.sup.14,
--C(.dbd.O)NR.sup.14R.sup.14, --NR.sup.14R.sup.14,
--S(O).sub.2NR.sup.14R.sup.14, --NR.sup.14S(O).sub.2CF.sub.3,
--C(.dbd.O)R.sup.14, --NR.sup.14C(.dbd.O)H,
--NR.sup.14C(.dbd.O)R.sup.14, --OC(.dbd.O)R.sup.14,
--S(.dbd.O)R.sup.14, --S(O).sub.2R.sup.14,
--NR.sup.14C(.dbd.O)OR.sup.14, --NR.sup.14S(O.sub.2)R.sup.14 and
arylalkyl;
[0187] R.sup.14, at each occurrence, is independently selected from
hydrogen, alkyl, aryl, cycloalkyl and heteroaryl;
[0188] R.sub.21 is hydrogen, alkyl, haloalkyl, hydroxyalkyl, aryl,
halo, --CN, --C(.dbd.O)OR.sup.10 or --C(.dbd.O)NR.sup.9R.sup.9;
[0189] T.sub.1, T.sub.2 and T.sub.4 are hydrogen; and
[0190] T.sub.3 is hydrogen or alkyl.
[0191] In a sixteenth embodiment of the first aspect, the present
invention provides a compound of Formula I, or an enantiomer, a
diastereomer, or a pharmaceutically acceptable salt thereof,
wherein:
[0192] Z is CH or N;
[0193] R.sup.1 is phenyl, benzyl, benzooxazolyl, piperidinyl or
pyrimidinyl, any of which may be optionally substituted with one or
more R.sup.6's;
[0194] R.sup.2 is piperidinyl, pyrimidinyl or --C(.dbd.O)OR.sup.5,
wherein the piperidinyl and pyrimidinyl may be optionally
substituted with one or more R.sup.6's;
[0195] R.sup.5 is alkyl;
[0196] R.sup.6, at each occurrence, is independently selected from
alkyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl,
heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, --NH.sub.2,
--CN, --NO.sub.2, --C(.dbd.O)OH, --C(.dbd.O)OR.sup.10, --OCF.sub.3,
--OCHF.sub.2, --OR.sup.10, --OH, --SH, --SR.sup.10,
--C(.dbd.O)NR.sup.9R.sup.9, --NR.sup.9R.sup.9,
--S(O).sub.2NR.sup.9R.sup.9, --NR.sup.9S(O).sub.2CF.sub.3,
--C(.dbd.O)R.sup.10, --NR.sup.9C(.dbd.O)H,
--NR.sup.9C(.dbd.O)R.sup.10, --OC(.dbd.O)R.sup.10,
--S(.dbd.O)R.sup.10, --S(O).sub.2R.sup.10 and .dbd.O, wherein the
alkyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl,
heteroarylalkyl, heterocyclyl and heterocyclylalkyl may each be
optionally substituted with 0-5 R.sup.9a;
[0197] R.sup.8a, at each occurrence, is independently selected from
alkyl, haloalkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl,
heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo,
--NH.sub.2, --CN, --NO.sub.2, --C(.dbd.O)OH, --C(.dbd.O)OR.sup.14,
--OCF.sub.3, --OCHF.sub.2, --OR.sup.14, --OH, --SH, --SR.sup.14,
--C(.dbd.O)NR.sup.14R.sup.14, --NR.sup.14R.sup.14,
--S(O).sub.2NR.sup.14R.sup.14, --NR.sup.14S(O).sub.2CF.sub.3,
--C(.dbd.O)R.sup.14, --NR.sup.14C(.dbd.O)H,
--NR.sup.14C(.dbd.O)R.sup.14, --OC(.dbd.O)R.sup.14,
--S(.dbd.O)R.sup.14, --S(O).sub.2R.sup.14, .dbd.O,
--NR.sup.14C(.dbd.O)OR.sup.14 and
--NR.sup.14S(O.sub.2)R.sup.14;
[0198] R.sup.9, at each occurrence, is independently selected from
hydrogen, alkyl, cycloalkyl, aryl, heteroaryl and heterocyclyl,
wherein the alkyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl
may each be optionally substituted with 0-5 R.sup.8a, and the
heteroaryl and heterocyclyl each contain 1-4 heteroatoms selected
from N, O and S;
[0199] R.sup.9a, at each occurrence, is independently selected from
alkyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl,
heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, --NH.sub.2,
--CN, --NO.sub.2, --C(.dbd.O)OH, --C(.dbd.O)OR.sup.14, --OCF.sub.3,
--OCHF.sub.2, --OR.sup.14, --OH, --SH, --SR.sup.14,
--C(.dbd.O)NR.sup.14R.sup.14, --NR.sup.14R.sup.14,
--S(O).sub.2NR.sup.14R.sup.14, --NR.sup.14S(O).sub.2CF.sub.3,
--C(.dbd.O)R.sup.14, --NR.sup.14C(.dbd.O)H,
--NR.sup.14C(.dbd.O)R.sup.14, --OC(.dbd.O)R.sup.14,
--S(.dbd.O)R.sup.14, --S(O).sub.2R.sup.14,
--NR.sup.14C(.dbd.O)OR.sup.14, --NR.sup.14S(O.sub.2)R.sup.14,
.dbd.O and arylalkyl;
[0200] R.sup.10, at each occurrence, is independently selected from
alkyl, cycloalkyl, aryl and heteroaryl, wherein the cycloalkyl,
aryl and heteroaryl may each be optionally substituted with 0-3
R.sup.10a, and the heteroaryl contains 1-4 heteroatoms selected
from N, O and S;
[0201] R.sup.10a, at each occurrence, is independently selected
from alkyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl,
heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo,
--NH.sub.2, --CN, --NO.sub.2, --C(.dbd.O)OH, --C(.dbd.O)OR.sup.14,
--OCF.sub.3, --OCHF.sub.2, --OR.sup.14, --OH, --SH, --SR.sup.14,
--C(.dbd.O)NR.sup.14R.sup.14, --NR.sup.14R.sup.14,
--S(O).sub.2NR.sup.14R.sup.14, --NR.sup.14S(O).sub.2CF.sub.3,
--C(.dbd.O)R.sup.14, --NR.sup.14C(.dbd.O)H,
--NR.sup.14C(.dbd.O)R.sup.14, --OC(.dbd.O)R.sup.14,
--S(.dbd.O)R.sup.14, --S(O).sub.2R.sup.14,
--NR.sup.14C(.dbd.O)OR.sup.14, --NR.sup.14S(O.sub.2)R.sup.14 and
arylalkyl;
[0202] R.sup.14, at each occurrence, is independently selected from
hydrogen, alkyl, aryl, cycloalkyl and heteroaryl;
[0203] R.sub.21 is hydrogen, alkyl, haloalkyl, hydroxyalkyl, aryl,
halo, --CN, --C(.dbd.O)OR.sup.10 or --C(.dbd.O)NR.sup.9R.sup.9;
[0204] T.sub.1, T.sub.2 and T.sub.4 are hydrogen; and
[0205] T.sub.3 is hydrogen or alkyl.
[0206] In a seventeenth embodiment of the first aspect, the present
invention provides a compound of Formula I, or an enantiomer, a
diastereomer, or a pharmaceutically acceptable salt thereof,
wherein the compound is selected from one of the examples.
[0207] For each of the embodiments described in this application,
further and more particular values of the terms used in each of the
embodiments may be selected from the following definitions; these
values may be used individually in any of the embodiments or in any
combination. It is noted that for any occurrences of ".dbd.O",
these may be used with suitable accommodation in the bond structure
at that site as will be appreciated by those skilled in the
art.
[0208] The heteroaryl, heteroarylalkyl, heterocyclyl and
heterocyclylalkyl used in each occurrence may each contain 1-4
heteroatoms selected from N, O and S.
[0209] For each of the embodiments described in this application,
further and more particular values of the terms used in each of the
embodiments may be selected from the following definitions; these
values may be used individually in any of the embodiments or in any
combination. It is noted that for any occurrences of ".dbd.O",
these may be used with suitable accommodation in the bond structure
at that site as will be appreciated by those skilled in the
art.
[0210] The heteroaryl, heteroarylalkyl, heterocyclyl and
heterocyclylalkyl used in each occurrence may each contain 1-4
heteroatoms selected from N, O and S.
[0211] In a second aspect, the present invention provides a
compound, or an enantiomer, a diastereomer, or a pharmaceutically
acceptable salt thereof, selected from the group consisting of the
compounds exemplified in the examples.
[0212] In a third aspect, the present invention relates to
pharmaceutical compositions comprised of a therapeutically
effective amount of a compound of the present invention, alone or,
optionally, in combination with a pharmaceutically acceptable
carrier and/or one or more other agent(s), for example, a
glucagon-like peptide-1 receptor agonist or fragment thereof.
[0213] In one embodiment of the third aspect, the present invention
provides a pharmaceutical composition comprised of a
therapeutically effective amount of a compound of Formula I, II(y),
or II(z) as defined above, alone or, optionally, in combination
with a pharmaceutically acceptable carrier and/or one or more other
agent(s), for example, a glucagon-like peptide-1 receptor agonist
or fragment thereof.
[0214] In another embodiment of the third aspect, the present
invention provides a pharmaceutical composition comprised of a
therapeutically effective amount of a compound selected from the
group of compounds exemplified in the Examples, alone or,
optionally, in combination with a pharmaceutically acceptable
carrier and/or one or more other agent(s), for example, a
glucagon-like peptide-1 receptor agonist or fragment thereof.
[0215] In a fourth aspect, the present invention relates to methods
of modulating the activity of the GPR119G protein-coupled receptor
comprising administering to a mammalian patient, for example, a
human patient, in need thereof a therapeutically effective amount
of a compound of the present invention, alone, or optionally, in
combination with another compound of the present invention and/or
at least one other type of therapeutic agent.
[0216] In one embodiment of the fourth aspect, the present
invention relates to a method for preventing, modulating, or
treating the progression or onset of diseases or disorders
associated with the activity of the GPR119G protein-coupled
receptor comprising administering to a mammalian patient, for
example, a human patient, in need of prevention, modulation, or
treatment a therapeutically effective amount of a compound of the
present invention, alone, or, optionally, in combination with
another compound of the present invention and/or at least one other
type of therapeutic agent.
[0217] Examples of diseases or disorders associated with the
activity of the GPR119G protein-coupled receptor that can be
prevented, modulated, or treated according to the present invention
include, but are not limited to, diabetes, hyperglycemia, impaired
glucose tolerance, insulin resistance, hyperinsulinemia,
retinopathy, neuropathy, nephropathy, delayed wound healing,
atherosclerosis and its sequelae, abnormal heart function,
myocardial ischemia, stroke, Metabolic Syndrome, hypertension,
obesity, dislipidemia, dyslipidemia, hyperlipidemia,
hypertriglyceridemia, hypercholesterolemia, low HDL, high LDL,
non-cardiac ischemia, infection, cancer, vascular restenosis,
pancreatitis, neurodegenerative disease, lipid disorders, cognitive
impairment and dementia, bone disease, HIV protease associated
lipodystrophy and glaucoma.
[0218] In another embodiment of the fourth aspect, the present
invention relates to a method for preventing, modulating, or
treating the progression or onset of diabetes, hyperglycemia,
obesity, dyslipidemia, hypertension and cognitive impairment
comprising administering to a mammalian patient, for example, a
human patient, in need of prevention, modulation, or treatment a
therapeutically effective amount of a compound of the present
invention, alone, or, optionally, in combination with another
compound of the present invention and/or at least one other type of
therapeutic agent.
[0219] In another embodiment of the fourth aspect, the present
invention relates to a method for preventing, modulating, or
treating the progression or onset of diabetes, comprising
administering to a mammalian patient, for example, a human patient,
in need of prevention, modulation, or treatment a therapeutically
effective amount of a compound of the present invention, alone, or,
optionally, in combination with another compound of the present
invention and/or at least one other type of therapeutic agent.
[0220] In another embodiment of the fourth aspect, the present
invention relates to a method for preventing, modulating, or
treating the progression or onset of hyperglycemia comprising
administering to a mammalian patient, for example, a human patient,
in need of prevention, modulation, or treatment a therapeutically
effective amount of a compound of the present invention, alone, or,
optionally, in combination with another compound of the present
invention and/or at least one other type of therapeutic agent.
[0221] In another embodiment of the fourth aspect, the present
invention relates to a method for preventing, modulating, or
treating the progression or onset of obesity comprising
administering to a mammalian patient, for example, a human patient,
in need of prevention, modulation, or treatment a therapeutically
effective amount of a compound of the present invention, alone, or,
optionally, in combination with another compound of the present
invention and/or at least one other type of therapeutic agent.
[0222] In another embodiment of the fourth aspect, the present
invention relates to a method for preventing, modulating, or
treating the progression or onset of dyslipidemia comprising
administering to a mammalian patient, for example, a human patient,
in need of prevention, modulation, or treatment a therapeutically
effective amount of a compound of the present invention, alone, or,
optionally, in combination with another compound of the present
invention and/or at least one other type of therapeutic agent.
[0223] In another embodiment of the fourth aspect, the present
invention relates to a method for preventing, modulating, or
treating the progression or onset of hypertension comprising
administering to a mammalian patient, for example, a human patient,
in need of prevention, modulation, or treatment a therapeutically
effective amount of a compound of the present invention, alone, or,
optionally, in combination with another compound of the present
invention and/or at least one other type of therapeutic agent.
[0224] In another embodiment of the fourth aspect, the present
invention relates to a formulated product wherein the selected
formulation is made by combining (a) a compound of Formula I (using
any of the compound embodiments listed above) and (b) a dipeptidyl
peptidase-IV (DPP4) inhibitor (for example, a member selected from
saxagliptin, sitagliptin, vildagliptin and alogliptin).
[0225] The invention may be embodied in other specific forms
without departing from the spirit or essential attributes thereof.
This invention also encompasses all combinations of alternative
aspects of the invention noted herein. It is understood that any
and all embodiments of the present invention may be taken in
conjunction with any other embodiment to describe additional
embodiments of the present invention. Furthermore, any elements of
an embodiment may be combined with any and all other elements from
any of the embodiments to describe additional embodiments.
DEFINITIONS
[0226] The compounds herein described may have asymmetric centers.
Compounds of the present invention containing an asymmetrically
substituted atom may be isolated in optically active or racemic
forms. It is well known in the art how to prepare optically active
forms, such as by resolution of racemic forms or by synthesis from
optically active starting materials. Many geometric isomers of
olefins, C.dbd.N double bonds, and the like can also be present in
the compounds described herein, and all such stable isomers are
contemplated in the present invention. Cis and trans geometric
isomers of the compounds of the present invention are described and
may be isolated as a mixture of isomers or as separated isomeric
forms. All chiral, diastereomeric, racemic forms and all geometric
isomeric forms of a structure are intended, unless the specific
stereochemistry or isomeric form is specifically indicated.
[0227] One enantiomer of a compound of Formula I may display
superior activity compared with the other. Thus, all of the
stereochemistries are considered to be a part of the present
invention. When required, separation of the racemic material can be
achieved by high performance liquid chromatography (HPLC) using a
chiral column or by a resolution using a resolving agent such as
camphonic chloride as in Young, S. D. et al., Antimicrobial Agents
and Chemotherapy, 2602-2605 (1995).
[0228] To the extent that compounds of Formula I, and salts
thereof, may exist in their tautomeric form, all such tautomeric
forms are contemplated herein as part of the present invention.
[0229] The term "substituted," as used herein, means that any one
or more hydrogens on the designated atom or ring is replaced with a
selection from the indicated group, provided that the designated
atom's or ring atom's normal valency is not exceeded, and that the
substitution results in a stable compound. When a substituent is
keto (i.e., .dbd.O), then 2 hydrogens on the atom are replaced.
[0230] When any variable (e.g., R.sup.4) occurs more than one time
in any constituent or formula for a compound, its definition at
each occurrence is independent of its definition at every other
occurrence. Thus, for example, if a group is shown to be
substituted with (R.sup.4).sub.m and m is 0-3, then said group may
optionally be substituted with up to three R.sup.4 groups and
R.sup.4 at each occurrence is selected independently from the
definition of R.sup.4. Also, combinations of substituents and/or
variables are permissible only if such combinations result in
stable compounds.
[0231] When a bond to a substituent is shown to cross a bond
connecting two atoms in a ring, then such substituent may be bonded
to any atom on the ring. When a substituent is listed without
indicating the atom via which such substituent is bonded to the
rest of the compound of a given formula, then such substituent may
be bonded via any atom in such substituent. Combinations of
substituents and/or variables are permissible only if such
combinations result in stable compounds.
[0232] As used herein, "alkyl" is intended to include both branched
and straight-chain saturated aliphatic hydrocarbon groups
containing 1 to 20 carbons, preferably 1 to 10 carbons, more
preferably 1 to 8 carbons, in the normal chain, such as methyl,
ethyl, propyl, isopropyl, butyl, t-butyl, isobutyl, pentyl, hexyl,
isohexyl, heptyl, 4,4-dimethylpentyl, octyl,
2,2,4-trimethyl-pentyl, nonyl, decyl, undecyl, dodecyl, the various
branched chain isomers thereof, and the like as well as such groups
may optionally include 1 to 4 substituents such as halo, for
example F, Br, Cl, or I, or CF.sub.3, alkyl, alkoxy, aryl, aryloxy,
aryl(aryl) or diaryl, arylalkyl, arylalkyloxy, alkenyl, cycloalkyl,
cycloalkylalkyl, cycloalkylalkyloxy, amino, hydroxy, hydroxyalkyl,
acyl, heteroaryl, heteroaryloxy, heteroarylalkyl, heteroarylalkoxy,
aryloxyalkyl, alkylthio, arylalkylthio, aryloxyaryl, alkylamido,
alkanoylamino, arylcarbonylamino, nitro, cyano, thiol, haloalkyl,
trihaloalkyl, and/or alkylthio.
[0233] Unless otherwise indicated, the term "alkenyl" as used
herein by itself or as part of another group refers to straight or
branched chain radicals of 2 to 20 carbons, preferably 2 to 12
carbons, and more preferably 2 to 8 carbons in the normal chain,
which include one to six double bonds in the normal chain, such as
vinyl, 2-propenyl, 3-butenyl, 2-butenyl, 4-pentenyl, 3-pentenyl,
2-hexenyl, 3-hexenyl, 2-heptenyl, 3-heptenyl, 4-heptenyl,
3-octenyl, 3-nonenyl, 4-decenyl, 3-undecenyl, 4-dodecenyl,
4,8,12-tetradecatrienyl, and the like, and which may be optionally
substituted with 1 to 4 substituents, namely, halogen, haloalkyl,
alkyl, alkoxy, alkenyl, alkynyl, aryl, arylalkyl, cycloalkyl,
amino, hydroxy, heteroaryl, cycloheteroalkyl, alkanoylamino,
alkylamido, arylcarbonyl-amino, nitro, cyano, thiol, alkylthio,
and/or any of the alkyl substituents set out herein.
[0234] Unless otherwise indicated, the term "alkynyl" as used
herein by itself or as part of another group refers to straight or
branched chain radicals of 2 to 20 carbons, preferably 2 to 12
carbons and more preferably 2 to 8 carbons in the normal chain,
which include one triple bond in the normal chain, such as
2-propynyl, 3-butynyl, 2-butynyl, 4-pentynyl, 3-pentynyl,
2-hexynyl, 3-hexynyl, 2-heptynyl, 3-heptynyl, 4-heptynyl,
3-octynyl, 3-nonynyl, 4-decynyl, 3-undecynyl, 4-dodecynyl, and the
like, and which may be optionally substituted with 1 to 4
substituents, namely, halogen, haloalkyl, alkyl, alkoxy, alkenyl,
alkynyl, aryl, arylalkyl, cycloalkyl, amino, heteroaryl,
cycloheteroalkyl, hydroxy, alkanoylamino, alkylamido,
arylcarbonylamino, nitro, cyano, thiol, and/or alkylthio, and/or
any of the alkyl substituents set out herein.
[0235] Unless otherwise indicated, the term "cycloalkyl" as
employed herein alone or as part of another group includes
saturated or partially unsaturated (containing 1 or 2 double bonds)
cyclic hydrocarbon groups containing 1 to 10 rings, preferably 1 to
3 rings, including monocyclic alkyl, bicyclic alkyl (or
bicycloalkyl) and tricyclic alkyl, containing a total of 3 to 20
carbons forming the ring, preferably 3 to 15 carbons, more
preferably 3 to 10 carbons, forming the ring and which may be fused
to 1 or 2 aromatic rings as described for aryl, which includes
cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl,
cyclooctyl, cyclodecyl, cyclododecyl, cyclohexenyl,
##STR00006##
any of which groups may be optionally substituted with 1 to 4
substituents such as halogen, alkyl, alkoxy, hydroxy, aryl,
aryloxy, arylalkyl, cycloalkyl, alkylamido, alkanoylamino, oxo,
acyl, arylcarbonylamino, amino, nitro, cyano, thiol, and/or
alkylthio, and/or any of the substituents for alkyl.
[0236] Where alkyl groups as defined above have single bonds for
attachment to other groups at two different carbon atoms, they are
termed "alkylene" groups and may optionally be substituted as
defined above for "alkyl".
[0237] Where alkenyl groups as defined above and alkynyl groups as
defined above, respectively, have single bonds for attachment at
two different carbon atoms, they are termed "alkenylene groups" and
"alkynylene groups", respectively, and may optionally be
substituted as defined above for "alkenyl" and "alkynyl".
[0238] "Halo" or "halogen" as used herein refers to fluoro, chloro,
bromo, and iodo; and "haloalkyl" is intended to include both
branched and straight-chain saturated aliphatic hydrocarbon groups,
for example CF.sub.3, having the specified number of carbon atoms,
substituted with 1 or more halogen (for example --C.sub.vF, where
v=1 to 3 and w=1 to (2v+1)).
[0239] Unless otherwise indicated, the term "aryl" as employed
herein alone or as part of another group refers to monocyclic and
bicyclic aromatic groups containing 6 to 10 carbons in the ring
portion (such as phenyl or naphthyl, including 1-naphthyl and
2-naphthyl) and may optionally include 1 to 3 additional rings
fused to a carbocyclic ring or a heterocyclic ring (such as aryl,
cycloalkyl, heteroaryl, or cycloheteroalkyl rings, for example,
##STR00007##
and may be optionally substituted through available carbon atoms
with 1, 2, or 3 substituents, for example, hydrogen, halo,
haloalkyl, alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl,
trifluoromethyl, trifluoromethoxy, alkynyl, cycloalkyl-alkyl,
cycloheteroalkyl, cycloheteroalkylalkyl, aryl, heteroaryl,
arylalkyl, aryloxy, aryloxyalkyl, arylalkoxy, arylthio, arylazo,
heteroarylalkyl, heteroarylalkenyl, heteroarylheteroaryl,
heteroaryloxy, hydroxy, nitro, cyano, amino, substituted amino
wherein the amino includes 1 or 2 substituents (which are alkyl,
aryl, or any of the other aryl compounds mentioned in the
definitions), thiol, alkylthio, arylthio, heteroarylthio,
arylthioalkyl, alkoxyarylthio, alkylcarbonyl, arylcarbonyl,
alkylaminocarbonyl, arylaminocarbonyl, alkoxycarbonyl,
aminocarbonyl, alkylcarbonyloxy, arylcarbonyloxy,
alkylcarbonylamino, arylcarbonylamino, arylsulfinyl,
arylsulfinylalkyl, arylsulfonylamino, or arylsulfonaminocarbonyl,
and/or any of the alkyl substituents set out herein.
[0240] Unless otherwise indicated, the term "lower alkoxy",
"alkoxy", "aryloxy" or "aralkoxy" as employed herein alone or as
part of another group includes any of the above alkyl, aralkyl, or
aryl groups linked to an oxygen atom.
[0241] Unless otherwise indicated, the term "amino" as employed
herein alone or as part of another group refers to amino that may
be substituted with one or two substituents, which may be the same
or different, such as alkyl, aryl, arylalkyl, heteroaryl,
heteroarylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl,
cycloalkyl, cycloalkylalkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl,
or thioalkyl. In addition, the amino substituents may be taken
together with the nitrogen atom to which they are attached to form
1-pyrrolidinyl, 1-piperidinyl, 1-azepinyl, 4-morpholinyl,
4-thiamorpholinyl, 1-piperazinyl, 4-alkyl-1-piperazinyl,
4-arylalkyl-1-piperazinyl, 4-diarylalkyl-1-piperazinyl,
1-pyrrolidinyl, 1-piperidinyl, or 1-azepinyl, optionally
substituted with alkyl, alkoxy, alkylthio, halo, trifluoromethyl,
or hydroxy.
[0242] Unless otherwise indicated, the term "lower alkylthio,"
"alkylthio," "arylthio," or "aralkylthio" as employed herein alone
or as part of another group includes any of the above alkyl,
aralkyl, or aryl groups linked to a sulfur atom.
[0243] Unless otherwise indicated, the term "lower alkylamino,"
"alkylamino," "arylamino," or "arylalkylamino" as employed herein
alone or as part of another group includes any of the above alkyl,
aryl, or arylalkyl groups linked to a nitrogen atom.
[0244] As used herein, the term "heterocyclyl" or "heterocyclic
system" is intended to mean a stable 4- to 14-membered monocyclic,
bicyclic or tricyclic heterocyclic ring which is saturated or
partially unsaturated and which consists of carbon atoms and 1, 2,
3, or 4 heteroatoms independently selected from the group
consisting of N, NH, O and S and including any bicyclic group in
which any of the above-defined heterocyclic rings is fused to a
benzene ring. The nitrogen and sulfur heteroatoms may optionally be
oxidized. The heterocyclic ring may be attached to its pendant
group at any heteroatom or carbon atom, which results in a stable
structure. The heterocyclic rings described herein may be
substituted on carbon or on a nitrogen atom if the resulting
compound is stable. If specifically noted, a nitrogen in the
heterocycle may optionally be quaternized. It is preferred that
when the total number of S and O atoms in the heterocycle exceeds
1, then these heteroatoms are not adjacent to one another.
[0245] Examples of heterocycles include, but are not limited to,
pyrrolidonyl, 4-piperidonyl, chromanyl, decahydroquinolinyl,
dihydrofuro[2,3-b]tetrahydrofuran, indolinyl, isochromanyl,
isoindolinyloctahydroisoquinolinyl, piperazinyl, piperidinyl,
piperidonyl, 4-piperidonyl, tetrahydrofuranyl,
tetrahydroisoquinolinyl, tetrahydroquinolinyl, morpholinyl,
dihydrofuranyl, tetrahydrothiophenyl, pyranyl, dihydropyranyl,
1,4-dioxanyl and 1,3-dioxanyl. Also included are fused ring and
spiro compounds containing, for example, the above
heterocycles.
[0246] As used herein, the term "aromatic heterocyclic system" or
"heteroaryl" is intended to mean a stable 5- to 7-membered
monocyclic or bicyclic or 7- to 10-membered bicyclic heterocyclic
aromatic ring which consists of carbon atoms and from 1 to 4
heteroatoms independently selected from the group consisting of N,
O and S and is aromatic in nature.
[0247] Examples of heteroaryls are 1H-indazole,
2H,6H-1,5,2-dithiazinyl, indolyl, 4aH-carbazole, 4H-quinolizinyl,
6H-1,2,5-thiadiazinyl, acridinyl, azocinyl, benzimidazolyl,
benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl,
benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl,
benzisothiazolyl, benzimidazalonyl, carbazolyl, 4aH-carbazolyl,
13-carbolinyl, chromanyl, chromenyl, cinnolinyl,
decahydroquinolinyl, 2H,6H-1,5,2-dithiazinyl,
dihydrofuro-[2,3-b]tetrahydrofuran, furanyl, furazanyl,
imidazolidinyl, imidazolinyl, imidazolyl, indazolyl, indolenyl,
indolinyl, indolizinyl, indolyl, isobenzofuranyl, isochromanyl,
isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl
(benzimidazolyl), isothiazolyl, isoxazolyl, morpholinyl,
naphthyridinyl, octahydroisoquinolinyl, oxadiazolyl,
1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl,
1,3,4-oxadiazolyl, oxazolidinyl, oxazolyl, oxazolidinylperimidinyl,
phenanthridinyl, phenanthrolinyl, phenarsazinyl, phenazinyl,
phenothiazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl,
piperazinyl, piperidinyl, pteridinyl, pteridinyl, purinyl, pyranyl,
pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl,
pyrazolotriazinyl, pyridazinyl, pyridooxazole, pyridoimidazole,
pyridothiazole, pyridinyl, pyridyl, pyrimidinyl, pyrrolidinyl,
quinazolinyl, quinolinyl, 4H-quinolizinyl, quinoxalinyl,
quinuclidinyl, carbolinyl, 6H-1,2,5-thiadiazinyl,
1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl,
1,3,4-thiadiazolyl, thianthrenyl, thiazolyl, thienyl,
thienothiazolyl, thienooxazolyl, thienoimidazolyl, thiophenyl,
triazinyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl,
1,3,4-triazolyl, tetrazolyl, and xanthenyl. In another aspect of
the invention, examples of heteroaryls are indolyl, benzimidazolyl,
benzofuranyl, benzothiofuranyl, benzoxazolyl, benzthiazolyl,
benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl,
benzimidazalonyl, cinnolinyl, furanyl, imidazolyl, indazolyl,
indolyl, isoquinolinyl isothiazolyl, isoxazolyl, oxazolyl,
pyrazinyl, pyrazolyl, pyrazolotriazinyl, pyridazinyl, pyridyl,
pyridinyl, pyrimidinyl, pyrrolyl, quinazolinyl, quinolinyl,
thiazolyl, thienyl, and tetrazolyl.
[0248] The term "heterocyclylalkyl" as used herein alone or as part
of another group refers to heterocyclyl groups as defined above
linked through a C atom or heteroatom to an alkyl chain.
[0249] The term "heteroarylalkyl" or "heteroarylalkenyl" as used
herein alone or as part of another group refers to a heteroaryl
group as defined above linked through a C atom or heteroatom to an
alkyl chain, alkylene, or alkenylene as defined above.
[0250] The term "cyano" as used herein, refers to a --CN group.
[0251] The term "nitro" as used herein, refers to an --NO.sub.2
group.
[0252] The term "hydroxy" as used herein, refers to an OH
group.
[0253] The phrase "pharmaceutically acceptable" is employed herein
to refer to those compounds, materials, compositions, and/or dosage
forms which are, within the scope of sound medical judgment,
suitable for use in contact with the tissues of human beings and
animals without excessive toxicity, irritation, allergic response,
or other problem or complication, commensurate with a reasonable
benefit/risk ratio.
[0254] As used herein, "pharmaceutically acceptable salts" refer to
derivatives of the disclosed compounds wherein the parent compound
is modified by making acid or base salts thereof. Examples of
pharmaceutically acceptable salts include, but are not limited to,
mineral or organic acid salts of basic residues such as amines;
alkali or organic salts of acidic residues such as carboxylic
acids; and the like. The pharmaceutically acceptable salts include
the conventional non-toxic salts or the quaternary ammonium salts
of the parent compound formed, for example, from non-toxic
inorganic or organic acids. For example, such conventional
non-toxic salts include those derived from inorganic acids such as
hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric
and the like; and the salts prepared from organic acids such as
acetic, propionic, succinic, glycolic, stearic, lactic, malic,
tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic,
phenylacetic, glutamic, benzoic, salicylic, sulfanilic,
2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane
disulfonic, oxalic, isethionic, and the like.
[0255] The pharmaceutically acceptable salts of the present
invention can be synthesized from the parent compound which
contains a basic or acidic moiety by conventional chemical methods.
Generally, such salts can be prepared by reacting the free acid or
base forms of these compounds with a stoichiometric amount of the
appropriate base or acid in water or in an organic solvent, or in a
mixture of the two; generally, nonaqueous media like ether, ethyl
acetate, ethanol, isopropanol, or acetonitrile are preferred. Lists
of suitable salts are found in Remington's Pharmaceutical Sciences,
17th ed., Mack Publishing Company, Easton, Pa., p. 1418 (1985), the
disclosure of which is hereby incorporated by reference.
[0256] Any compound that can be converted in vivo to provide the
bioactive agent (i.e., a compound of Formula I) is a prodrug within
the scope and spirit of the invention.
[0257] The term "prodrugs" as employed herein includes esters and
carbonates formed by reacting one or more hydroxyls of compounds of
Formula I with alkyl, alkoxy or aryl substituted acylating agents
employing procedures known to those skilled in the art to generate
acetates, pivalates, methylcarbonates, benzoates, and the like.
[0258] Various forms of prodrugs are well known in the art and are
described in: [0259] a) Wermuth, C. G. et al., The Practice of
Medicinal Chemistry, Chapter 31, Academic Press (1996); [0260] b)
Design of Prodrugs, H. Bundgaard, ed., Elsevier (1985); [0261] c)
Bundgaard, H., Chapter 5, "Design and Application of Prodrugs," A
Textbook of Drug Design and Development, pp. 113-191, P.
Krosgaard-Larsen et al., eds., Harwood Academic Publishers (1991);
and [0262] d) Testa, B. et al., Hydrolysis in Drug and Prodrug
Metabolism, Wiley-VCH (2003).
[0263] Said references are incorporated herein by reference,
particularly as to the description of prodrugs.
[0264] In addition, compounds of Formula I are, subsequent to their
preparation, preferably isolated and purified to obtain a
composition containing an amount by weight equal to or greater than
99% of a compound of Formula I ("substantially pure" compound),
which is then used or formulated as described herein. Such
"substantially pure" compounds of Formula I are also contemplated
herein as part of the present invention.
[0265] All stereoisomers of the compounds of the instant invention
are contemplated, either in admixture or in pure or substantially
pure form. The compounds of the present invention can have
asymmetric centers at any of the carbon atoms including any one of
the R substituents and/or exhibit polymorphism. Consequently,
compounds of Formula I can exist in enantiomeric, or diastereomeric
forms, or in mixtures thereof. The processes for preparation can
utilize racemates, enantiomers, or diastereomers as starting
materials. When diastereomeric or enantiomeric products are
prepared, they can be separated by conventional methods for
example, chromatographic or fractional crystallization.
[0266] The invention also includes isotopically-labeled compounds
of the invention, wherein one or more atoms is replaced by an atom
having the same atomic number, but an atomic mass or mass number
different from the atomic mass or mass number usually found in
nature. Examples of isotopes suitable for inclusion in the
compounds of the invention include isotopes of hydrogen, such as
.sup.2H and .sup.3H, carbon such as .sup.11C, .sup.13C, and
.sup.14C, chlorine, such as .sup.36Cl, fluorine such as .sup.18F,
iodine, such as .sup.123I and .sup.125I, nitrogen, such as .sup.13N
and .sup.15N, oxygen, such as .sup.15O, .sup.17O, and .sup.18O,
phosphorus, such as .sup.32P, and sulfur, such as .sup.35S. Certain
isotopically-labeled compounds of the invention, for example, those
incorporating a radioactive isotope, are useful in drug and/or
substrate tissue distribution studies. The radioactive isotopes
tritium, .sup.3H, and carbon-14, .sup.14C, are particularly useful
for this purpose in view of their ease of incorporation and ready
means of detection. Substitution with heavier isotopes such as
deuterium, .sup.2H, may afford certain therapeutic advantages
resulting from greater metabolic stability, for example, increase
in vivo half-life or reduced dosage requirements, and hence may be
preferred in some circumstances. Substitution with positron
emitting isotopes, such as .sup.11C, .sup.18F, .sup.15O, and
.sup.13N, can be useful in Positron Emission Topography (PET)
studies for examining substrate receptor occupancy.
[0267] Isotopically-labeled compounds of the invention can
generally be prepared by conventional techniques known to those
skilled in the art or by processes analogous to those described
herein, using an appropriate isotopically-labeled reagent in place
of the non-labeled reagent otherwise employed.
[0268] "Stable compound" and "stable structure" are meant to
indicate a compound that is sufficiently robust to survive
isolation to a useful degree of purity from a reaction mixture, and
formulation into an efficacious therapeutic agent. The present
invention is intended to embody stable compounds.
[0269] "Therapeutically effective amount" is intended to include an
amount of a compound of the present invention alone or an amount of
the combination of compounds claimed or an amount of a compound of
the present invention in combination with other active ingredients
effective to modulate GPR119 or effective to treat or prevent
various disorders.
[0270] As used herein, "treating" or "treatment" cover the
treatment of a disease-state in a mammal, particularly in a human,
and include: (a) preventing the disease-state from occurring in a
mammal, in particular, when such mammal is predisposed to the
disease-state but has not yet been diagnosed as having it; (b)
modulating the disease-state, i.e., arresting it development;
and/or (c) relieving the disease-state, i.e., causing regression of
the disease state.
Synthesis
[0271] The compounds of the present invention can be prepared in a
number of ways well known to one skilled in the art of organic
synthesis. The compounds of the present invention can be
synthesized using the methods described below, together with
synthetic methods known in the art of synthetic organic chemistry,
or variations thereon as appreciated by those skilled in the art.
Preferred methods include, but are not limited to, those described
below. All references cited herein are hereby incorporated in their
entirety by reference as to the relevant subject matter referenced
in the citation.
[0272] The novel compounds of Formula I may be prepared using the
reactions and techniques described in this section. The reactions
are performed in solvents appropriate to the reagents and materials
employed and are suitable for the transformations being effected.
Also, in the description of the synthetic methods described below,
it is to be understood that all proposed reaction conditions,
including solvent, reaction atmosphere, reaction temperature,
duration of the experiment and workup procedures, are chosen to be
the conditions standard for that reaction, which should be readily
recognized by one skilled in the art. One skilled in the art of
organic synthesis understands that the functionality present on
various portions of the edict molecule must be compatible with the
reagents and reactions proposed. Not all compounds of Formula I
falling into a given class may be compatible with some of the
reaction conditions required in some of the methods described. Such
restrictions to the substituents, which are compatible with the
reaction conditions, will be readily apparent to one skilled in the
art and alternate methods must be used.
##STR00008##
[0273] Compounds of Formula I may be prepared by procedures
depicted in Scheme 1. Intermediate 1, obtained from commercial
sources, can be reacted with R.sup.1X (where R.sup.1 other than H
is as defined with respect to Formula I, and X is a halide) in the
presence of a ligand such as 8-hydroxyquinoline, CuI and a base
such as K.sub.2CO.sub.3 in a suitable solvent, such as DMF, DMSO,
etc., at an elevated temperature to yield intermediate 2. Cleavage
of the benzyl group of intermediate 2 can be performed using the
methods known in the art such as hydrogenolysis catalyzed by
palladium. Intermediate 3 can then be alkylated with intermediate
4, which can be prepared by reaction of the corresponding alcohols
with methanesulfonyl chloride, in the presence of a base such as
K.sub.2CO.sub.3 at an elevated temperature. The above alcohols are
commercially available or can be prepared by various methods known
to one skilled in the art, for example, those found in Sandler, S.
et al., Organic Functional Group Preparations, Vol. I, Academic
Press, Inc. (1983). Removal of the protecting group ("PG") of
intermediate 5 can be carried out with appropriate reagents known
to those skilled in the art (for specific details, see Greene, T.
W. et al., Protecting Groups in Organic Synthesis, John Wiley &
Sons Inc. (1991)). The deprotected product can then be treated with
R.sup.2X (where R.sup.2 is defined as in Formula I, and X is a
leaving group such as halide, mesylate, triflate, etc.), which are
commercially available or can be prepared by various methods known
in the art, at the conditions that are routine for those skilled in
the art of organic synthesis to afford compounds of Formula I.
Alternatively, the intermediate 6 can also be reacted with
isocyanates or isothiocyanates in the presence of a base, such as
Et.sub.3N, to provide the compounds of Formula I.
##STR00009##
[0274] Compounds of Formula I, wherein Y is defined as --S--,
--S(.dbd.O)-- or --S(O).sub.2--, may be prepared by procedures
outlined in Scheme 2. Halogenation of intermediate 3 generated as
described in Scheme I can be achieved with POBr.sub.3, PBr.sub.3 or
POCl.sub.3 using the conditions known to one skilled in the art.
The halogenated pyridone can then be reacted with intermediate 8,
which can be prepared according to the procedures described in U.S.
Pat. No. 6,556,384 B1 (Owen, D. et al.), which is incorporated by
reference herein as to these preparations, in the presence of a
base such as NaH to yield intermediate 9. Oxidation of intermediate
9 with an oxidant such as mCPBA in a suitable solvent such as
CH.sub.2Cl.sub.2 affords intermediate 10 and intermediate 11.
Intermediate 9, intermediate 10 or intermediate 11 can be carried
forward to compounds of Formula I following the procedures
described above in Scheme 1 by substituting intermediate 9, 10 or
11 for intermediate 5.
##STR00010##
[0275] Compounds of Formula I, wherein Y is defined as NR.sup.3,
may be prepared by procedures illustrated in Scheme 3. Intermediate
7 prepared as described in Scheme 3 can be reacted with
intermediate 12, which are commercially available or can be
prepared by the methods known to one skilled in the art, in the
presence of a catalyst such as Pd(P(tBu).sub.3).sub.2 and a base
such as NaO.sup.tBu in a suitable solvent such as toluene to yield
intermediate 13. The products can then be further elaborated to
compounds of Formula I using the procedures described above in
Scheme 1 by substituting intermediate 13 for intermediate 5.
[0276] Alternatively, compounds of Formula I, wherein Y is defined
as --N(R.sup.3)--, may also be prepared by the procedures similar
to those provided in Scheme 3. Those invention compounds can be
alternatively obtained by treatment of the compounds of Formula I,
wherein R.sup.3.dbd.H, with a suitable electrophile R.sup.3X (where
X is a halide, mesylate, triflate, etc.) in the presence of a base
such as K.sub.2CO.sub.3, CsCO.sub.3, NaO.sup.tBu, etc.
##STR00011##
[0277] Alternatively, compounds of Formula I can be synthesized by
procedures outlined in Scheme 4. Intermediate 14, obtained from
commercial sources, can be reacted with intermediate 15, which are
commercially available or can be generated by many methods readily
recognized by one skilled in the art, for example, those found in
Sandler, S. et al., Organic Functional Group Preparations, Vol. I,
Academic Press, Inc. (1983), in the presence of a base such as NaH
to yield intermediate 16. Hydrolysis of intermediate 16 can be
achieved by treatment with DABCO in the presence of a base such as
K.sub.2CO.sub.3 in dioxane/water at an elevated temperature.
Intermediate 17 can then be reacted with R.sup.1X (where R.sup.1 is
defined with respect to Formula I, and X is a halide) in the
presence of a ligand such as 8-hydroxyquinoline, CuI and a base
such as K.sub.2CO.sub.3 in a suitable solvent, such as DMF, DMSO,
etc., at an elevated temperature to yield intermediate 18. The
intermediate 18 can be carried forward to compounds of Formula I
following the procedures described above in Scheme 1 by
substituting intermediate 18 for intermediate 5.
##STR00012##
[0278] Compounds of Formula I may be prepared by procedures
illustrated in Scheme 5. Intermediate 3 generated as described in
Scheme I can be reacted with intermediate 19, which are
commercially available or can be made by various methods readily
recognized by one skilled in the art, for example, those found in
Sandler, S. et al., Organic Functional Group Preparations, Vol. I,
Academic Press, Inc. (1983), via Mitsunobo reaction to yield
intermediate 20, which can be converted to Formula I using the
procedures described above in Scheme 1 by substituting intermediate
20 for intermediate 5.
##STR00013##
[0279] Alternatively, compounds of Formula I may be synthesized as
provided in Scheme 6. Intermediate 21, obtained from commercial
sources, can be reacted with intermediate 4 prepared as described
in Scheme 1 to give intermediate 22. Hydrolysis of intermediate 22
can be achieved by treatment with DABCO in the presence of a base
such as K.sub.2CO.sub.3 in dioxane/water at an elevated
temperature. Intermediate 23 can be treated with R.sup.1X (where
R.sup.1 is defined with respect to Formula I and X is a halide) in
the presence of a ligand such as 8-hydroxyquinoline, CuI and a base
such as K.sub.2CO.sub.3 in a suitable solvent, such as DMF, DMSO,
etc., at an elevated temperature to yield intermediate 24. The
intermediate 24 can be carried forward to compounds of Formula I
following the procedures described above in Scheme 1 by
substituting intermediate 24 for intermediate 5.
##STR00014##
[0280] Compounds of Formula I can also be prepared by procedures
illustrated in Scheme 7. Intermediate 25 (R.sup.1--NH.sub.2, where
R.sup.1 is as defined in Formula I), which are commercially
available or can be made by methods recognized by one skilled in
the art, can be converted to formamidine intermediate 26 in a two
step procedure described by Donetti, A. et al., J. Med. Chem.,
27:380 (1984). Intermediate 26 can be reacted with dimethyl
malonate to yield intermediate 27 using literature procedures (J.
Med. Chem., 45:3639 (2002)). The intermediate 27 can then be
carried forward to compounds of Formula I following the procedures
described above in Scheme 1 by substituting intermediate 28 for
intermediate 3.
##STR00015##
[0281] Compounds of Formula I, wherein R.sup.21 is defined as H and
Y as --O--, may be prepared by procedures depicted in Scheme 8.
Intermediate 28, obtained from commercial sources, can be reacted
with R.sup.1X (where R.sup.1 other than H is as defined with
respect to Formula I, and X is a halide) in the presence of a
ligand such as 8-hydroxyquinoline, CuI and a base such as
K.sub.2CO.sub.3 in a suitable solvent, such as DMF, DMSO, etc., at
an elevated temperature to yield intermediate 29 (alternatively, it
can be reacted with R.sup.1X (where R.sup.1 other than H is as
defined with respect to Formula I, and X is a halide) in the
presence of a base such as NaH in a suitable solvent, such as DMF,
DMSO, etc., at an elevated temperature). Cleavage of the methoxy
group of intermediate 29 can be performed using the methods known
in the art, such as hydrolysis by NaOH. Intermediate 30 can then be
alkylated with intermediate 4, which can be prepared by reaction of
the corresponding alcohols with methanesulfonyl chloride, in the
presence of a base such as K.sub.2CO.sub.3 at an elevated
temperature. The above alcohols are commercially available or can
be prepared by various methods known to one skilled in the art
(typical examples may be found in Sandler, S. et al., Organic
Functional Group Preparations, Vol. I, Academic Press, Inc.
(1983)). Removal of the protecting group of intermediate 31 can be
carried out with appropriate reagents well known to those skilled
in the art (for specific details, see Greene, T. W. et al.,
Protecting Groups in Organic Synthesis, John Wiley & Sons Inc.
(1991)). The deprotected product can then be treated with R.sup.2X
(where R.sup.2 is defined as in Formula I, and X is a leaving group
such as halide, mesylate, triflate, etc.), which are commercially
available or can be prepared by many methods known in the art,
under various conditions that are routine for those skilled in the
art of organic synthesis to afford compounds of Formula I.
Alternatively, the intermediate 32 can also be reacted with
isocyanates or isothiocyanates in the presence of a base such as
Et.sub.3N to provide other compounds of Formula I.
##STR00016##
[0282] Alternatively, Compounds of Formula I, wherein R.sup.21 is
defined as H and Y as --O--, may be prepared by procedures depicted
in Scheme 9. Intermediate 30 can then be alkylated with
intermediate 33, which can be prepared by reaction of the
corresponding alcohols with methanesulfonyl chloride, in the
presence of a base such as K.sub.2CO.sub.3 at an elevated
temperature. The above alcohols are commercially available or can
be prepared by various methods known to one skilled in the art
(typical examples may be found in Sandler, S. et al., Organic
Functional Group Preparations, Vol. I, Academic Press, Inc. (1983))
to afford compounds of Formula I.
##STR00017##
[0283] Alternatively, compounds of Formula I, wherein R.sup.21 is
defined as halogen and Y as --O--, may be prepared by procedures
illustrated in Scheme 10. Intermediate 34, obtained from commercial
sources, can be reacted with intermediate 35, which are also
commercially available or can be made by various methods readily
recognized by one skilled in the art (typical examples may be found
in Sandler, S. et al., Organic Functional Group Preparations, Vol.
I, Academic Press, Inc. (1983)) in the presence of a base such as
NaH in a suitable solvent, such as DMF, DMSO, etc., at an elevated
temperature to yield intermediate 36. Condensation of the
intermediate 36 with R.sup.1NHNH.sub.2 (where R.sup.1 other than H
is as defined with respect to Formula I) to afford intermediate 37.
Treatment of intermediate 37 with POX.sub.3 at an elevated
temperature to yield intermediate 38. Removal of the protecting
group of intermediate 39 can be carried out with appropriate
reagents known to those skilled in the art (for specific details,
see Greene, T. W. et al., Protecting Groups in Organic Synthesis,
John Wiley & Sons Inc. (1991)). The deprotected product can
then be treated with alkylating agent R.sup.2Z (where R.sup.2 is
defined as in Formula I, and Z is a leaving group such as halide,
mesylate, triflate, etc.), which are commercially available or can
be prepared by various methods known in the art, at various
conditions that are routine for those skilled in the art of organic
synthesis to afford compounds of Formula I. Alternatively the
intermediate 39 can also be reacted with isocyanates or
isothiocyanates in the presence of a base such as Et.sub.3N to
provide the compounds of Formula I.
[0284] Alternatively, compounds of Formula I, wherein Y is defined
as --O-- and R.sup.21 as CN, amines, alkoxys, alkyls, aryls,
alkenes, or alkynes, may be prepared by procedures depicted in
Scheme 11. Intermediate 40a can then be coupled with commercially
available CuCN, amines, alcohols, boronic acids by various methods
known in the art, at various conditions that are routine for those
skilled in the art of organic synthesis to afford compounds of
Formula I.
##STR00018##
##STR00019##
[0285] Alternatively, compounds of Formula I, wherein Y is defined
as --O-- and R.sup.21 as esters and amides, may be prepared by
procedures illustrated in Scheme 12. Intermediate 41, obtained from
commercial sources, can be reacted with aryldiazonium chloride,
which are also commercially available, and followed by thermal ring
closure to yield intermediate 42 (typical examples may be found in
Schober, B. D., J. Heterocyclic Chem., 26:169 (1989)). Intermediate
42 can then be alkylated with intermediate 4, which can be prepared
by reaction of the corresponding alcohols with methanesulfonyl
chloride, in the presence of a base such as K.sub.2CO.sub.3 at an
elevated temperature. The above alcohols are commercially available
or can be prepared by various methods known to one skilled in the
art (typical examples may be found in Sandler, S. et al., Organic
Functional Group Preparations, Vol. I, Academic Press, Inc.
(1983)). Removal of the protecting group of intermediate 43 can be
carried out with appropriate reagents well known to those skilled
in the art (for specific details, see Greene, T. W. et al.,
Protecting Groups in Organic Synthesis, John Wiley & Sons Inc.
(1991)). The deprotected product Intermediate 44 can then be
treated with R.sup.2X (where R.sup.2 is defined as in Formula I,
and X is a leaving group such as halide, mesylate, triflate, etc.),
which are commercially available or can be prepared by various
methods known in the art, under various conditions that are routine
for those skilled in the art of organic synthesis to afford
compounds of Formula I as intermediate 45. Alternatively the
intermediate 44 can also be reacted with isocyanates or
isothiocyanates in the presence of a base such as Et.sub.3N to
provide the compounds of Formula I as intermediate 45. Further
elaboration of intermediate 45 with commercially available amines
at an elevated temperature can afford alternative compounds of
Formula I.
##STR00020##
[0286] Compounds of Formula I, wherein Y is defined as --S--,
--S(.dbd.O)-- or --S(O).sub.2--, may be prepared by procedures
outlined in Scheme 13. Halogenation of intermediate 30, generated
as described in Scheme 10, can be achieved with POBr.sub.3,
PBr.sub.3 or POCl.sub.3 using the conditions known to one skilled
in the art. The halogenated intermediate 46 can then be reacted
with intermediate 47, which can be prepared according to the
procedures described in U.S. Pat. No. 6,556,384 B1 (Owen, D. et
al.), in the presence of a base such as NaH to yield intermediate
48. Oxidation of intermediate 48 with an oxidant such as mCPBA in a
suitable solvent such as CH.sub.2Cl.sub.2 affords intermediate 49
and intermediate 50. Intermediate 48, intermediate 49 or
intermediate 50 can be carried forward to compounds of Formula I
following the procedures described above in Scheme 8 by
substituting intermediate 48, 49 or 50 for intermediate 31.
##STR00021##
[0287] Compounds of Formula I, wherein Y is defined as
--N(R.sup.7)--, may be prepared by procedures illustrated in Scheme
14. Intermediate 46 prepared as described in Scheme 13 can be
reacted with intermediate 51, which are commercially available or
can be prepared by the methods known to one skilled in the art, in
the presence of a catalyst such as Pd(P(tBu).sub.3).sub.2 and a
base such as NaO.sup.tBu in a suitable solvent such as toluene to
yield intermediate 52. The products can then be further elaborated
to compounds of Formula I using the procedures described above in
Scheme 8 by substituting intermediate 52 for intermediate 31.
[0288] Alternatively, compounds of Formula I, wherein Y is defined
as --N(R.sup.7)--, may also be prepared by treatment of the
compounds of Formula I, wherein R.sup.7.dbd.H, with a suitable
electrophile R.sup.7X (where X is a halide, mesylate, triflate,
etc.) in the presence of a base such as K.sub.2CO.sub.3,
CsCO.sub.3, NaOtBu, etc.
ABBREVIATIONS
[0289] The following abbreviations are employed in the Examples and
elsewhere herein:
EtOAc=ethyl acetate DMF=dimethylformamide THF=tetrahydrofuran
K.sub.2CO.sub.3=potassium carbonate Na.sub.2CO.sub.3=sodium
carbonate MgSO.sub.4=magnesium sulfate SiO.sub.2=silicon dioxide
CH.sub.2Cl.sub.2=methylene chloride MeOH=methanol HCl=hydrochloric
acid Cs.sub.2CO.sub.3=cesium carbonate KOH=potassium hydroxide
DME=1,2-dimethoxyethane
Pd(dppf)Cl.sub.2=[1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium
(II) t-BuONa=sodium tert-butoxide
Pd.sub.2(dba).sub.3=tris(dibenzylideneacetone)dipalladium (0)
TFA=trifluoroacetic acid
BINAP=rac-2,2'-bis(diphenylphosphino)-1,1'-binaphthyl
DABCO=1,4-diazabicyclo[2.2.2]octane mCPBA=m-chloroperoxybenzoic
acid min=minute(s) h or hr=hour(s) mL or ml=milliliter g=gram(s)
mg=milligram(s) mmol=millimole(s) LRMS=low resolution mass
spectrometry NMR=nuclear magnetic resonance
EXAMPLES
[0290] The following Examples are offered as illustrative as a
partial scope and particular embodiments of the invention and are
not meant to be limiting of the scope of the invention.
Abbreviations and chemical symbols have their usual and customary
meanings unless otherwise indicated. Unless otherwise indicated,
the compounds described herein have been prepared, isolated and
characterized using the Schemes and other methods disclosed herein
or may be prepared using the same.
Example 1
trans-tert-Butyl
2-methyl-4-(1-(4-(methylsulfonyl)phenyl)-2-oxo-1,2-dihydropyridin-4-yloxy-
)piperidine-1-carboxylate
##STR00022##
[0291] Step A. Preparation of tert-butyl
4-hydroxy-2-methylpiperidine-1-carboxylate
[0292] To a solution of tert-butyl
2-methyl-4-oxopiperidine-1-carboxylate (727 mg, 3.41 mmol, Small
Molecules Inc.) in MeOH (6.0 mL) at 0.degree. C. was added sodium
borohydride (193 mg, 5.11 mmol, Aldrich) in several portions. The
reaction mixture was stirred at 0.degree. C. for 1 hr and warmed up
to room temperature and continuously stirred for another 2.5 hrs.
The resulting mixture was then quenched with saturated NH.sub.4Cl
aqueous solution and evaporated under reduced pressure to remove
MeOH followed by extraction with CH.sub.2Cl.sub.2 (3.times.). The
combined extracts were dried (Na.sub.2SO.sub.4) and concentrated in
vacuo to give the title compound (745 mg) as a colorless sticky oil
which was used without further purification.
Step B. Preparation of tert-butyl
2-methyl-4-(methylsulfonyloxy)piperidine-1-carboxylate
[0293] To a mixture of tert-butyl
4-hydroxy-2-methylpiperidine-1-carboxylate (745 mg, 3.46 mmol) and
triethylamine (0.965 mL, 6.92 mmol, EMD) in CH.sub.2Cl.sub.2 (20.0
mL) at 0.degree. C. was added methanesulfonyl chloride (0.324 mL,
4.15 mmol, Aldrich) dropwise. The reaction mixture was stirred at
0.degree. C. for 5 min and at room temperature for 3 hrs and then
quenched with 0.5N HCl solution. The mixture was separated and
aqueous layer was extracted further with CH.sub.2Cl.sub.2
(2.times.). The combined organic layers were washed with brine,
dried (Na.sub.2SO.sub.4) and evaporated under reduced pressure. The
residue was purified by flash chromatography on silica gel (0-100%
EtOAc in hexane) to give both cis and trans isomers of tert-butyl
4-hydroxy-2-methylpiperidine-1-carboxylate(cis-isomer, 498.1 mg,
off-white solid, 49%; trans-isomer, 146.4 mg, colorless oil, 14%).
The structures were assigned based on 1D-NOE of NMR.
Step C. Preparation of
4-(benzyloxy)-1-(4-(methylsulfonyl)phenyl)pyridine-2(1H)-one
[0294] A mixture of 4-benzyloxy-2(1H)-pyridone (6.87 g, 34.1 mmol,
Aldrich), 4-bromophenyl methyl sulphone (8.01 g, 34.1 mmol,
Combi-Blocks Inc.), copper(I) iodide (1.30 g, 6.82 mmol, Aldrich),
8-hydroxyquinoline (0.99 g, 6.82 mmol, Alfa Aesar) and potassium
carbonate (6.12 g, 44.3 mmol, EMD) in DMSO (100 mL) was heated at
145.degree. C. for 6 h, cooled to room temperature and then diluted
with 10% NH.sub.4OH aqueous solution (50 mL) and EtOAc (100 mL).
The resulting mixture was filtered and the solid was washed with
H.sub.2O and EtOAc to give 8.0 g crude product as a greenish solid.
MS (ESI) 356 (M+H).
Step D. Preparation of
4-hydroxy-1-(4-(methylsulfonyl)phenyl)pyridine-2(1H)-one
[0295] A stirring suspension of
4-(benzyloxy)-1-(4-(methylsulfonyl)phenyl)-pyridine-2(1H)-one (3.0
g, 8.44 mmol) and palladium on activated carbon (1.63 g, 10 wt. %,
wet, Aldrich) in THF (150 mL) and methanol (250 mL) was under
hydrogen (balloon) for 1 hr. The resulting mixture was purged with
nitrogen and then diluted with THF (150 mL) and methanol (50 mL).
After stirring under nitrogen for 30 min, the mixture was filtered
through a pad of CELITE.RTM. 545 filter aid and the filtrate was
evaporated under reduced pressure to give 2.28 g crude product as a
dark greenish solid. MS (ESI) 266 (M+H).
Step E. Example 1
[0296] A mixture of
4-hydroxy-1-(4-(methylsulfonyl)phenyl)pyridine-2(1H)-one (173 mg,
0.652 mmol), cis-tert-butyl
2-methyl-4-(methylsulfonyloxy)piperidine-1-carboxylate (191 mg,
0.652 mmol) and potassium carbonate (180 mg, 1.304 mmol) in DMF
(3.0 mL) was heated at 140.degree. C. for 6 hrs and 100.degree. C.
overnight. To the above mixture additional potassium carbonate (90
mg, 1 equiv.) was added and the reaction was heated at 120.degree.
C. for 3 hrs and then cooled to room temperature. The mixture was
diluted with EtOAc and water and the aqueous layer was extracted
further with EtOAc (4.times.). The combined organic layers were
washed with brine/water (1:1, 2.times.), dried (Na.sub.2SO.sub.4)
and evaporated under reduced pressure. The residue was purified by
flash chromatography on silica gel (0-100% EtOAc/hexane) to yield
trans-isomer of tert-butyl
2-methyl-4-(1-(4-(methylsulfonyl)phenyl)-2-oxo-1,2-dihydropyridin-4-yloxy-
)piperidine-1-carboxylate (31.4 mg, 10.4%) as an off-white solid.
.sup.1H NMR (500 MHz, CDCl.sub.3). .delta. 8.07 (d, J=8.25 Hz, 2H),
7.61 (d, J=8.25 Hz, 2H), 7.22 (d, J=7.70 Hz, 1H), 6.02 (dd, J=7.70,
2.20 Hz, 1H), 5.97 (d, J=2.20 Hz, 1H), 4.50-4.66 (m, 2
[0297] H), 4.09-4.13 (m, 1H), 3.09 (s, 3H), 2.91-3.05 (m, 1H),
2.10-2.22 (m, 1H), 1.96-2.07 (m, 1H), 1.69-1.85 (m, 1H), 1.51-1.64
(m, 1H), 1.48 (s, 9H), 1.23 (d, J=7.15 Hz, 3H). MS (ESI) 463
(M+H).
Example 2
cis-tert-Butyl
2-methyl-4-(1-(4-(methylsulfonyl)phenyl)-2-oxo-1,2-dihydropyridin-4-yloxy-
)piperidine-1-carboxylate
##STR00023##
[0299] A mixture of
4-hydroxy-1-(4-(methylsulfonyl)phenyl)pyridin-2(1H)-one (125 mg,
0.471 mmol), trans-tert-butyl
2-methyl-4-(methylsulfonyloxy)piperidine-1-carboxylate (138.2 mg,
0.471 mmol, Example 1) and potassium carbonate (163 mg, 1.178 mmol)
in DMF (4.0 mL) was heated at 110.degree. C. for 20 hrs. The
reaction mixture was cooled to room temperature and diluted with
EtOAc and water. The aqueous layer was extracted further with EtOAc
(3.times.). The combined organic layers were washed with
brine/water (1:1, 2.times.), dried (Na.sub.2SO.sub.4) and
evaporated under reduced pressure. The residue was purified by
flash chromatography on silica gel (0-100% EtOAc in hexane) to
yield cis isomer of tert-butyl
2-methyl-4-(1-(4-(methylsulfonyl)phenyl)-2-oxo-1,2-dihydropyridin-4-yloxy-
)piperidine-1-carboxylate (114.6 mg, 52% yield) as an off-white
solid. .sup.1H NMR (500 MHz, CDCl.sub.3). .delta. 8.07 (d, J=8.80
Hz, 2H), 7.62 (d, J=8.25 Hz, 2H), 7.24 (d, J=7.70 Hz, 1H), 6.06
(dd, J=7.70, 2.75 Hz, 1H), 5.95 (d, J=2.20 Hz, 1H), 4.64-4.70 (m,
1H), 4.35-4.45 (m, 1H), 3.91-3.98 (m, 1H), 3.18-3.28 (m, 1H), 3.09
(s, 9H), 1.95-2.04 (m, 2H), 1.89-1.96 (m, 1 H), 1.75-1.84 (m, 1H),
1.48 (s, 9H), 1.27 (d, J=7.15 Hz, 3H). MS (ESI) 463 (M+H).
Example 3
cis-4-(2-Methyl-1-(5-propylpyrimidin-2-yl)piperidin-4-yloxy)-1-(4-(methyls-
ulfonyl)phenyl)pyridin-2(1H)-one, TFA salt
##STR00024##
[0300] Step A. Preparation of
cis-4-(2-methylpiperidin-4-yloxy)-1-(4-(methylsulfonyl)-phenyl)pyridine-2-
(1H)-one hydrochloric acid salt
[0301] To a solution of cis-tert-butyl
2-methyl-4-(1-(4-(methylsulfonyl)phenyl)-2-oxo-1,2-dihydropyridin-4-yloxy-
)piperidine-1-carboxylate (98.9 mg, 0.214 mmol) in MeOH (1.0 mL) at
0.degree. C. was added hydrochloric acid (2.0 mL, 8.00 mmol, 4.0 M
in dioxane, Aldrich). The reaction mixture was warmed up to room
temperature and continuously stirred at room temperature. After
stirring for 1.5 hrs, the mixture was evaporated under reduced
pressure to give the title compound (114.5 mg) as an off-white
solid. This material was used in the next step without further
purification. MS (ESI) 363 (M+H).
Step B. Example 3
[0302] A mixture of
cis-4-(2-methylpiperidin-4-yloxy)-1-(4-(methylsulfonyl)-phenyl)pyridin-2(-
1H)-one hydrochloric acid salt (45 mg, 0.124 mmol),
2-chloro-5-propylpyrimidine (38.9 mg, 0.248 mmol, Wako) and cesium
carbonate (162 mg, 0.497 mmol, Aldrich) in DMF (0.8 mL) was heated
under microwave conditions
[0303] (180.degree. C., 2 hrs). The resulting mixture was diluted
with EtOAc and water. The aqueous layer was extracted further with
EtOAc (3.times.). The combined extracts were washed with brine,
dried (Na.sub.2SO.sub.4) and evaporated under reduced pressure. The
residue was purified by preparative HPLC(C.sub.1.sup.8 column;
0-100% methanol in water containing 0.05% trifluoroacetic acid) to
yield Example 3 (12.7 mg, off-white solid, 20%) upon
lyophilization. .sup.1H NMR (500 MHz, CDCl.sub.3). .delta. 8.40 (s,
2H), 8.09 (d, J=8.80 Hz, 2H), 7.63 (d, J=8.80 Hz, 2H), 7.30 (d,
J=7.70 Hz, 1H), 6.15 (dd, J=7.70, 2.20 Hz, 1H), 6.12 (d, J=2.75 Hz,
1H), 4.99-5.07 (m, 1H), 4.79 (app brs, 1H), 4.51-4.58 (m, 1H),
3.51-3.63 (m, 1H), 3.11 (s, 3H), 2.50 (t, J=7.70 Hz, 2H), 2.21 (t,
J=14.57 Hz, 2H), 1.91-2.13 (m, 2H), 1.56-1.71 (m, 2H), 1.42 (d,
J=7.15 Hz, 3H), 0.98 (t, J=7.15 Hz, 3H). MS (ESI) 483 (M+H).
Example 4
trans-4-(2-Methyl-1-(5-propylpyrimidin-2-yl)piperidin-4-yloxy)-1-(4-(methy-
lsulfonyl)phenyl)pyridin-2(1H)-one, TFA salt
##STR00025##
[0305] Example 4 was prepared according to procedures described in
Example 3 substituting trans-tert-butyl
2-methyl-4-(1-(4-(methylsulfonyl)phenyl)-2-oxo-1,2-dihydropyridin-4-yloxy-
)piperidine-1-carboxylate for cis-tert-butyl
2-methyl-4-(1-(4-(methylsulfonyl)phenyl)-2-oxo-1,2-dihydropyridin-4-yloxy-
)piperidine-1-carboxylate in Step A. .sup.1H NMR (500 MHz,
CDCl.sub.3). .delta. 8.33 (s, 2H), 8.08 (d, J=8.25 Hz, 2H), 7.62
(d, J=8.80 Hz, 2H), 7.21-7.29 (m, 1H), 6.17 (d, J=2.75 Hz, 1H),
6.09 (dd, J=7.70, 2.75 Hz, 1H), 5.11-5.27 (m, 1H), 4.69-4.82 (m,
2H), 3.16-3.32 (m, 1H), 3.03-3.15 (m, 3H), 2.48 (t, J=7.42 Hz, 2H),
2.31-2.38 (m, 1H), 2.17-2.20 (m, 1H), 1.81-1.96 (m, 1H), 1.67-1.80
(m, 1H), 1.53-1.69 (m, 2H), 1.35 (d, J=7.15 Hz, 3H), 0.97 (t,
J=7.42 Hz, 3H). MS (ESI) 483 (M+H).
Example 5
1-(2-Methylbenzo[d]oxazol-5-yl)-4-(1-(5-propylpyrimidin-2-yl)piperidin-4-y-
loxy)pyridin-2(1H)-one
##STR00026##
[0306] Step A. Preparation of
1-(5-propylpyrimidin-2-yl)piperidin-4-ol
[0307] To a stirring solution of piperidin-4-ol (2.33 g, 23.0 mmol,
Aldrich) and potassium carbonate (6.36 g, 46.0 mmol, EMD) in DMF
(15 mL) at room temperature was added 2-chloro-5-propylpyrimidine
(4.33 g, 27.6 mmol, Wako). The reaction mixture was heated at
100.degree. C. for 3 h then diluted with H.sub.2O. The resulting
mixture was extracted with EtOAc (2.times.). The organic layers
were combined, dried over Na.sub.2SO.sub.4 and concentrated in
vacuo to a brown oil. The oil was purified by flash chromatography
(SiO.sub.2, 0 to 100% EtOAc in CH.sub.2Cl.sub.2) to yield 5.01 g of
desired product as a white solid. MS (ESI) 222 (M+H).
Step B. Preparation of 1-(5-propylpyrimidin-2-yl)piperidin-4-yl
methanesulfonate
[0308] To a stirring solution of
1-(5-propylpyrimidin-2-yl)piperidin-4-ol (9.2 g, 41.6 mmol),
Et.sub.3N (12.85 mL, 91 mmol, Aldrich) in CH.sub.2Cl.sub.2 (80 mL)
at 0.degree. C. was added a solution of Methanesulfonyl chloride
(3.54 mL, 45.7 mmol, ACROS.RTM.) in CH.sub.2Cl.sub.2 (20 mL)
dropwise. The reaction mixture was stirred at room temperature for
1 h and washed with 1N HCl in H.sub.2O, saturated NaHCO.sub.3 in
H.sub.2O and brine. The organic layer was dried over
Na.sub.2SO.sub.4 and concentrated in vacuo to yield 11.7 g of the
desired product as an off-white solid. MS (ESI) 300 (M+H).
Step C. Preparation of
4-(1-(5-propylpyrimidin-2-yl)piperidin-4-yloxy)pyridine-2(1H)-one
[0309] A stirring suspension of 4-hydroxypyridin-2(1H)-one (5.23 g,
47.1 mmol, Aldrich), 1-(5-propylpyrimidin-2-yl)piperidin-4-yl
methanesulfonate (11.7 g, 39.2 mmol), potassium carbonate (12.5 g,
90.0 mmol, EMD) and DMSO (48 mL) was heated at 100.degree. C. for 3
hours and then cooled to room temperature. The resulting mixture
was diluted with H.sub.2O and extracted with EtOAc (2.times.). The
organic layers were combined and concentrated in vacuo to a brown
solid. The solid was purified by flash chromatography (SiO.sub.2,
100% EtOAc and then SiO.sub.2, 10% MeOH in CH.sub.2Cl.sub.2) to
yield 5.00 g of desired product as an off-white solid. MS (ESI) 315
(M+H).
Step D. Example 5
[0310] A mixture of 5-bromo-2-methylbenzo[d]oxazole (81 mg, 0.38
mmol),
4-(1-(5-propylpyrimidin-2-yl)piperidin-4-yloxy)pyridin-2(1H)-one
(80 mg, 0.25 mmol), quinolin-8-ol (11 mg, 0.076 mmol, Alfa Aesar),
potassium carbonate (46 mg, 0.33 mmol), Copper(I) iodide (15 mg,
0.076 mmol, Alfa Aesar) in DMSO (2 mL) was heated under microwave
condition 160.degree. C. for 30 min. The resulting mixture was
diluted with H.sub.2O and extracted with EtOAc (2.times.). The
combined organic layers were concentrated in vacuo to a green oil.
The oil was purified by flash chromatography (SiO.sub.2, 0 to 5%
MeOH in CH.sub.2Cl.sub.2) to yield 37 mg of desired product as a
light brown solid. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm
8.30 (s, 2H) 7.81 (d, J=8.53 Hz, 1H) 7.74 (d, J=2.01 Hz, 1H) 7.66
(d, J=7.53 Hz, 1H) 7.39 (dd, J=8.78, 2.01 Hz, 1H) 6.05-6.17 (m, 2H)
4.74-4.89 (m, 1H) 4.22-4.34 (m, 2H) 3.49-3.61 (m, 2H) 2.71 (s, 3H)
2.44 (t, J=7.53 Hz, 2H) 2.00-2.16 (m, 2H) 1.50-1.75 (m, 4H) 0.94
(t, J=7.28 Hz, 3H). MS (ESI) 446 (M+H).
Example 6
1-(2-Isopropylbenzo[d]oxazol-5-yl)-4-(1-(5-propylpyrimidin-2-yl)piperidin--
4-yloxy)pyridin-2(1H)-one
##STR00027##
[0312] Example 6 was prepared according to procedures described in
Example 5 substituting 5-bromo-2-isopropylbenzo[d]oxazole for
5-bromo-2-methylbenzo-[d]oxazole in Step D. .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. ppm 8.18 (s, 2H), 7.64 (d, J=2.20 Hz, 1H), 7.57
(d, J=8.25 Hz, 1H), 7.32 (dd, J=8.52, 1.92 Hz, 1H), 7.23-7.26 (m,
1H), 5.98-6.07 (m, 2H), 4.53-4.64 (m, 1H), 4.16-4.29 (m, 2H),
3.57-3.70 (m, 2 H), 3.19-3.37 (m, 1H), 2.42 (t, J=7.42 Hz, 2H),
2.03-2.17 (m, 2H), 1.78-1.93 (m, 2H), 1.53-1.65 (m, 2H), 1.47 (d,
J=7.15 Hz, 6H), 0.95 (t, J=7.42 Hz, 3H). MS (ESI) 474 (M+H).
Example 7
1-(2-Methylbenzo[d]oxazol-6-yl)-4-(1-(5-propylpyrimidin-2-yl)piperidin-4-y-
loxy)pyridin-2(1H)-one, hydrochloride salt
##STR00028##
[0314] Example 7 was prepared according to procedures described in
Example 5 substituting 6-bromo-2-methylbenzo[d]oxazole for
5-bromo-2-methylbenzo-[d]oxazole in Step D except that the product
was dissolved in CH.sub.2Cl.sub.2 and 1 equivalent of HCl (1N HCl
in Et.sub.2O) was added, the resulting mixture stirred for 5 min
and then concentrated in vacuo to give Example 3. .sup.1H NMR (400
MHz, DMSO-d.sub.6) .delta. ppm 8.29 (s, 2H) 7.77 (d, J=1.76 Hz, 1H)
7.73 (d, J=8.28 Hz, 1H) 7.61 (d, J=7.53 Hz, 1H) 7.31 (dd, J=8.53,
2.01 Hz, 1H) 5.98-6.16 (m, 2H) 4.71-4.84 (m, 1H) 4.10-4.28 (m, 2H)
3.44-3.59 (m, 2H) 2.65 (s, 3H) 2.40 (t, J=7.53 Hz, 2H) 2.00-2.10
(m, 2H) 1.57-1.72 (m, 2H) 1.46-1.57 (m, 2H) 0.88 (t, J=7.40 Hz,
3H). MS (ESI) 446 (M+H).
Example 8
tert-Butyl
4-(1-(4-(methylsulfonyl)phenyl)-6-oxo-1,6-dihydropyridazin-4-yl-
oxy)piperidine-1-carboxylate
##STR00029##
[0315] Step A. Preparation of
5-methoxy-2-(4-(methylsulfonyl)phenyl)pyridazin-3(2H)-one
[0316] To a mixture of 5-methoxypyridazin-3(2H)-one (631 mg, 5.00
mmol) in DMF (5 mL) at room temperature under argon was added NaH
(240 mg, 6.0 mmol) in three portions over 2 minutes. After stirring
the reaction mixture at room temperature for 30 minutes,
1-fluoro-4-(methylsulfonyl)benzene (1.045 g, 6.0 mmol) was added.
The resulting reaction mixture was heated at 100.degree. C. under
argon for 5 hour. After cooling the reaction mixture to room
temperature, 3 mL of 1 M NaOH solution was added. The resulting
reaction mixture was heated at 60.degree. C. for 3 hours. After
cooling the reaction to room temperature, 10 mL of Et.sub.2O along
with 20 mL of water were added. The organic layer was separated and
discarded. The aq. phase was acidified with 1N HCl to pH=5. Solid
precipitates were collected by filtration and further washed with
water (5 mL.times.2) and Methanol (3 mL.times.2) to yield 231 mg of
product as tan solid. The filtrate was extracted with EtOAc (10
mL.times.3). The combined organic phases were washed with brine (20
mL), dried (MgSO.sub.4), filtered and concentrated. The crude
product was purified by flash chromatography (60 to 100%
EtOAc/Hexanes) to yield 371 mg of additional product. A total 602
mg (45%) of desired product was obtained. .sup.1H NMR (400 MHz,
DMSO) .delta. ppm 3.26 (s, 3H), 6.10 (d, J=2.64 Hz, 1H), 7.82 (d,
J=8.79 Hz, 2H), 7.89 (d, J=2.64 Hz, 1H), 8.01 (d, J=8.79 Hz, 2H),
11.85 (s, 1H). MS (ESI) 267 (M+H).
Step B. Preparation of tert-butyl
4-(methylsulfonyloxy)piperidine-1-carboxylate
[0317] To a stirring solution of
tert-butyl-4-hydroxy-1-piperidinecarboxylate (10.28 g, 51.08 mmol,
Aldrich) and Et.sub.3N (14.25 mL, 102.16 mmol, EMD) in
CH.sub.2Cl.sub.2 (300 mL) at room temperature was added
methanesulfonyl chloride (4.35 mL, 56.19 mmol, Aldrich) dropwise.
The reaction mixture was stirred at room temperature for 4 h and
washed with 0.1N HCl aqueous solution, H.sub.2O and brine. The
organic layer was dried with Na.sub.2SO.sub.4 and concentrate in
vacuo to yield 14.3 g of the crude product as a light orange
solid.
Step C. Example 8
[0318] To a mixture of
5-hydroxy-2-(4-(methylsulfonyl)phenyl)pyridazin-3(2H)-one (26.6 mg,
0.10 mmol) in DMF (1 mL) at room temperature under argon was added
potassium carbonate (41.4 mg, 0.30 mmol, EMD) and tert-butyl
4-(methylsulfonyloxy)piperidine-1-carboxylate (53.3 mg, 0.15 mmol).
The reaction mixture was heated at 90.degree. C. overnight and then
cooled to room temperature. The resulting mixture was diluted with
EtOAc (10 mL) and H.sub.2O (10 mL) and the aqueous layer was
extracted further with EtOAc (5 mL.times.2). The combined extracts
were washed with brine (10 mL.times.3), dried (Na.sub.2SO.sub.4)
and evaporated. The residual was purified by flash chromatography
(0 to 10% MeOH/CH.sub.2Cl.sub.2) to yield 38.9 mg (87%) of Example
8 as a white solid. .sup.1H NMR (400 MHz, CDCl.sub.3). .delta.
1.39-1.51 (m, 9H), 1.68-1.86 (m, 2H), 1.91-2.07 (m, 2H), 3.06 (s,
3H), 3.21-3.42 (m, 2H), 3.64-3.82 (m, 2H), 4.35-4.58 (m, 1H), 6.21
(d, J=2.64 Hz, 1H), 7.72 (d, J=2.64 Hz, 1H), 7.88 (d, J=8.79 Hz,
2H), 8.03 (d, J=8.79 Hz, 2H). MS (ESI) 394 (M+H-tBu).
Example 9
2-(4-(Methylsulfonyl)phenyl)-5-(1-(5-propylpyrimidin-2-yl)piperidin-4-ylox-
y)pyridazin-3(2H)-one
##STR00030##
[0320] Example 9 was prepared in 60% yield according to procedures
described in Example 8 substituting
1-(5-propylpyrimidin-2-yl)piperidin-4-yl methanesulfonate for
tert-butyl 4-(methylsulfonyloxy)piperidine-1-carboxylate. .sup.1H
NMR (400 MHz, CDCl.sub.3). .delta. 0.93 (t, J=7.47 Hz, 3H),
1.44-1.71 (m, 2H), 1.72-1.97 (m, 2H), 1.97-2.18 (m, 2H), 2.40 (t,
J=7.47 Hz, 2H), 3.07 (s, 3H), 3.43-3.78 (m, 2H), 4.00-4.36 (m, 2
H), 4.44-4.74 (m, 1H), 6.26 (d, J=2.64 Hz, 1H), 7.74 (d, J=2.64 Hz,
1H), 7.89 (d, J=8.35 Hz, 2H), 8.03 (d, J=8.79 Hz, 2H), 8.17 (s,
2H). MS (ESI) 470 (M+H).
Example 10
5-(1-(5-Cyclopropylpyrimidin-2-yl)piperidin-4-yloxy)-2-(4-(methylsulfonyl)-
phenyl)pyridazin-3(2H)-one
##STR00031##
[0322] Example 10 was prepared in 45% yield according to procedures
described in Example 8 substituting
1-(5-cyclopropylpyrimidin-2-yl)piperidin-4-yl methanesulfonate for
tert-butyl 4-(methylsulfonyloxy)piperidine-1-carboxylate. .sup.1H
NMR (400 MHz, CDCl.sub.3). .delta. 0.59 (d, J=6.15 Hz, 2H),
0.79-1.00 (m, 2H), 1.65-1.77 (m, 1H), 1.77-1.94 (m, 2H), 1.99-2.20
(m, 2H), 3.07 (s, 3H), 3.45-3.72 (m, 2H), 4.08-4.28 (m, 2H), 4.56
(s, 1H), 6.25 (d, J=3.08 Hz, 1H), 7.73 (d, J=3.08 Hz, 1H), 7.89 (d,
J=8.79 Hz, 2H), 8.03 (d, J=8.79 Hz, 2H), 8.13 (s, 2H). MS (ESI) 468
(M+H).
Example 11
5-(145-Acetylpyrimidin-2-yl)piperidin-4-yloxy)-2-(4-(methylsulfonyl)phenyl-
)pyridazin-3(2H)-one
##STR00032##
[0324] Example 11 was prepared in 45% yield according to procedures
described in Example 8 substituting
1-(5-acetylpyrimidin-2-yl)piperidin-4-yl methanesulfonate for
tert-butyl 4-(methylsulfonyloxy)piperidine-1-carboxylate. .sup.1H
NMR (400 MHz, CDCl.sub.3) .delta. ppm 1.80-1.99 (m, 2H), 2.01-2.21
(m, 2H), 2.41-2.59 (m, 3H), 3.07 (s, 3H), 3.80-4.03 (m, 2H),
4.10-4.36 (m, 2H), 4.50-4.76 (m, 1H), 7.75 (d, J=3.08 Hz, 1H), 7.89
(d, J=8.79 Hz, 2H), 8.03 (d, J=8.79 Hz, 2H), 8.85 (s, 2H). MS (ESI)
470 (M+H).
Example 12
5-(1-(5-Ethylpyrimidin-2-yl)piperidin-4-yloxy)-2-(4-(methylsulfonyl)phenyl-
)pyridazin-3(2H)-one
##STR00033##
[0325] Step A. Preparation of
2-(4-(methylsulfonyl)phenyl)-5-(piperidin-4-yloxy)pyridazin-3(2H)-one,
TFA salt
[0326] A mixture of Example 8 (10 mg, 0.022 mmol) and TFA (17 uL,
0.22 mmol) in CH.sub.2Cl.sub.2 (1 mL) was stirred for 5 hours and
then concentrated in vacuo. The obtained solid was dissolved in
methanol (2 mL) and evaporated to give 9.7 mg of the crude product
as a tan solid. MS (ESI) 350 (M+H).
Step B. Example 12
[0327] To a mixture of
2-(4-(methylsulfonyl)phenyl)-5-(piperidin-4-yloxy)-pyridazin-3(2H)-one
TFA salt (9.7 mg, 0.02 mmol) in DMF (1 mL) at room temperature
under argon was added DIPEA (7.7 uL, 0.04 mmol) and
2-chloro-5-ethylpyrimidine (4.7 mg, 0.03 mmol). The reaction
mixture was heated at 95.degree. C. overnight and cooled to room
temperature. The resulting mixture was diluted with EtOAc (10 mL)
and H.sub.2O (10 mL) and the aqueous layer was extracted further
with EtOAc (5 mL.times.2). The combined extracts were washed with
brine (10 mL.times.3), dried (Na.sub.2SO.sub.4) and evaporated. The
crude product was purified by preparative HPLC(C.sub.18 column;
10-100% methanol in water) to give Example 12 (3.6 mg, tan solid,
35%) upon lyophilization. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta.
ppm 1.24 (t, J=7.69 Hz, 3H), 1.85-2.05 (m, 2H), 2.05-2.26 (m, 2H),
2.56 (q, J=7.62 Hz, 2H), 3.07 (s, 3H), 3.75-3.98 (m, 2H), 3.97-4.30
(m, 2H), 4.51-4.81 (m, 1H), 6.31 (d, J=2.64 Hz, 1H), 7.76 (d,
J=3.08 Hz, 1H), 7.88 (d, J=8.79 Hz, 2H), 8.04 (d, J=8.79 Hz, 2H),
8.36 (s, 2H). MS (ESI) 456 (M+H).
Example 13
[0328] tert-Butyl
4-(1-(4-methoxybenzyl)-6-oxo-3-phenyl-1,6-dihydropyridazin-4-yloxy)piperi-
dine-1-carboxylate
##STR00034##
Step A. Preparation of
5-chloro-2-(4-methoxybenzyl)-6-phenylpyridazin-3(2H) one
[0329] To a mixture of 5-chloro-6-phenylpyridazin-3(2H)-one (207
mg, 1.0 mmol) in DMF (3 mL) at room temperature under argon was
added K.sub.2CO.sub.3 (415 mg, 3.0 mmol), and followed by addition
of 1-(bromomethyl)-4-methoxybenzene (241 mg, 1.2 mmol). The
resulting reaction mixture was stirred at room temperature
overnight. Water (25 mL) was added to the reaction mixture and
stirred for 1 hour. The product was collected by filtration and
dried overnight under reduce pressure to yield 278 mg (81%) of
5-chloro-2-(4-methoxybenzyl)-6-phenylpyridazin-3(2H)-one as a tan
solid. MS (ESI) 327 (M+H).
Step B. Example 13
[0330] To a mixture of tert-butyl 4-hydroxypiperidine-1-carboxylate
(121 mg, 0.60 mmol) in THF (3 mL) at room temperature under argon
was added NaH (24 mg, 0.60 mmol). After stirring at room
temperature under argon for 30 minutes,
5-chloro-2-(4-methoxybenzyl)-6-phenylpyridazin-3(2H)-one (163 mg,
0.50 mmol) was added. The resulting reaction mixture was stirred at
room temperature for three days. EtOAc (10 mL) and brine (10 mL)
were added to the reaction mixture. Layers were separated. Organic
layer were washed with water (15 mL), and brine (15 mL). Organic
phase was dried (MgSO.sub.4), filtered and concentrated. The crude
product was dissolved in a small amount of DCM (.about.2 ml) and
loaded onto a 40 g ISCO silica gel column which was eluted with a
20 min gradient from 0% to 100% EtOAc/Hexanes. 138.9 mg (56.3%) of
tert-butyl-4-(1-(4-methoxybenzyl)-6-oxo-3-phenyl-1,6-dihydropyridazin-4-y-
loxy)piperidine-1-carboxylate was obtained as a white solid.
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. ppm 1.43 (s, 9H)
1.62-1.82 (m, 2H) 1.80-1.98 (m, 2H) 3.16-3.57 (m, J=5.27, 5.27 Hz,
4H) 3.76 (s, 1H) 4.35-4.64 (m, 1H) 5.26 (s, 2H) 6.21 (s, 1H) 6.84
(d, J=8.79 Hz, 2H) 7.33-7.53 (m, 5H) 7.64 (dd, J=6.81, 3.30 Hz,
2H). MS (ESI) 492 (M+H).
Example 14
[0331] Methyl
4-(1-(tert-butoxycarbonyl)piperidin-4-yloxy)-1-(3,4-dichlorophenyl)-6-oxo-
-1,6-dihydropyridazine-3-carboxylate
##STR00035##
Step A. Preparation of 3,4-dichlorobenzenediazonium
[0332] To a mixture of 3,4-dichloroaniline (3.24 g, 20 mmol) in 10
mL of conc. HCl and water (20 mL) at 0.degree. C. was added sodium
nitrite (1.38 g, 20 mmol)in 15 mL of water. The resulting reaction
mixture was stirred at 0.degree. C. for 30 min. HPLC analysis
indicated the reaction was completed. The reaction mixture was used
directly in next step.
Step B. Preparation of (E)-dimethyl
2-(2-(3,4-dichlorophenyl)hydrazono)-3-oxopentanedioate
[0333] To a mixture of dimethyl 3-oxopentanedioate (3.48 g, 20
mmol) in ethanol (12 mL) and water (40 mL) at room temperature was
added sodium acetate (12.0 g, 146 mmol), and was followed by the
addition of 3,4-dichlorobenzenediazonium solution (20 mmol). The
resulting reaction mixture was stirred at room temperature for 1 h.
The product was collected by filtration, then washed with water
(.about.50 mL) and dried overnight under reduced pressure to yield
6.776 g (93%) of (E)-dimethyl
2-(2-(3,4-dichlorophenyl)hydrazono)-3-oxopentanedioate as a yellow
solid. MS (ESI) 347 (M+H).
Step C. Preparation of methyl
1-(3,4-dichlorophenyl)-4-hydroxy-6-oxo-1,6-dihydropyridazine-3-carboxylat-
e
[0334] (E)-Dimethyl
2-(2-(3,4-dichlorophenyl)hydrazono)-3-oxopentanedioate (6.7 g, 19.3
mmol) in 1, 2 dichlorobenzene (20 mL) was heated at 180.degree. C.
overnight. After cooling, the reaction to room temperature, water
50 mL was added to the reaction mixture and it was stirred for 1
hour. The product was collected by filtration and further washed
with water 20 mL and methanol (10 mL.times.3), then dried overnight
under reduce pressure to yield 3.73 g (55.2%) of methyl
1-(3,4-dichlorophenyl)-4-hydroxy-6-oxo-1,6-dihydropyridazine-3-carboxylat-
e as a tan solid. MS (ESI) 315 (M+H).
[0335] Step D. Example 14
[0336] To a mixture of methyl
1-(3,4-dichlorophenyl)-4-hydroxy-6-oxo-1,6-dihydropyridazine-3-carboxylat-
e (315 mg, 1.0 mmol) in DMF (3 mL) at room temperature under argon
was added K.sub.2CO.sub.3 (415 mg, 3.0 mmol) and tert-butyl
4-(methylsulfonyloxy)piperidine-1-carboxylate (419 mg, 1.5 mmol).
The reaction mixture was heated at 95.degree. C. overnight. EtOAc
(20 mL) and water (20 mL) were added to the reaction mixture.
Layers were separated. Organic layer were washed with water (15
mL), and brine (15 mL). Organic phase was dried (MgSO.sub.4),
filtered and concentrated. The crude product was dissolved in a
small amount of DCM (.about.2 ml) and loaded onto a 40 g ISCO
silica gel column which was eluted with a 20 min gradient from 20%
to 100% EtOAc/Hexanes. 72 mg (14.2%) of methyl
4-(1-(tert-butoxycarbonyl)piperidin-4-yloxy)-1-(3,4-dichlorophenyl)-6-oxo-
-1,6-dihydropyridazine-3-carboxylate was obtained as a gum. .sup.1H
NMR (400 MHz, CDCl.sub.3) .delta. ppm 1.40-1.50 (m, 9H) 1.68-1.82
(m, 1H) 1.92 (d, J=3.08 Hz, 3H) 3.23-3.45 (m, 2H) 3.49-3.59 (m, 1H)
3.59-3.73 (m, 1H) 3.82-4.03 (m, 3H) 4.48-5.43 (m, 1H) 6.12-6.38 (m,
1H) 7.38-7.64 (m, 2H) 7.75 (dd, J=7.91, 2.20 Hz, 1H). MS (ESI) 442
(M+H-tBu).
Example 15
tert-Butyl
4-(1-(3,4-dichlorophenyl)-3-(methylcarbamoyl)-6-oxo-1,6-dihydro-
pyridazin-4-yloxy)piperidine-1-carboxylate
##STR00036##
[0337] Step A. Preparation of
4-(1-(tert-butoxycarbonyl)piperidin-4-yloxy)-1-(3,4-dichlorophenyl)-6-oxo-
-1,6-dihydropyridazine-3-carboxylic acid
[0338] Methyl
4-(1-(tert-butoxycarbonyl)piperidin-4-yloxy)-1-(3,4-dichlorophenyl)-6-oxo-
-1,6-dihydropyridazine-3-carboxylate (example 14) (59.8 mg, 0.12
mmol) in THF (2 mL) at room temperature under argon was added 2M
NaOH (0.18 mL, 0.36 mmol). The reaction mixture was stirred at room
temperature overnight. Most of the product was precipitated out.
Solvents were removed in vacuo. 10 mL of water and 1 mL of 1M HCl
were added. The product was collected by filtration and further
washed with water (3 mL.times.2). After drying overnight, 56.7 mg
(96%) of
4-(1-(tert-butoxycarbonyl)piperidin-4-yloxy)-1-(3,4-dichlorophenyl)-6-oxo-
-1,6-dihydropyridazine-3-carboxylic acid was obtained as a white
solid. MS (ESI) 428 (M+H-tBu).
Step B. Example 15
[0339] To a mixture of
4-(1-(tert-butoxycarbonyl)piperidin-4-yloxy)-1-(3,4-dichlorophenyl)-6-oxo-
-1,6-dihydropyridazine-3-carboxylic acid (23 mg, 0.047 mmol) in THF
(1 ml) at room temperature under argon was added HOBt (8.0 mg,
0.052 mmol), EDC (10.01 mg, 0.052 mmol), and was followed by 1 M
methylamine in THF (0.237 mL, 0.237 mmol). The reaction mixture was
stirred at room temperature overnight. EtOAc (10 mL) and 1 N NaOH
(10 mL) were added to the reaction mixture. Layers were separated.
Organic layer were washed with water (10 mL), and brine (10 mL).
Organic phase was dried (MgSO.sub.4), filtered and concentrated.
The crude product was purified by preparative HPLC (C.sub.18
column; 10-100% methanol in water without TFA) to give tert-butyl
4-(1-(3,4-dichlorophenyl)-3-(methylcarbamoyl)-6-oxo-1,6-dihydropyridazin--
4-yloxy)piperidine-1-carboxylate (10 mg, white solid, 40.9%).
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. ppm 1.45 (s, 9H)
1.78-2.05 (m, 4H) 2.96 (d, J=5.27 Hz, 3H) 3.43-3.57 (m, 2H)
3.57-3.72 (m, 2H) 4.49-4.71 (m, 1H) 6.28 (s, 1H) 6.58-6.69 (m,
J=3.95 Hz, 1H) 7.46 (dd, 1H) 7.54 (d, 1H) 7.70 (d, J=2.20 Hz, 1H).
MS (ESI) 441 (M+H-tBu).
Example 16
tert-Butyl
4-(3-carbamoyl-1-(3,4-dichlorophenyl)-6-oxo-1,6-dihydropyridazi-
n-4-yloxy)piperidine-1-carboxylate
##STR00037##
[0341] Example 16 was prepared in 68.7% yield according to
procedures described in Example 15 substituting 1 M methylamine in
THF for 0.5 M ammonia in dioxane. .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. ppm 1.46 (s, 9H) 1.77-2.10 (m, 4H) 3.38-3.57 (m, 2H)
3.57-3.73 (m, 2H) 4.44-4.78 (m, 1H) 5.57 (s, 1H) 6.30 (s, 1H) 6.65
(s, 1H) 7.47 (dd, 1H) 7.51-7.58 (m, 1H) 7.71 (d, J=2.20 Hz, 1H). MS
(ESI) 427 (M+H-tBu).
Example 17
tert-Butyl
4-(1-(3,4-dichlorophenyl)-3-(hydroxymethyl)-6-oxo-1,6-dihydropy-
ridazin-4-yloxy)piperidine-1-carboxylate
##STR00038##
[0343] To a mixture of
4-(1-(tert-butoxycarbonyl)piperidin-4-yloxy)-1-(3,4-dichlorophenyl)-6-oxo-
-1,6-dihydropyridazine-3-carboxylic acid (from example 15 step A)
(5 mg, 0.01 mmol) in THF (1 ml) at room temperature under argon was
added 1 M BH.sub.3 in THF (31 uL, 0.031 mmol). The reaction mixture
was stirred at room temperature for one hour. Methanol (2 mL) was
carefully added to the reaction mixture and stirred at room
temperature for two hours. Solvents were removed in vacuo. EtOAc
(10 mL) and 1 N NaOH (10 mL) were added to the reaction mixture.
Layers were separated. Organic layer were washed with water (10
mL), and brine (10 mL). Organic phase was dried (MgSO.sub.4),
filtered and concentrated. The crude product was purified by
preparative HPLC (C.sub.18 column; 10-100% methanol in water
without TFA) to give tert-butyl
4-(1-(3,4-dichlorophenyl)-3-(hydroxymethyl)-6-oxo-1,6-dihydropyridazin-4--
yloxy)piperidine-1-carboxylate (2.3 mg, gum, 42.6%). .sup.1H NMR
(400 MHz, CDCl.sub.3) .delta. ppm 1.45-1.48 (m, 9H) 1.68-1.93 (m,
J=3.95 Hz, 2H) 1.88-2.17 (m, 2H) 2.65-2.84 (m, 1H) 3.27-3.46 (m,
2H) 3.55-3.76 (m, 2H) 4.43-4.60 (m, 1H) 4.67 (s, 2H) 6.08-6.35 (m,
1H) 7.40-7.62 (m, 2H) 7.63-7.83 (m, 1H). MS (ESI) 414
(M+H-tBu).
Example 18
Methyl
4-(1-(tert-butoxycarbonyl)piperidin-4-yloxy)-1-(4-(methylsulfonyl)p-
henyl)-6-oxo-1,6-dihydropyridazine-3-carboxylate
##STR00039##
[0344] Step A. Preparation of
4-(methylsulfonyl)benzenediazonium
[0345] To a mixture of 4-(methylsulfonyl)aniline (3.42 g, 20 mmol)
in 10 mL of conc. HCl and water (20 mL) at 0.degree. C. was added
sodium nitrite (1.38 g, 20 mmol) in 15 mL of water. The resulting
reaction mixture was stirred at 0.degree. C. for about 30 min. The
reaction mixture was used directly to next step.
Step B. Preparation of (E)-dimethyl 2-(2-(4-(methylsulfonyl)phenyl)
hydrazono)-3-oxopentanedioate
[0346] To a mixture of dimethyl 3-oxopentanedioate (3.48 g, 20
mmol) in ethanol (12 mL) and water (40 mL) at room temperature was
added sodium acetate (12.0 g, 146 mmol), and was followed by
addition of 4-(methylsulfonyl)benzenediazonium solution (20 mmol).
The resulting reaction mixture was stirred at room temperature for
1 h. The product was collected by filtration, then washed with
water (.about.50 mL) and dried overnight under reduce pressure to
yield 7.0 g (83%) of (E)-dimethyl
2-(2-(4-(methylsulfonyl)phenyl)hydrazono)-3-oxopentanedioate as a
yellow solid. MS (ESI) 357 (M+H).
Step C. Preparation of methyl
4-hydroxy-1-(4-(methylsulfonyl)phenyl)-6-oxo-1,6-dihydropyridazine-3-carb-
oxylate
[0347] The mixture of (E)-dimethyl
2-(2-(4-(methylsulfonyl)phenyl)hydrazono)-3-oxopentanedioate (7.0
g, 19.6 mmol) in 1, 2 dichlorobenzene (20 mL) was heated at
180.degree. C. overnight. After cooling the reaction to room
temperature, water 50 mL was added to the reaction mixture and
stirred for 1 hour. The product was collected by filtration and
further washed with water 20 mL and methanol (10 mL.times.3), then
dried overnight under reduced pressure to yield 3.13 g (49.1%) of
methyl
4-hydroxy-1-(4-(methylsulfonyl)phenyl)-6-oxo-1,6-dihydropyridazine-3-carb-
oxylate. MS (ESI) 325 (M+H).
Step D. Example 18
[0348] Example 18 was prepared in 12.2% yield according to
procedures described in Example 14 substituting methyl
1-(3,4-dichlorophenyl)-4-hydroxy-6-oxo-1,6-dihydropyridazine-3-carboxylat-
e for methyl
4-hydroxy-1-(4-(methylsulfonyl)phenyl)-6-oxo-1,6-dihydropyridazine-3-carb-
oxylate. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. ppm 1.40-1.50
(m, 9H) 1.68-1.82 (m, 1H) 1.92 (d, J=3.08 Hz, 3H) 3.23-3.45 (m, 2H)
3.49-3.59 (m, 1H) 3.59-3.73 (m, 1H) 3.82-4.03 (m, 3H) 4.48-5.43 (m,
1H) 6.12-6.38 (m, 1H) 7.38-7.64 (m, 2H) 7.75 (dd, J=7.91, 2.20 Hz,
1H). MS (ESI) 452 (M+H-tBu).
Example 19
tert-Butyl
4-(1-(4-methoxybenzyl)-6-oxo-1,6-dihydropyridazin-4-yloxy)piper-
idine-1-carboxylate
##STR00040##
[0349] Step A. Preparation of
5-methoxy-2-(4-methoxybenzyl)pyridazin-3(2H)-one
[0350] To a stirring solution of
5-chloro-6-phenylpyridazin-3(2H)-one (78 mg, 0.618 mmol) in DMF (3
mL) at room temperature under argon was added K.sub.2CO.sub.3 (256
mg, 1.855 mmol), and was followed by addition of
1-(bromomethyl)-4-methoxybenzene (149 mg, 0.742 mmol). The
resulting reaction mixture was stirred at room temperature
overnight. EtOAc (20 mL) and brine (30 mL) were added to the
reaction mixture. Layers were separated. Organic layer were washed
with water (15 mL), and brine (15 mL). Organic phase was dried
(MgSO.sub.4), filtered and concentrated. Crude product (117 mg) (MS
(ESI) 247 (M+H)) was used directly to next step.
Step B. Preparation of
5-hydroxy-2-(4-methoxybenzyl)pyridazin-3(2H)-one
[0351] To a stirring solution of
5-methoxy-2-(4-methoxybenzyl)pyridazin-3(2H)-one (117 mg, 0.47
mmol) in THF (3 mL) at room temperature under argon was added 1M
NaOH (2.0 mL, 2.0 mmol). The resulting reaction mixture was heated
at 80.degree. C. under argon for a day and monitored by LCMS until
the reaction was completed. EtOAc (20 mL), 1 M HCl (2 mL), and
water (10 mL) were added to the reaction mixture. Layers were
separated. Organic layer were washed with water (15 mL), and brine
(15 mL). Organic phase was dried (MgSO.sub.4), filtered and
concentrated. The crude product was dissolved in a small amount of
DCM (.about.2 ml) and loaded onto a 40 g ISCO silica gel column
which was eluted with a 20 min gradient from 20% to 100%
EtOAc/Hexanes. 95 mg (77%) of
5-hydroxy-2-(4-methoxybenzyl)pyridazin-3(2H)-one was obtained as a
gum. MS (ESI) 233 (M+H).
Step C. Example 19
[0352] Example 19 was prepared in 84% yield according to procedures
described in Example 14 substituting methyl
1-(3,4-dichlorophenyl)-4-hydroxy-6-oxo-1,6-dihydropyridazine-3-carboxylat-
e for 5-hydroxy-2-(4-methoxybenzyl)pyridazin-3(2H)-one. .sup.1H NMR
(400 MHz, CDCl.sub.3) .delta. ppm 1.45 (s, 9H) 1.71 (dd, J=12.08,
4.17 Hz, 2H) 1.83-2.00 (m, 2H) 3.18-3.38 (m, 2H) 3.56-3.74 (m, 2H)
3.77 (s, 3H) 4.10-4.55 (m, 1H) 5.18 (s, 2H) 6.08 (d, J=2.64 Hz, 1H)
6.84 (d, J=8.79 Hz, 2H) 7.36 (d, J=8.79 Hz, 2H) 7.51 (d, J=2.64 Hz,
1H). MS (ESI) 360 (M+H-tBu).
Example 20
tert-Butyl
4-(3-cyano-1-(3,4-dichlorophenyl)-6-oxo-1,6-dihydropyridazin-4--
yloxy)piperidine-1-carboxylate
##STR00041##
[0354] To a stirring solution of tert-butyl
4-(3-carbamoyl-1-(3,4-dichlorophenyl)-6-oxo-1,6-dihydropyridazin-4-yloxy)-
piperidine-1-carboxylate (example 16) (9 mg, 0.019 mmol) in THF (1
mL) at room temperature under argon was added TEA (5.65 mg, 0.056
mmol), and was followed by addition of TFAA (11.73 mg, 0.056 mmol).
The resulting reaction mixture was stirred at room temperature
overnight. Solvent was removed in vacuo. The crude product was
purified by preparative HPLC (C.sub.18 column; 10-100% methanol in
water without TFA) to give tert-butyl
4-(3-cyano-1-(3,4-dichlorophenyl)-6-oxo-1,6-dihydropyridazin-4-yloxy)pipe-
ridine-1-carboxylate (6 mg, white solid, 69.2%). .sup.1H NMR (400
MHz, CDCl.sub.3) .delta. ppm 1.47 (s, 9H) 1.74-1.94 (m, 2H)
1.92-2.12 (m, 2H) 3.32-3.55 (m, 2H) 3.58-3.81 (m, 2H) 4.42-4.72 (m,
1H) 6.26 (s, 1H) 7.45 (dd, J=8.79, 2.20 Hz, 1H) 7.55 (d, 1H) 7.72
(d, J=2.20 Hz, 1H). MS (ESI) 409 (M+H-tBu).
Example 21
4-(1-(5-Cyclopropylpyrimidin-2-yl)piperidin-4-yloxy)-1-(3,4-dichlorophenyl-
)-6-oxo-1,6-dihydropyridazine-3-carbonitrile
##STR00042##
[0355] Step A. Preparation of
1-(3,4-dichlorophenyl)-6-oxo-4-(piperidin-4-yloxy)-1,6-dihydropyridazine--
3-carbonitrile, HCl salt
[0356] To a stirring solution of Example 20 (400 mg, 0.860 mmol) in
DCM (3 mL) at room temperature under argon was added 4 M HCl in
dioxane (1.075 mL, 4.3 mmol). The reaction mixture was stirred at
room temperature overnight. Et.sub.2O (10 mL) was added to the
reaction mixture. The solid product was collected by filtration and
further washed with ether (5 mL.times.2). After drying under vacuum
for 2 hours, 302 mg (96%) of
1-(3,4-dichlorophenyl)-6-oxo-4-(piperidin-4-yloxy)-1,6-dihydropyridazine--
3-carbonitrile HCl salt was obtained as an off-white solid. MS
(ESI) 365 (M+H).
Step B. Example 21
[0357] To a stirring solution of
1-(3,4-dichlorophenyl)-6-oxo-4-(piperidin-4-yloxy)-1,6-dihydropyridazine--
3-carbonitrile HCl (50 mg, 0.137 mmol) in NMP (2 mL) at room
temperature under argon was added DIPEA (53.1 mg, 0.411 mmol) and
2-chloro-5-cyclopropylpyrimidine (31.7 mg, 0.205 mmol). The
resulting reaction mixture was heated at 100.degree. C. under argon
overnight. 15 mL of EtOAc was added to the reaction mixture. The
reaction mixture was washed with water (15 mL), and brine (15 mL).
Organic phase was dried (MgSO.sub.4), filtered and concentrated.
The crude product was dissolved in a small amount of DCM (.about.2
ml) and loaded onto a 40 g ISCO silica gel column which was eluted
with a 20 min gradient from 20% to 100% EtOAc/Hexanes. 27 mg
(38.8%) of
4-(1-(5-cyclopropylpyrimidin-2-yl)piperidin-4-yloxy)-1-(3,4-dichloropheny-
l)-6-oxo-1,6-dihydropyridazine-3-carbonitrile was obtained as a
white solid. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. ppm
0.50-0.66 (m, 2H) 0.82-0.98 (m, 2H) 1.64-1.79 (m, 1H) 1.83-1.99 (m,
2H) 1.99-2.16 (m, 2H) 3.60-3.90 (m, 2H) 3.96-4.25 (m, 2H) 4.56-4.87
(m, 1H) 6.31 (s, 1H) 7.41-7.50 (m, 1H) 7.50-7.60 (m, 1H) 7.73 (d,
J=2.20 Hz, 1H) 8.05-8.18 (m, 2H). MS (ESI) 483 (M+H).
Example 22
1-(3,4-Dichlorophenyl)-6-oxo-4-(1-(5-propylpyrimidin-2-yl)piperidin-4-ylox-
y)-1,6-dihydropyridazine-3-carbonitrile
##STR00043##
[0359] Example 22 was prepared in 31% yield according to procedures
described in Example 21 substituting
2-chloro-5-cyclopropylpyrimidine for 2-chloro-5-propylpyrimidine.
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. ppm 0.93 (t, J=7.47 Hz,
3H) 1.45-1.67 (m, 4H) 1.81-2.00 (m, 2H) 2.00-2.17 (m, 2H) 2.41 (t,
J=7.47 Hz, 2H) 3.57-3.89 (m, 2H) 4.01-4.29 (m, 2H) 4.57-4.79 (m,
1H) 6.26-6.36 (m, 1H) 7.38-7.50 (m, 1H) 7.50-7.63 (m, 1H) 7.73 (d,
J=2.64 Hz, 1H) 8.07-8.28 (m, 2H). MS (ESI) 485 (M+H).
Example 23
4-(1-(5-Chloropyrimidin-2-yl)piperidin-4-yloxy)-1-(3,4-dichlorophenyl)-6-o-
xo-1,6-dihydropyridazine-3-carbonitrile
##STR00044##
[0361] Example 23 was prepared in 42% yield according to procedures
described in Example 21 substituting
2-chloro-5-cyclopropylpyrimidine for 5-chloro-2-iodopyrimidine.
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. ppm 1.86-2.00 (m, 2H)
2.01-2.13 (m, 2H) 3.71-3.94 (m, 2H) 3.95-4.19 (m, 2H) 4.54-4.82 (m,
1H) 6.31 (s, 1H) 7.46 (dd, J=8.79, 2.64 Hz, 1H) 7.51-7.60 (m, 1H)
7.73 (d, J=2.64 Hz, 1H) 8.24 (s, 2H). MS (ESI) 477 (M+H).
Example 24
1-(3,4-Dichlorophenyl)-4-(1-(5-iodopyrimidin-2-yl)piperidin-4-yloxy)-6-oxo-
-1,6-dihydropyridazine-3-carbonitrile
##STR00045##
[0362] Step A. Preparation of 2-chloro-5-iodopyrimidine
[0363] To a stirring solution of 5-iodopyrimidin-2-amine (2.21 g,
10.0 mmol) in CH.sub.3CN (20 ml) at room temperature under argon
was added copper (II) chloride (2.02 g, 15 mmol) and tert-butyl
nitrite (1.55 g, 15 mmol). The reaction mixture was placed in a
preheated oil bath (60.degree. C.) under Argon. The reaction
mixture was cooled to room temperature and 20 ml of ether was
added. The resulting insoluble material was filtered and the
filtrate was concentrated. The crude product was dissolved in a
small amount of DCM (.about.2 ml) and loaded onto an 80 g ISCO
silica gel column which was eluted with a 20 min gradient from 0%
to 100% EtOAc/Hexanes. 778 mg (31%) of 2-chloro-5-iodopyrimidine
was obtained as an off-white solid. .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. ppm 8.79 (s, 2H).
Step B. Example 24
[0364] Example 24 was prepared in 52% yield according to procedures
described in Example 21 substituting
2-chloro-5-cyclopropylpyrimidine for 2-chloro-5-iodopyrimidine.
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. ppm 1.86-2.00 (m, 2H)
2.01-2.13 (m, 2H) 3.71-3.94 (m, 2H) 3.95-4.19 (m, 2H) 4.54-4.82 (m,
1H) 6.31 (s, 1H) 7.46 (dd, J=8.79, 2.64 Hz, 1H) 7.51-7.60 (m, 1H)
7.73 (d, J=2.64 Hz, 1H) 8.24 (s, 2H). MS (ESI) 569 (M+H).
Example 25
tert-Butyl
4-(3-amino-1-(3,4-dichlorophenyl)-6-oxo-1,6-dihydropyridazin-4--
yloxy)piperidine-1-carboxylate
##STR00046##
[0365] Step A. Preparation of tert-butyl
4-(1-(3,4-dichlorophenyl)-6-oxo-342-(trimethylsilyl)ethoxy)carbonylamino)-
-1,6-dihydropyridazin-4-yloxy)piperidine-1-carboxylate
[0366] To a stirring solution of
4-(1-(tert-butoxycarbonyl)piperidin-4-yloxy)-1-(3,4-dichlorophenyl)-6-oxo-
-1,6-dihydropyridazine-3-carboxylic acid (from example 15 step A)
(48 mg, 0.10 mmol) in dioxane (10 mL) at room temperature under
argon was added diphenyl phosphorazidate (65 mg, 0.20 mmol) and TEA
(51 mg, 0.50 mmol). The resulting reaction mixture was stirred at
room temperature for 1 hour, then 2-(trimethylsilyl)ethanol (118
mg, 1.0 mmol) was added. The resulting reaction mixture was heated
at 80.degree. C. under argon overnight. Solvent was concentrated.
Crude reaction mixture was used directly to next step. MS (ESI) 597
(M-H).
Step B. Example 25
[0367] To a stirring solution of tert-butyl
4-(1-(3,4-dichlorophenyl)-6-oxo-342-(trimethylsilyl)ethoxy)
carbonylamino)-1,6-dihydropyridazin-4-yloxy)piperidine-1-carboxylate
(60 mg, 0.10 mmol) in THF (10 ml) at room temperature under argon
was added 1M TBAF in THF (1 mL, 1.0 mmol). The reaction mixture was
stirred at room temperature overnight. Solvent was removed in
vacuo. The crude product was directly purified by preparative HPLC
(C.sub.18 column; 10-100% methanol in water without TFA) to give
tert-butyl
4-(3-amino-1-(3,4-dichlorophenyl)-6-oxo-1,6-dihydropyridazin-4-yloxy)pipe-
ridine-1-carboxylate (28 mg, white solid, 55%). .sup.1H NMR (400
MHz, CDCl.sub.3) .delta. ppm 1.34-1.55 (m, 9H) 1.65-1.91 (m, 2H)
2.04 (dd, J=12.96, 3.30 Hz, 2H) 3.06-3.39 (m, 2H) 3.59-3.94 (m, 2H)
4.29-4.71 (m, 2H) 6.20 (s, 1H) 7.43-7.50 (m, 1H) 7.54-7.64 (m, 1H)
7.80 (d, J=2.20 Hz, 1H). MS (ESI) 455 (M+H).
Example 26
1-(3,4-Dichlorophenyl)-6-oxo-4-(1-(5-(trifluoromethyl)pyrimidin-2-yl)piper-
idin-4-yloxy)-1,6-dihydropyridazine-3-carbonitrile
##STR00047##
[0369] To a stirring solution of
1-(3,4-dichlorophenyl)-4-(1-(5-iodopyrimidin-2-yl)piperidin-4-yloxy)-6-ox-
o-1,6-dihydropyridazine-3-carbonitrile (example 24) (49.3 mg, 0.087
mmol) in DMF (2 mL) at room temperature under argon was added
copper(I) iodide (33 mg, 0.173 umol) and fluorosulfonyl(difluoro)
acetic acid methyl ester (33.3 mg, 0.173 mol). The reaction mixture
was heated at 100.degree. C. overnight. The reaction was cooled to
room temperature. EtOAc (10 mL) was added to the reaction mixture,
which was washed with brine (15 mL.times.3). Organic phase was
dried (MgSO.sub.4), filtered and concentrated. The crude product
was dissolved in a small amount of DCM (.about.2 ml) and loaded
onto a 40 g ISCO silica gel column which was eluted with a 20 min
gradient from 0% to 100% EtOAc/Hexanes. 43 mg (92%) of
1-(3,4-dichlorophenyl)-6-oxo-4-(1-(5-(trifluoromethyl)pyrimidin-2-yl)p-
iperidin-4-yloxy)-1,6-dihydropyridazine-3-carbonitrile was obtained
as a brown solid. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. ppm
1.86-2.00 (m, 2H) 2.01-2.13 (m, 2H) 3.71-3.94 (m, 2 H) 3.95-4.19
(m, 2H) 4.54-4.82 (m, 1H) 6.31 (s, 1H) 7.46 (dd, J=8.79, 2.64 Hz,
1H) 7.51-7.60 (m, 1H) 7.73 (d, J=2.64 Hz, 1H) 8.24 (s, 2H). MS
(ESI) 511 (M+H).
Example 27
tert-Butyl
4-(3-chloro-1-(3,4-dichlorophenyl)-6-oxo-1,6-dihydropyridazin-4-
-yloxy) piperidine-1-carboxylate
##STR00048##
[0371] To a stirring solution of tert-butyl
4-(3-amino-1-(3,4-dichlorophenyl)-6-oxo-1,6-dihydropyridazin-4-yloxy)pipe-
ridine-1-carboxylate (20 mg, 0.044 mmol) in CH.sub.3CN (5 ml) at
room temperature under argon was added copper(II) chloride (8.86
mg, 0.066 mmol) and tert-butyl nitrite (6.79 mg, 0.066 mmol). The
reaction mixture was placed in a preheated oil bath (60.degree. C.)
under Argon. The reaction mixture was cooled to room temperature
and 20 ml of ether was added. The resulting insoluble material was
filtered and the filtrate was concentrated. The crude product was
directly purified by preparative HPLC (C.sub.18 column; 10-100%
methanol in water without TFA) to give tert-butyl
4-(3-chloro-1-(3,4-dichlorophenyl)-6-oxo-1,6-dihydropyridazin-4-yloxy)pip-
eridine-1-carboxylate (2.3 mg, white solid, 11%). .sup.1H NMR (400
MHz, CDCl.sub.3) .delta. ppm 1.47 (s, 9H) 1.81-1.92 (m, 3H)
1.92-2.05 (m, 2H) 3.48 (s, 2H) 3.57-3.70 (m, 2H) 4.21-4.77 (m, 1H)
6.24 (s, 1H) 7.51 (s, 2H) 7.76 (s, 1H). MS (ESI) 420 (M+H-tBu).
Example 28
2-(3,4-Dichlorophenyl)-5-(1-(5-propylpyrimidin-2-yl)piperidin-4-yloxy)pyri-
dazin-3(2H)-one
##STR00049##
[0372] Step A. Preparation of
1-(3,4-dichlorophenyl)-6-oxo-4-(piperidin-4-yloxy)-1,6-dihydropyridazine--
3-carboxylic acid
[0373] To a stirring solution of
4-(1-(tert-butoxycarbonyl)piperidin-4-yloxy)-1-(3,4-dichlorophenyl)-6-oxo-
-1,6-dihydropyridazine-3-carboxylic acid (from example 15 step A)
(105 mg, 0.217 mmol) in DCM (2 mL) at room temperature under argon
was added 4 M HCl in dioxane (0.271 mL, 1.1 mmol). The reaction
mixture was stirred at room temperature overnight. Et.sub.2O (10
mL) was added to the reaction mixture. The solid product was
collected by filtration and further washed with ether (5
mL.times.2). After drying under reduce pressure over night, 83 mg
(100%) of
1-(3,4-dichlorophenyl)-6-oxo-4-(piperidin-4-yloxy)-1,6-dihydropyridazine--
3-carboxylic acid HCl salt was obtained as an off-white solid. MS
(ESI) 384 (M+H).
Step B. Preparation of
1-(3,4-dichlorophenyl)-6-oxo-4-(1-(5-propylpyrimidin-2-yl)piperidin-4-ylo-
xy)-1,6-dihydropyridazine-3-carboxylic acid
[0374] To a stirring solution of
1-(3,4-dichlorophenyl)-6-oxo-4-(piperidin-4-yloxy)-1,6-dihydropyridazine--
3-carboxylic acid HCl (83 mg, 0.217 mmol) in NMP (2 mL) at room
temperature under argon was added DIPEA (84 mg, 0.651 mmol) and
2-chloro-5-propylpyrimidine (51 mg, 0.326 mmol). The resulting
reaction mixture was heated at 100.degree. C. under argon
overnight. 15 mL of EtOAc was added to the reaction mixture. The
reaction mixture was washed with water (15 mL), and brine (15 mL).
Organic phase was dried (MgSO.sub.4), filtered and concentrated.
The crude product was directly purified by preparative HPLC
(C.sub.18 column; 10-100% methanol in water without TFA) to give
1-(3,4-dichlorophenyl)-6-oxo-4-(1-(5-propylpyrimidin-2-yl)piperidin-4-ylo-
xy)-1,6-dihydropyridazine-3-carboxylic acid (57 mg, white solid,
52%). MS (ESI) 504 (M+H).
Step C. Example 28
[0375] To a stirring solution of
1-(3,4-dichlorophenyl)-6-oxo-4-(1-(5-propylpyrimidin-2-yl)piperidin-4-ylo-
xy)-1,6-dihydropyridazine-3-carboxylic acid (15 mg, 0.03 mmol) in
NMP (2 mL) at room temperature under argon was added
K.sub.2CO.sub.3 (8.22 mg, 0.06 mmol). The reaction mixture was
heated at 150.degree. C. overnight. The crude product was directly
purified by preparative HPLC (C.sub.18 column; 10-100% methanol in
water without TFA) to give
2-(3,4-dichlorophenyl)-5-(1-(5-propylpyrimidin-2-yl)piperidin-4-yloxy)pyr-
idazin-3(2H)-one (9.5 mg, tan solid, 66%). .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. ppm 0.93 (t, J=7.47 Hz, 2H) 1.38-1.72 (m, 2H)
1.81-2.02 (m, 2H) 2.00-2.21 (m, 2H) 2.40 (t, J=7.69 Hz, 2H)
3.50-3.80 (m, 2H) 4.06-4.37 (m, 2H) 4.47-4.68 (m, 1H) 5.56 (s, 1H)
7.28 (dd, J=8.57, 2.42 Hz, 2H) 7.44-7.72 (m, 2H) 8.16 (s, 2H). MS
(ESI) 461 (M+H).
Example 29
Methyl
4-(1-(tert-butoxycarbonyl)piperidin-4-yloxy)-1-(4-cyano-3-fluorophe-
nyl)-6-oxo-1,6-dihydropyridazine-3-carboxylate
##STR00050##
[0376] Step A. Preparation of 4-amino-2-fluorobenzonitrile
[0377] The mixture of 2-fluoro-4-nitrobenzonitrile (8.31 g, 50
mmol) and tin (II) chloride dihydrate (56.4 g, 250 mmol) in 250 mL
of EtOAc was stirred at 25.degree. C. overnight. LCMS (78109-084)
indicated the reaction was completed. 25 mL of sat. K.sub.2CO.sub.3
was added to the reaction. The resulting mixture was stirred at
room temperature for 2 h and was followed by addition of 100 g of
solid K.sub.2CO.sub.3. The mixture was stirred at room temperature
for 2 hours. Solid was removed by filtration and further washed
with EtOAc (50 mL.times.2). The filtrate was concentrated to yield
6.81 g (100%) of 4-amino-2-fluorobenzonitrile as an off white
solid. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. ppm 4.30 (s, 2H)
6.29-6.51 (m, 2H) 7.27-7.40 (m, 1H). MS (ESI) 137 (M+H).
Step B. Preparation of 4-cyano-3-fluorobenzenediazonium
[0378] 4-Cyano-3-fluorobenzenediazonium was prepared in 100% yield
according to procedures described in Example 18 (Step A)
substituting 4-(methylsulfonyl)aniline for
4-amino-2-fluorobenzonitrile. The reaction mixture was used
directly to next step.
Step C. Preparation of (E)-dimethyl
2-(2-(4-cyano-3-fluorophenyl)hydrazono)-3-oxopentanedioate
[0379] (E)-Dimethyl
2-(2-(4-cyano-3-fluorophenyl)hydrazono)-3-oxopentanedioate was
prepared in 86% yield according to procedures described in Example
18 (Step B) substituting 4-(methylsulfonyl)benzenediazonium for
4-cyano-3-fluorobenzenediazonium. MS (ESI) 322 (M+H).
Step D. Preparation of methyl
1-(4-cyano-3-fluorophenyl)-4-hydroxy-6-oxo-1,6-dihydropyridazine-3-carbox-
ylate
[0380] Methyl
1-(4-cyano-3-fluorophenyl)-4-hydroxy-6-oxo-1,6-dihydropyridazine-3-carbox-
ylate was prepared in 73% yield according to procedures described
in Example 18 (Step C) substituting (E)-dimethyl
2-(2-(4-(methylsulfonyl)phenyl)hydrazono)-3-oxopentanedioate for
(E)-Dimethyl
2-(2-(4-cyano-3-fluorophenyl)hydrazono)-3-oxopentanedioate. MS
(ESI) 322 (M+H).
Step E. Example 29
[0381] Example 29 was prepared in 74% yield according to procedures
described in Example 14 substituting methyl
1-(3,4-dichlorophenyl)-4-hydroxy-6-oxo-1,6-dihydropyridazine-3-carboxylat-
e for methyl
1-(4-cyano-3-fluorophenyl)-4-hydroxy-6-oxo-1,6-dihydropyridazine-3-carbox-
ylate with MS (4A) in the reaction mixture. .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. ppm 1.46 (s, 9H) 1.72-2.13 (m, 4H) 3.26-3.74
(m, 17 H) 3.94 (s, 3H) 4.35-4.78 (m, 1H) 6.26 (s, 1H) 7.52-7.87 (m,
3H). MS (ESI) 473 (M+H).
Example 30
Methyl
4-(1-(tert-butoxycarbonyl)piperidin-4-yloxy)-1-(6-cyanopyridin-3-yl-
)-6-oxo-1,6-dihydropyridazine-3-carboxylate
##STR00051##
[0382] Step A. Preparation of 6-cyanopyridine-3-diazonium
[0383] 6-Cyanopyridine-3-diazonium was prepared in 100% yield
according to procedures described in Example 18 (Step A)
substituting 4-(methylsulfonyl) aniline for 5-aminopicolinonitrile.
The reaction mixture was used directly to next step.
Step B. Preparation of (E)-dimethyl 2-(2-(6-cyanopyridin-3-yl)
hydrazono)-3-oxopentanedioate
[0384] (E)-Dimethyl
2-(2-(6-cyanopyridin-3-yl)hydrazono)-3-oxopentanedioate was
prepared in 87% yield according to procedures described in Example
18 (Step B) substituting 4-(methylsulfonyl)benzenediazonium for
6-cyanopyridine-3-diazonium. MS (ESI) 305 (M+H).
Step C. Preparation of methyl
1-(6-cyanopyridin-3-yl)-4-hydroxy-6-oxo-1,6-dihydropyridazine-3-carboxyla-
te
[0385] Methyl
1-(6-cyanopyridin-3-yl)-4-hydroxy-6-oxo-1,6-dihydropyridazine-3-carboxyla-
te was prepared in 90% yield according to procedures described in
Example 18 (Step C) substituting (E)-dimethyl
2-(2-(4-(methylsulfonyl)phenyl)hydrazono)-3-oxopentanedioate for
(E)-dimethyl
2-(2-(6-cyanopyridin-3-yl)hydrazono)-3-oxopentanedioate. MS (ESI)
273 (M+H).
Step D. Example 30
[0386] Example 30 was prepared in 67% yield according to procedures
described in Example 14 substituting methyl
1-(3,4-dichlorophenyl)-4-hydroxy-6-oxo-1,6-dihydropyridazine-3-carboxylat-
e for Methyl
1-(6-cyanopyridin-3-yl)-4-hydroxy-6-oxo-1,6-dihydropyridazine-3-carboxyla-
te with MS (4A) in the reaction mixture. .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. ppm 1.46 (s, 9H) 1.73-2.20 (m, 4H) 3.29-3.74
(m, 4H) 3.95 (s, 3H) 4.52-4.83 (m, 1H) 6.27 (s, 1H) 7.79 (d, J=8.35
Hz, 1H) 8.25 (dd, J=8.57, 2.42 Hz, 1H) 9.09 (d, J=2.20 Hz, 1H). MS
(ESI) 465 (M+H).
Example 31
tert-Butyl
4-(3-cyano-1-(4-(methylsulfonyl)phenyl)-6-oxo-1,6-dihydropyrida-
zin-4-yloxy)piperidine-1-carboxylate
##STR00052##
[0387] Step A. Preparation of tert-butyl
4-(3-carbamoyl-1-(4-(methylsulfonyl)phenyl)-6-oxo-1,6-dihydropyridazin-4--
yloxy)piperidine-1-carboxylate
[0388] To a stirring solution of methyl
4-(1-(tert-butoxycarbonyl)piperidin-4-yloxy)-1-(4-(methylsulfonyl)phenyl)-
-6-oxo-1,6-dihydropyridazine-3-carboxylate (1015 mg, 2.0 mmol) in
THF (15 mL) at room temperature under argon was added 7M ammonia in
methanol (4.3 mL, 30 mmol). The reaction mixture was stirred at
room temperature overnight. The solvents were removed in vacuo. The
crude product 1.0 g (100%) was used directly to next step. MS (ESI)
437 (M+H-tBu).
Step B. Example 31
[0389] To a stirring solution of tert-butyl
4-(3-carbamoyl-1-(4-(methylsulfonyl)phenyl)-6-oxo-1,6-dihydropyridazin-4--
yloxy)piperidine-1-carboxylate (985 mg, 2.0 mmol) in THF (50 mL) at
room temperature under argon was added TEA (405 mg, 4.0 mmol), and
was followed by addition of TFAA (840 mg, 4.0 mmol). The resulting
reaction mixture was stirred at room temperature overnight. The
solvent was removed in vacuo. The crude product was dissolved in a
small amount of DCM (.about.5 ml) and loaded onto a 40 g ISCO
silica gel column which was eluted with a 20 min gradient from 20%
to 100% EtOAc/Hexanes. 908 mg (91%) of tert-butyl
4-(3-cyano-1-(4-(methylsulfonyl)phenyl)-6-oxo-1,6-dihydropyridazin-4-ylox-
y)piperidine-1-carboxylate was obtained as a white solid. .sup.1H
NMR (400 MHz, CDCl.sub.3) .delta. ppm 1.43-1.51 (m, 9H) 1.81-1.95
(m, 2H) 1.95-2.09 (m, 2H) 3.27-3.57 (m, 2H) 3.57-3.88 (m, 2H)
4.38-4.81 (m, 1H) 6.29 (s, 1H) 7.83 (d, J=8.35 Hz, 1H) 8.20 (dd,
J=8.57, 2.42 Hz, 1H) 9.04 (d, J=2.64 Hz, 1H). MS (ESI) 419
(M+H-tBu).
Example 32
Methyl
1-(4-cyano-3-fluorophenyl)-6-oxo-4-(1-(5-propylpyrimidin-2-yl)piper-
idin-4-yloxy)-1,6-dihydropyridazine-3-carboxylate
##STR00053##
[0390] Step A. Preparation of methyl
1-(4-cyano-3-fluorophenyl)-6-oxo-4-(piperidin-4-yloxy)-1,6-dihydropyridaz-
ine-3-carboxylate, HCl salt
[0391] To a stirring solution of methyl
4-(1-(tert-butoxycarbonyl)piperidin-4-yloxy)-1-(4-cyano-3-fluorophenyl)-6-
-oxo-1,6-dihydropyridazine-3-carboxylate (142 mg, 0.30 mmol) in DCM
(3 mL) at room temperature under argon was added 4 M HCl in dioxane
(0.375 mL, 1.5 mmol). The reaction mixture was stirred at room
temperature overnight. Et.sub.2O (10 mL) was added to the reaction
mixture. The solid product was collected by filtration and further
washed with ether (2 mL.times.2). After drying under reduced
pressure for 2 hours, 105 mg of methyl
1-(4-cyano-3-fluorophenyl)-6-oxo-4-(piperidin-4-yloxy)-1,6-dihydro-
pyridazine-3-carboxylate HCl salt was obtained as an off-white
solid. MS (ESI) 373 (M+H).
Step B. Example 32
[0392] To a stirring solution of methyl
1-(4-cyano-3-fluorophenyl)-6-oxo-4-(piperidin-4-yloxy)-1,6-dihydropyridaz-
ine-3-carboxylate HCl (37.2 mg, 0.10 mmol) in NMP (3 mL) at room
temperature under argon was added DIPEA (38.8 mg, 0.30 mmol) and
2-chloro-5-propylpyrimidine (23.5 mg, 0.15 mmol). The resulting
reaction mixture was heated at 95.degree. C. under argon overnight.
15 mL of EtOAc was added to the reaction mixture. The reaction
mixture was washed with water (15 mL), and brine (15 mL). Organic
phase was dried (MgSO.sub.4), filtered and concentrated. The crude
product was directly purified by preparative HPLC (C.sub.18 column;
10-100% methanol in water without TFA) to give methyl
1-(4-cyano-3-fluorophenyl)-6-oxo-4-(1-(5-propylpyrimidin-2-yl)piperidin-4-
-yloxy)-1,6-dihydropyridazine-3-carboxylate (16 mg, white solid,
32%). .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. ppm 0.56-1.12 (m,
3H) 1.37-1.67 (m, 2H) 1.70-2.20 (m, 4H) 2.39 (q, J=7.47 Hz, 2H)
3.64-4.09 (m, 7H) 4.02-4.40 (m, 1H) 4.40-4.95 (m, 1H) 6.31 (s, 1H)
7.45-7.91 (m, 3H) 7.91-8.46 (m, 2H). MS (ESI) 493 (M+H).
Example 33
Methyl
1-(4-cyano-3-fluorophenyl)-4-(1-(5-cyclopropylpyrimidin-2-yl)piperi-
din-4-yloxy)-6-oxo-1,6-dihydropyridazine-3-carboxylate
##STR00054##
[0394] Example 33 was prepared in 31% yield according to procedures
described in Example 32 (Step B) substituting
2-chloro-5-propylpyrimidine for 2-chloro-5-cyclopropylpyrimidine.
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. ppm 0.41-0.73 (m, 2H)
0.74-1.08 (m, 2H) 1.50-1.78 (m, 2H) 1.76-2.31 (m, 8H) 3.33-3.78 (m,
2H) 3.82-4.01 (m, 3H) 4.00-4.43 (m, 2H) 4.55-4.80 (m, 1H) 6.30 (s,
1H) 7.55-7.81 (m, 3H) 8.00-8.29 (m, 2H). MS (ESI) 491 (M+H).
Example 34
tert-Butyl
4-(3-cyano-1-(4-cyano-3-fluorophenyl)-6-oxo-1,6-dihydropyridazi-
n-4-yloxy)piperidine-1-carboxylate
##STR00055##
[0395] Step A. Preparation of tert-butyl
4-(3-carbamoyl-1-(4-cyano-3-fluorophenyl)-6-oxo-1,6-dihydropyridazin-4-yl-
oxy)piperidine-1-carboxylate
[0396] tert-Butyl
4-(3-carbamoyl-1-(4-cyano-3-fluorophenyl)-6-oxo-1,6-dihydropyridazin-4-yl-
oxy)piperidine-1-carboxylate was prepared in 91% yield according to
procedures described in Example 31 (Step A) substituting methyl
441-(tert-butoxycarbonyl)piperidin-4-yloxy)-1-(4-(methylsulfonyl)phenyl)--
6-oxo-1,6-dihydropyridazine-3-carboxylate for methyl
4-(1-(tert-butoxycarbonyl)piperidin-4-yloxy)-1-(4-cyano-3-fluorophenyl)-6-
-oxo-1,6-dihydropyridazine-3-carboxylate (example 29). MS (ESI) 402
(M+H-tBu).
Step B. Example 34
[0397] Example 34 was prepared in 84% yield according to procedures
described in Example 31 (Step B) substituting tert-butyl
4-(3-carbamoyl-1-(4-(methylsulfonyl)phenyl)-6-oxo-1,6-dihydropyridazin-4--
yloxy)piperidine-1-carboxylate for tert-Butyl
4-(3-carbamoyl-1-(4-cyano-3-fluorophenyl)-6-oxo-1,6-dihydropyridazin-4-yl-
oxy)piperidine-1-carboxylate. .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. ppm 1.47 (s, 9H) 1.77-1.94 (m, 2H) 1.94-2.08 (m, 2H)
3.35-3.57 (m, 2H) 3.56-3.74 (m, 2H) 4.40-4.78 (m, 1H) 6.28 (s, 1H)
7.57-7.70 (m, 2H) 7.71-7.80 (m, 1H). MS (ESI) 384 (M+H-tBu).
Example 35
tert-Butyl
4-(3-cyano-1-(6-cyanopyridin-3-yl)-6-oxo-1,6-dihydropyridazin-4-
-yloxy)piperidine-1-carboxylate
##STR00056##
[0398] Step A. Preparation of tert-butyl
4-(3-carbamoyl-1-(6-cyanopyridin-3-yl)-6-oxo-1,6-dihydropyridazin-4-yloxy-
)piperidine-1-carboxylate
[0399] tert-Butyl
4-(3-carbamoyl-1-(6-cyanopyridin-3-yl)-6-oxo-1,6-dihydropyridazin-4-yloxy-
)piperidine-1-carboxylate was prepared in 77% yield according to
procedures described in Example 31 (Step A) substituting methyl
441-(tert-butoxycarbonyl)piperidin-4-yloxy)-1-(4-(methylsulfonyl)phenyl)--
6-oxo-1,6-dihydropyridazine-3-carboxylate for methyl
4-(1-(tert-butoxycarbonyl)piperidin-4-yloxy)-1-(6-cyanopyridin-3-yl)-6-ox-
o-1,6-dihydropyridazine-3-carboxylate (example 30). MS (ESI) 441
(M+H).
Step B. Example 35
[0400] Example 35 was prepared in 89% yield according to procedures
described in Example 31 (Step B) substituting tert-butyl
4-(3-carbamoyl-1-(4-(methylsulfonyl)phenyl)-6-oxo-1,6-dihydropyridazin-4--
yloxy)piperidine-1-carboxylate for tert-butyl
[0401]
4-(3-carbamoyl-1-(6-cyanopyridin-3-yl)-6-oxo-1,6-dihydropyridazin-4-
-yloxy)piperidine-1-carboxylate. .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. ppm 1.43-1.51 (m, 9H) 1.81-1.95 (m, 2H) 1.95-2.09 (m, 2H)
3.27-3.57 (m, 2H) 3.57-3.88 (m, 2 H) 4.38-4.81 (m, 1H) 6.29 (s, 1H)
7.83 (d, J=8.35 Hz, 1H) 8.20 (dd, J=8.57, 2.42 Hz, 1H) 9.04 (d,
J=2.64 Hz, 1H). MS (ESI) 423 (M+H).
Example 36
1-(4-Cyano-3-fluorophenyl)-4-(1-(5-iodopyrimidin-2-yl)piperidin-4-yloxy)-6-
-oxo-1,6-dihydropyridazine-3-carbonitrile
##STR00057##
[0402] Step A. Preparation of
1-(4-cyano-3-fluorophenyl)-6-oxo-4-(piperidin-4-yloxy)-1,6-dihydropyridaz-
ine-3-carbonitrile, HCl salt
[0403] To a stirring solution of tert-butyl
4-(3-cyano-1-(4-cyano-3-fluorophenyl)-6-oxo-1,6-dihydropyridazin-4-yloxy)-
piperidine-1-carboxylate (example 34) (22 mg, 0.050 mmol) in DCM (3
mL) at room temperature under argon was added 4 M HCl in dioxane
(0.375 mL, 1.5 mmol). The reaction mixture was stirred at room
temperature overnight. Et.sub.2O (10 mL) was added to the reaction
mixture. The solid product was collected by filtration and further
washed with ether (2 mL.times.2). After drying under vacuum for 2
hours, 19 mg (100%) of
1-(4-cyano-3-fluorophenyl)-6-oxo-4-(piperidin-4-yloxy)-1,6-dihydropyridaz-
ine-3-carbonitrile HCl salt was obtained as an off-white solid. MS
(ESI) 340 (M+H).
Step B. Example 36
[0404] Example 36 was prepared in 71% yield according to procedures
described in Example 21 substituting
2-chloro-5-cyclopropylpyrimidine and
1-(3,4-dichlorophenyl)-6-oxo-4-(piperidin-4-yloxy)-1,6-dihydropyridazine--
3-carbonitrile HCl for 2-chloro-5-iodopyrimidine and
1-(4-cyano-3-fluorophenyl)-6-oxo-4-(piperidin-4-yloxy)-1,6-dihydropyridaz-
ine-3-carbonitrile HCl salt. .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. ppm 1.83-2.00 (m, 2H) 1.98-2.20 (m, 2H) 3.71-3.95 (m, 2H)
3.95-4.13 (m, 2H) 4.53-4.84 (m, 1H) 6.31 (s, 1H) 7.57-7.70 (m, 2H)
7.70-7.81 (m, 1H) 8.41 (s, 2H). MS (ESI) 544 (M+H).
Example 37
1-(6-Cyanopyridin-3-yl)-4-(1-(5-iodopyrimidin-2-yl)piperidin-4-yloxy)-6-ox-
o-1,6-dihydropyridazine-3-carbonitrile
##STR00058##
[0405] Step A. Preparation of
1-(6-cyanopyridin-3-yl)-6-oxo-4-(piperidin-4-yloxy)-1,6-dihydropyridazine-
-3-carbonitrile, HCl salt
[0406] To a stirring solution of tert-butyl
4-(3-cyano-1-(6-cyanopyridin-3-yl)-6-oxo-1,6-dihydropyridazin-4-yloxy)pip-
eridine-1-carboxylate (22 mg, 0.050 mmol) in DCM (3 mL) at room
temperature under argon was added 4 M HCl in dioxane (0.375 mL, 1.5
mmol). The reaction mixture was stirred at room temperature
overnight. Et.sub.2O (10 mL) was added to the reaction mixture. The
solid product was collected by filtration and further washed with
ether (2 mL.times.2). After drying under vacuum for 2 hours, 17.3
mg (100%) of
1-(6-cyanopyridin-3-yl)-6-oxo-4-(piperidin-4-yloxy)-1,6-dihydropyridazine-
-3-carbonitrile HCl salt was obtained as an off-white solid. MS
(ESI) 323 (M+H).
Step B. Example 37
[0407] Example 37 was prepared in 61% yield according to procedures
described in Example 21 substituting
2-chloro-5-cyclopropylpyrimidine and
1-(3,4-dichlorophenyl)-6-oxo-4-(piperidin-4-yloxy)-1,6-dihydropyridazine--
3-carbonitrile HCl for 2-chloro-5-iodopyrimidine and
1-(6-cyanopyridin-3-yl)-6-oxo-4-(piperidin-4-yloxy)-1,6-dihydropyridazine-
-3-carbonitrile HCl salt. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta.
ppm 1.83-2.00 (m, 2H) 1.98-2.20 (m, 2H) 3.71-3.95 (m, 2H) 3.95-4.13
(m, 2 H) 4.53-4.84 (m, 1H) 6.31 (s, 1H) 7.57-7.70 (m, 2H) 7.70-7.81
(m, 1H) 8.41 (s, 2H). MS (ESI) 527 (M+H).
Example 38
1-(4-Cyano-3-fluorophenyl)-6-oxo-4-(1-(5-propylpyrimidin-2-yl)piperidin-4--
yloxy)-1,6-dihydropyridazine-3-carbonitrile
##STR00059##
[0409] Example 38 was prepared in 56% yield according to procedures
described in Example 21 substituting
2-chloro-5-cyclopropylpyrimidine and
1-(3,4-dichlorophenyl)-6-oxo-4-(piperidin-4-yloxy)-1,6-dihydropyridazine--
3-carbonitrile HCl for 2-chloro-5-propylpyrimidine and
1-(4-cyano-3-fluorophenyl)-6-oxo-4-(piperidin-4-yloxy)-1,6-dihydropyridaz-
ine-3-carbonitrile HCl salt. .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. ppm 0.93 (t, J=7.25 Hz, 3H) 1.48-1.67 (m, 2H) 1.82-2.01 (m,
2H) 2.01-2.17 (m, 2H) 2.41 (t, J=7.69 Hz, 2H) 3.60-3.91 (m, 2H)
3.98-4.27 (m, 2H) 4.48-4.87 (m, 1H) 6.32 (s, 1H) 7.52-7.70 (m, 2H)
7.70-7.81 (m, 1H) 8.17 (s, 2H). MS (ESI) 460 (M+H).
Example 39
1-(4-Cyano-3-fluorophenyl)-6-oxo-4-(1-(5-(trifluoromethyl)pyrimidin-2-yl)
piperidin-4-yloxy)-1,6-dihydropyridazine-3-carbonitrile
##STR00060##
[0411] Example 39 was prepared in 76% yield according to procedures
described in Example 26 substituting
1-(3,4-dichlorophenyl)-4-(1-(5-iodopyrimidin-2-yl)piperidin-4-yloxy)-6-ox-
o-1,6-dihydropyridazine-3-carbonitrile for
1-(4-cyano-3-fluorophenyl)-4-(1-(5-iodopyrimidin-2-yl)piperidin-4-yloxy)--
6-oxo-1,6-dihydropyridazine-3-carbonitrile (example 36). .sup.1H
NMR (400 MHz, CDCl.sub.3) .delta. ppm 1.94-2.04 (m, 2H) 2.04-2.15
(m, 2H) 3.83-4.29 (m, 4H) 4.53-4.93 (m, 1H) 6.13-6.46 (m, 1H)
7.55-7.70 (m, 2H) 7.75 (t, J=7.69 Hz, 1H) 8.50 (s, 2H). MS (ESI)
486 (M+H).
Example 40
1-(6-Cyanopyridin-3-yl)-6-oxo-4-(1-(5-(trifluoromethyl)pyrimidin-2-yl)pipe-
ridin-4-yloxy)-1,6-dihydropyridazine-3-carbonitrile
##STR00061##
[0413] Example 40 was prepared in 71% yield according to procedures
described in Example 26 substituting
1-(3,4-dichlorophenyl)-4-(1-(5-iodopyrimidin-2-yl)piperidin-4-yloxy)-6-ox-
o-1,6-dihydropyridazine-3-carbonitrile for
1-(6-cyanopyridin-3-yl)-4-(1-(5-iodopyrimidin-2-yl)piperidin-4-yloxy)-6-o-
xo-1,6-dihydropyridazine-3-carbonitrile (example 37). .sup.1H NMR
(400 MHz, CDCl.sub.3) .delta. ppm 1.91-2.05 (m, 2H) 2.05-2.20 (m,
2H) 3.85-4.30 (m, 4H) 4.59-4.88 (m, 1H) 6.16-6.45 (m, 1H) 7.84 (d,
J=8.35 Hz, 1H) 8.21 (dd, J=8.57, 2.42 Hz, 1H) 8.51 (s, 2H) 9.06 (d,
J=2.64 Hz, 1H). MS (ESI) 469 (M+H).
Example 41
4-(1-(5-Bromopyrimidin-2-yl)piperidin-4-yloxy)-1-(4-cyano-3-fluorophenyl)--
6-oxo-1,6-dihydropyridazine-3-carbonitrile
##STR00062##
[0415] Example 41 was prepared in 89% yield according to procedures
described in Example 21 substituting
2-chloro-5-cyclopropylpyrimidine and
1-(3,4-dichlorophenyl)-6-oxo-4-(piperidin-4-yloxy)-1,6-dihydropyridazine--
3-carbonitrile HCl for 5-bromo-2-chloropyrimidine and
1-(4-cyano-3-fluorophenyl)-6-oxo-4-(piperidin-4-yloxy)-1,6-dihydropyridaz-
ine-3-carbonitrile HCl salt. .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. ppm 0 1.90-2.01 (m, 2H) 2.01-2.19 (m, 2H) 3.78-3.91 (m, 2H)
3.99-4.19 (m, 2H) 4.52-4.93 (m, 1H) 6.32 (s, 1H) 7.60-7.71 (m, 2H)
7.71-7.82 (m, 1H) 8.31 (s, 2H). MS (ESI) 497 (M+H).
Example 42
Methyl
4-(1-(5-bromopyrimidin-2-yl)piperidin-4-yloxy)-1-(4-cyano-3-fluorop-
henyl)-6-oxo-1,6-dihydropyridazine-3-carboxylate
##STR00063##
[0417] Example 42 was prepared in 78% yield according to procedures
described in Example 32 (Step B) substituting
2-chloro-5-propylpyrimidine for 5-bromo-2-chloropyrimidine. .sup.1H
NMR (400 MHz, CDCl.sub.3) .delta. ppm 1.45-1.50 (m, 9H) 1.80-1.95
(m, 2H) 1.95-2.08 (m, 2H) 3.08 (s, 3H) 3.33-3.58 (m, 2H) 3.55-3.81
(m, 2H) 4.45-4.78 (m, 1H) 6.30 (s, 1H) 7.83 (d, J=8.79 Hz, 2H) 8.07
(d, J=8.79 Hz, 2H). MS (ESI) 530 (M+H).
Example 43
Methyl
1-(4-bromo-3-fluorophenyl)-4-(1-(tert-butoxycarbonyl)piperidin-4-yl-
oxy)-6-oxo-1,6-dihydropyridazine-3-carboxylate
##STR00064##
[0418] Step A. Preparation of 4-bromo-3-fluorobenzenediazonium
[0419] 4-Bromo-3-fluorobenzenediazonium was prepared in 100% yield
according to procedures described in Example 18 (Step A)
substituting 4-(methylsulfonyl)aniline for 4-bromo-3-fluoroaniline.
The reaction mixture was used directly to next step.
Step B. Preparation of (E)-dimethyl
2-(2-(4-bromo-3-fluorophenyl)hydrazono)-3-oxopentanedioate
[0420] (E)-Dimethyl
2-(2-(4-bromo-3-fluorophenyl)hydrazono)-3-oxopentanedioate was
prepared in 78% yield according to procedures described in Example
18 (Step B) substituting 4-(methylsulfonyl)benzenediazonium for
4-bromo-3-fluorobenzenediazonium. MS (ESI) 375 (M+H).
Step C. Preparation of methyl
1-(4-bromo-3-fluorophenyl)-4-hydroxy-6-oxo-1,6-dihydropyridazine-3-carbox-
ylate
[0421] Methyl
1-(4-bromo-3-fluorophenyl)-4-hydroxy-6-oxo-1,6-dihydropyridazine-3-carbox-
ylate was prepared in 60% yield according to procedures described
in Example 18 (Step C) substituting (E)-dimethyl
2-(2-(4-(methylsulfonyl)phenyl)hydrazono)-3-oxopentanedioate for
(E)-Dimethyl
2-(2-(4-bromo-3-fluorophenyl)hydrazono)-3-oxopentanedioate. MS
(ESI) 343 (M+H).
Step D. Example 43
[0422] Example 43 was prepared in 80% yield according to procedures
described in Example 14 substituting methyl
1-(3,4-dichlorophenyl)-4-hydroxy-6-oxo-1,6-dihydropyridazine-3-carboxylat-
e for methyl
1-(4-bromo-3-fluorophenyl)-4-hydroxy-6-oxo-1,6-dihydropyridazine-3-carbox-
ylate with MS (4A) in the reaction mixture. .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. ppm 1.46 (s, 9H) 1.73-2.08 (m, 4H) 3.39-3.67
(m, 4H) 3.93 (s, 3H) 4.44-4.74 (m, 1H) 6.26 (s, 1H) 7.36 (d, J=8.79
Hz, 1H) 7.47 (dd, J=9.23, 2.20 Hz, 1H) 7.56-7.71 (m, 1H). MS (ESI)
472 (M+H-tBu).
Example 44
Methyl
1-(4-bromo-2-fluorophenyl)-4-(1-(tert-butoxycarbonyl)piperidin-4-yl-
oxy)-6-oxo-1,6-dihydropyridazine-3-carboxylate
##STR00065##
[0423] Step A. Preparation of 4-bromo-2-fluorobenzenediazonium
[0424] 4-Bromo-3-fluorobenzenediazonium was prepared in 100% yield
according to procedures described in Example 18 (Step A)
substituting 4-(methylsulfonyl)aniline for 4-bromo-2-fluoroaniline.
The reaction mixture was used directly to next step.
Step B. Preparation of (E)-dimethyl
2-(2-(4-bromo-2-fluorophenyl)hydrazono)-3-oxopentanedioate
[0425] (E)-Dimethyl 2-(2-(4-bromo-2-fluorophenyl)
hydrazono)-3-oxopentanedioate was prepared in 83% yield according
to procedures described in Example 18 (Step B) substituting
4-(methylsulfonyl)benzenediazonium for
4-bromo-2-fluorobenzenediazonium. MS (ESI) 375 (M+H).
Step C. Preparation of methyl
1-(4-bromo-2-fluorophenyl)-4-hydroxy-6-oxo-1,6-dihydropyridazine-3-carbox-
ylate
[0426] Methyl
1-(4-bromo-2-fluorophenyl)-4-hydroxy-6-oxo-1,6-dihydropyridazine-3-carbox-
ylate was prepared in 51% yield according to procedures described
in Example 18 (Step C) substituting (E)-dimethyl
2-(2-(4-(methylsulfonyl)phenyl)hydrazono)-3-oxopentanedioate for
(E)-Dimethyl
2-(2-(4-bromo-2-fluorophenyl)hydrazono)-3-oxopentanedioate. MS
(ESI) 343 (M+H).
Step D. Example 44
[0427] Example 44 was prepared in 75% yield according to procedures
described in Example 14 substituting methyl
1-(3,4-dichlorophenyl)-4-hydroxy-6-oxo-1,6-dihydropyridazine-3-carboxylat-
e for methyl
1-(4-bromo-2-fluorophenyl)-4-hydroxy-6-oxo-1,6-dihydropyridazine-3-carbox-
ylate with MS (4A) in the reaction mixture. .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. ppm 1.41-1.51 (m, 9H) 1.70-2.03 (m, 4H)
3.39-3.67 (m, 4H) 3.91 (s, 3H) 4.36-4.76 (m, 1H) 6.27 (s, 1H)
7.26-7.34 (m, 1H) 7.41 (d, J=9.23 Hz, 2H). MS (ESI) 472
(M+H-tBu).
Example 45
tert-Butyl
4-(1-(4-bromo-3-fluorophenyl)-3-cyano-6-oxo-1,6-dihydropyridazi-
n-4-yloxy)piperidine-1-carboxylate
##STR00066##
[0428] Step A. Preparation of tert-butyl
4-(1-(4-bromo-3-fluorophenyl)-3-carbamoyl-6-oxo-1,6-dihydropyridazin-4-yl-
oxy)piperidine-1-carboxylate
[0429] tert-Butyl
4-(1-(4-bromo-3-fluorophenyl)-3-carbamoyl-6-oxo-1,6-dihydropyridazin-4-yl-
oxy)piperidine-1-carboxylate was prepared in 100% yield according
to procedures described in Example 31 (Step A) substituting methyl
441-(tert-butoxycarbonyl)piperidin-4-yloxy)-1-(4-(methylsulfonyl)phenyl)--
6-oxo-1,6-dihydropyridazine-3-carboxylate for methyl
1-(4-bromo-3-fluorophenyl)-4-(1-(tert-butoxycarbonyl)piperidin-4-yloxy)-6-
-oxo-1,6-dihydropyridazine-3-carboxylate (Example 43). MS (ESI) 511
(M+H).
Step B. Example 45
[0430] Example 45 was prepared in 82% yield according to procedures
described in Example 31 (Step B) substituting tert-butyl
4-(3-carbamoyl-1-(4-(methylsulfonyl)phenyl)-6-oxo-1,6-dihydropyridazin-4--
yloxy)piperidine-1-carboxylate for tert-Butyl
4-(1-(4-bromo-3-fluorophenyl)-3-carbamoyl-6-oxo-1,6-dihydropyridazin-4-yl-
oxy)piperidine-1-carboxylate. .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. ppm 1.47 (s, 9H) 1.79-1.94 (m, 2H) 1.95-2.09 (m, J=3.85 Hz,
2H) 3.34-3.56 (m, 2H) 3.59-3.88 (m, 2H) 4.47-4.78 (m, 1H) 6.26 (s,
1H) 7.31 (d, J=8.80 Hz, 1H) 7.40-7.52 (m, 1H) 7.60-7.76 (m, 1H). MS
(ESI) 439 (M+H-tBu).
Example 46
tert-Butyl
4-(1-(4-bromo-2-fluorophenyl)-3-cyano-6-oxo-1,6-dihydropyridazi-
n-4-yloxy)piperidine-1-carboxylate
##STR00067##
[0431] Step A. Preparation of tert-butyl
4-(1-(4-bromo-2-fluorophenyl)-3-carbamoyl-6-oxo-1,6-dihydropyridazin-4-yl-
oxy)piperidine-1-carboxylate
[0432] tert-Butyl
4-(1-(4-bromo-2-fluorophenyl)-3-carbamoyl-6-oxo-1,6-dihydropyridazin-4-yl-
oxy)piperidine-1-carboxylate was prepared in 100% yield according
to procedures described in Example 31 (Step A) substituting methyl
441-(tert-butoxycarbonyl)piperidin-4-yloxy)-1-(4-(methylsulfonyl)phenyl)--
6-oxo-1,6-dihydropyridazine-3-carboxylate for Methyl
1-(4-bromo-2-fluorophenyl)-4-(1-(tert-butoxycarbonyl)piperidin-4-yloxy)-6-
-oxo-1,6-dihydropyridazine-3-carboxylate (Example 44). MS (ESI) 511
(M+H).
Step B. Example 46
[0433] Example 46 was prepared in 78% yield according to procedures
described in Example 31 (Step B) substituting tert-butyl
4-(3-carbamoyl-1-(4-(methylsulfonyl)phenyl)-6-oxo-1,6-dihydropyridazin-4--
yloxy)piperidine-1-carboxylate for tert-Butyl
4-(1-(4-bromo-2-fluorophenyl)-3-carbamoyl-6-oxo-1,6-dihydropyridazin-4-yl-
oxy)piperidine-1-carboxylate. .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. ppm 1.47 (s, 9H) 1.79-1.94 (m, 2H) 1.94-2.08 (m, J=3.85 Hz,
2H) 3.29-3.54 (m, 2H) 3.53-3.86 (m, 2H) 4.36-4.78 (m, 1H) 6.26 (s,
1H) 7.10-7.37 (m, 2H) 7.43 (d, J=8.80 Hz, 1H). MS (ESI) 439
(M+H-tBu).
Example 47
4-(1-(5-Chloropyrimidin-2-yl)piperidin-4-yloxy)-1-(4-(methylsulfonyl)pheny-
l)-6-oxo-1,6-dihydropyridazine-3-carbonitrile
##STR00068##
[0434] Step A. Preparation of
1-(4-(methylsulfonyl)phenyl)-6-oxo-4-(piperidin-4-yloxy)-1,6-dihydropyrid-
azine-3-carbonitrile, HCl salt
[0435] To a stirring solution of tert-butyl
4-(3-cyano-1-(4-(methylsulfonyl)phenyl)-6-oxo-1,6-dihydropyridazin-4-ylox-
y)piperidine-1-carboxylate (700 mg, 1.475 mmol) in DCM (10 mL) at
room temperature under argon was added 4 M HCl in dioxane (3.69 mL,
14.75 mmol). The reaction mixture was stirred at room temperature
overnight. Et.sub.2O (10 mL) was added to the reaction mixture. The
solid product was collected by filtration and further washed with
ether (2 mL.times.2). After drying under vacuum for 2 hours, 567 mg
(90%) of
1-(4-(methylsulfonyl)phenyl)-6-oxo-4-(piperidin-4-yloxy)-1,6-dihydropyrid-
azine-3-carbonitrile HCl salt was obtained as an off-white solid.
MS (ESI) 375 (M+H).
Step B. Example 47
[0436] To a stirring solution of
1-(4-(methylsulfonyl)phenyl)-6-oxo-4-(piperidin-4-yloxy)-1,6-dihydropyrid-
azine-3-carbonitrile HCl (124 mg, 0.33 mmol) in NMP (3 mL) at room
temperature under argon was added DIPEA (128 mg, 0.99 mmol) and
5-chloro-2-iodopyrimidine (159 mg, 0.66 mmol). The resulting
reaction mixture was heated at 100.degree. C. under argon
overnight. 15 mL of EtOAc was added to the reaction mixture. The
reaction mixture was washed with water (15 mL), and brine (15 mL).
Organic phase was dried (MgSO.sub.4), filtered and concentrated.
The crude product was dissolved in a small amount of DCM (.about.3
ml) and loaded onto a 40 g ISCO silica gel column which was eluted
with a 20 min gradient from 20% to 100% EtOAc/Hexanes. 121 mg (75%)
of
4-(1-(5-chloropyrimidin-2-yl)piperidin-4-yloxy)-1-(4-(methylsulfonyl)phen-
yl)-6-oxo-1,6-dihydropyridazine-3-carbonitrile was obtained as a
tan solid. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. ppm 1.75-2.27
(m, 4H) 3.08 (s, 3H) 3.66-3.97 (m, 2H) 3.97-4.24 (m, 2H) 4.54-4.95
(m, 1H) 6.34 (s, 1H) 7.84 (d, J=8.79 Hz, 2H) 8.07 (d, J=8.79 Hz,
2H) 8.24 (s, 2H). MS (ESI) 487 (M+H).
Example 48
4-(1-(5-Iodopyrimidin-2-yl)piperidin-4-yloxy)-1-(4-(methylsulfonyl)phenyl)-
-6-oxo-1,6-dihydropyridazine-3-carbonitrile
##STR00069##
[0438] Example 48 was prepared in 69% yield according to procedures
described in Example 47 (Step B) substituting
5-chloro-2-iodopyrimidine for 2-chloro-5-iodopyrimidine. .sup.1H
NMR (400 MHz, CDCl.sub.3) .delta. ppm 1.83-2.02 (m, 2H) 1.99-2.18
(m, 2H) 3.09 (s, 3H) 3.73-3.95 (m, 2H) 3.95-4.24 (m, 2H) 4.54-4.85
(m, 1H) 6.33 (s, 1H) 7.84 (d, J=8.79 Hz, 2H) 7.96-8.20 (m, 2H) 8.41
(s, 2H). MS (ESI) 579 (M+H).
Example 49
1-(4-(Methylsulfonyl)phenyl)-6-oxo-4-(1-(5-(trifluoromethyl)pyrimidin-2-yl-
)piperidin-4-yloxy)-1,6-dihydropyridazine-3-carbonitrile
##STR00070##
[0440] Example 49 was prepared in 74% yield according to procedures
described in Example 26 substituting
1-(3,4-dichlorophenyl)-4-(1-(5-iodopyrimidin-2-yl)piperidin-4-yloxy)-6-ox-
o-1,6-dihydropyridazine-3-carbonitrile for
4-(1-(5-iodopyrimidin-2-yl)piperidin-4-yloxy)-1-(4-(methylsulfonyl)phenyl-
)-6-oxo-1,6-dihydropyridazine-3-carbonitrile (example 48). .sup.1H
NMR (400 MHz, CDCl.sub.3) .delta. ppm 1.78-2.31 (m, 4H) 3.09 (s,
3H) 3.78-4.34 (m, 4H) 4.54-4.97 (m, 1H) 6.35 (s, 1H) 7.84 (d,
J=8.35 Hz, 2H) 8.08 (d, J=8.79 Hz, 2H) 8.51 (s, 2H). MS (ESI) 521
(M+H).
Example 50
6-(Hydroxymethyl)-5-(1-(5-chloropyrimidin-2-yl)piperidin-4-yloxy)-2-(4-(me-
thylsulfonyl)phenyl)pyridazin-3(2H)-one
##STR00071##
[0441] Step A. Preparation of tert-butyl
4-(3-(hydroxymethyl)-1-(4-(methylsulfonyl)phenyl)-6-oxo-1,6-dihydropyrida-
zin-4-yloxy)piperidine-1-carboxylate
[0442] To a stirring solution of methyl
4-(1-(tert-butoxycarbonyl)piperidin-4-yloxy)-1-(4-(methylsulfonyl)phenyl)-
-6-oxo-1,6-dihydropyridazine-3-carboxylate (example 18) (254 mg,
0.5 mmol) in THF/MeOH (1:1) (10 mL) at room temperature under argon
was added NaBH.sub.4 (95 mg, 2.5 mmol) at 0.degree. C. in an ice
bath under argon carefully. The reaction mixture was allowed to
warm to room temperature gradually and stirred overnight. EtOAc (20
mL) and water (20 mL) were added to the reaction mixture. Layers
were separated. Organic layer were washed with water (15 mL), and
brine (15 mL). Organic phase was dried (MgSO.sub.4), filtered and
concentrated. The crude product was dissolved in a small amount of
DCM (.about.2 ml) and loaded onto a 40 g ISCO silica gel column
which was eluted with a 20 min gradient from 20% to 100%
EtOAc/Hexanes. 230 mg (95%) of tert-butyl
4-(3-(hydroxymethyl)-1-(4-(methylsulfonyl)phenyl)-6-oxo-1,6-dihydropyrida-
zin-4-yloxy)piperidine-1-carboxylate was obtained as a white solid
MS (ESI) 434 (M+H-tBu).
Step B. Preparation of
6-(hydroxymethyl)-2-(4-(methylsulfonyl)phenyl)-5-(piperidin-4-yloxy)pyrid-
azin-3(2H)-one, HCl salt To a stirring solution of tert-butyl
4-(3-(hydroxymethyl)-1-(4-(methylsulfonyl)phenyl)-6-oxo-1,6-dihydropyrida-
zin-4-yloxy)piperidine-1-carboxylate (200 mg, 0.417 mmol) in DCM (3
mL) at room temperature under argon was added 4 M HCl in dioxane
(0.521 mL, 2.085 mmol). The reaction mixture was stirred at room
temperature overnight. Et.sub.2O (10 mL) was added to the reaction
mixture. The solid product was collected by filtration and further
washed with ether (2 mL.times.2). After drying under vacuum for 2
hours, 171 mg (100%) of
6-(hydroxymethyl)-2-(4-(methylsulfonyl)phenyl)-5-(piperidin-4-yloxy)pyrid-
azin-3(2H)-one HCl salt was obtained as an off-white solid. MS
(ESI) 380 (M+H).
Step C. Example 50
[0443] To a stirring solution of
6-(hydroxymethyl)-2-(4-(methylsulfonyl)phenyl)-5-(piperidin-4-yloxy)pyrid-
azin-3(2H)-one HCl (18.97 mg, 0.05 mmol) in NMP (2 mL) at room
temperature under argon was added DIPEA (19.4 mg, 0.150 mmol) and
5-chloro-2-iodopyrimidine (24 mg, 0.1.0 mmol). The resulting
reaction mixture was heated at 100.degree. C. under argon
overnight. 15 mL of EtOAc was added to the reaction mixture. The
reaction mixture was washed with water (15 mL), and brine (15 mL).
Organic phase was dried (MgSO.sub.4), filtered and concentrated.
The crude product was dissolved in a small amount of DCM (.about.2
ml) and loaded onto a 24 g ISCO silica gel column which was eluted
with a 20 min gradient from 20% to 100% EtOAc/Hexanes. 16 mg (62%)
of
5-(1-(5-chloropyrimidin-2-yl)piperidin-4-yloxy)-6-(hydroxymethyl)-2-(4-(m-
ethylsulfonyl)phenyl)pyridazin-3(2H)-one was obtained as a tan
solid. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. ppm 1.73-1.95 (m,
2H) 1.98-2.22 (m, 2H) 2.58 (s, 1H) 2.96-3.16 (m, 3H) 3.61-3.83 (m,
2H) 3.96-4.17 (m, 2H) 4.48-4.82 (m, 3H) 6.30 (s, 1H) 7.88 (d,
J=8.79 Hz, 2H) 8.04 (d, J=8.35 Hz, 2H) 8.24 (s, 2H). MS (ESI) 492
(M+H).
Example 51
6-(Hydroxymethyl)-5-(1-(5-iodopyrimidin-2-yl)piperidin-4-yloxy)-2-(4-(meth-
ylsulfonyl)phenyl)pyridazin-3(2H)-one
##STR00072##
[0445] Example 51 was prepared in 73% yield according to procedures
described in Example 50 (Step C) substituting
5-chloro-2-iodopyrimidine for 2-chloro-5-iodopyrimidine. .sup.1H
NMR (400 MHz, CDCl.sub.3) .delta. ppm 1.73-1.93 (m, 2H) 1.98-2.21
(m, 2H) 2.58 (s, 1H) 3.07 (s, 3H) 3.61-3.83 (m, 2H) 3.91-4.21 (m,
2H) 4.47-4.93 (m, 3H) 6.30 (s, 1H) 7.88 (d, J=8.79 Hz, 2H) 8.04 (d,
J=8.79 Hz, 2H) 8.40 (s, 2H). MS (ESI) 584 (M+H).
Example 52
4-(1-(5-Cyanopyrimidin-2-yl)piperidin-4-yloxy)-1-(4-(methylsulfonyl)phenyl-
)-6-oxo-1,6-dihydropyridazine-3-carbonitrile
##STR00073##
[0446] Step A. Preparation of 2-chloropyrimidine-5-carbonitrile
[0447] To a stirring solution of 2-aminopyrimidine-5-carbonitrile
(1.0 g, 8.33 mmol) in CH.sub.3CN (15 ml) at room temperature under
argon was added copper (II) chloride (1.679 g, 12.5 mmol) and
tert-butyl nitrite (1.288 g, 12.5 mmol). The reaction mixture was
placed in a preheated oil bath (60.degree. C.) under Argon. The
reaction mixture was cooled to room temperature and 20 ml of ether
was added. The resulting insoluble material was filtered and the
filtrate was concentrated. The crude product was dissolved in a
small amount of DCM (.about.2 ml) and loaded onto a 40 g ISCO
silica gel column which was eluted with a 20 min gradient from 0%
to 100% EtOAc/Hexanes. 723 mg (61%) of
2-chloropyrimidine-5-carbonitrile was obtained as a tan solid.
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. ppm 8.90 (s, 2H).
Step B. Example 52
[0448] Example 52 was prepared in 60% yield according to procedures
described in Example 32 (Step B) substituting
5-chloro-2-iodopyrimidine for 2-chloropyrimidine-5-carbonitrile.
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. ppm 1.89-2.20 (m, 4H)
3.09 (s, 3H) 4.00-4.10 (m, 2H) 4.10-4.20 (m, 2H) 4.71-5.07 (m, 1H)
6.34 (s, 1H) 7.84 (d, J=8.79 Hz, 2H) 8.08 (d, J=8.79 Hz, 2H) 8.52
(s, 2H). MS (ESI) 478 (M+H).
Example 53
1-(4-Bromo-3-fluorophenyl)-4-(1-(5-chloropyrimidin-2-yl)piperidin-4-yloxy)-
-6-oxo-1,6-dihydropyridazine-3-carbonitrile
##STR00074##
[0449] Step A. Preparation of
1-(4-bromo-3-fluorophenyl)-6-oxo-4-(piperidin-4-yloxy)-1,6-dihydropyridaz-
ine-3-carbonitrile, HCl salt
[0450] To a stirring solution of tert-butyl
4-(1-(4-bromo-3-fluorophenyl)-3-cyano-6-oxo-1,6-dihydropyridazin-4-yloxy)-
piperidine-1-carboxylate (493 mg, 1.0 mmol) in DCM (5 mL) at room
temperature under argon was added 4 M HCl in dioxane (1.25 mL, 5.0
mmol). The reaction mixture was stirred at room temperature
overnight. Et.sub.2O (10 mL) was added to the reaction mixture. The
solid product was collected by filtration and further washed with
ether (2 mL.times.2). After drying under vacuum for 2 hours, 411 mg
(100%) of
1-(4-bromo-3-fluorophenyl)-6-oxo-4-(piperidin-4-yloxy)-1,6-dihydropyridaz-
ine-3-carbonitrile HCl salt was obtained as an off-white solid. MS
(ESI) 393 (M+H).
Step B. Example 53
[0451] Example 53 was prepared in 87% yield according to procedures
described in Example 47 (Step B) substituting
1-(4-(methylsulfonyl)phenyl)-6-oxo-4-(piperidin-4-yloxy)-1,6-dihydropyrid-
azine-3-carbonitrile HCl for
1-(4-bromo-3-fluorophenyl)-6-oxo-4-(piperidin-4-yloxy)-1,6-dihydropyridaz-
ine-3-carbonitrile HCl salt. .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. ppm 1.85-2.01 (m, 2H) 2.00-2.13 (m, 2H) 3.48 (s, 1H)
3.72-3.94 (m, 2H) 3.96-4.21 (m, 2H) 4.48-4.94 (m, 1H) 6.31 (s, 1H)
7.32 (d, J=8.79 Hz, 1H) 7.45 (dd, J=9.01, 2.42 Hz, 1H) 7.62-7.80
(m, 1H) 8.24 (s, 2H). MS (ESI) 507 (M+H).
Example 54
1-(4-Bromo-2-fluorophenyl)-4-(1-(5-chloropyrimidin-2-yl)piperidin-4-yloxy)-
-6-oxo-1,6-(dihydropyridazine-3-carbonitrile
##STR00075##
[0452] Step A. Preparation of
1-(4-bromo-2-fluorophenyl)-6-oxo-4-(piperidin-4-yloxy)-1,6-dihydropyridaz-
ine-3-carbonitrile, HCl salt
[0453] To a stirring solution of tert-butyl
4-(1-(4-bromo-2-fluorophenyl)-3-cyano-6-oxo-1,6-dihydropyridazin-4-yloxy)-
piperidine-1-carboxylate (493 mg, 1.0 mmol) in DCM (5 mL) at room
temperature under argon was added 4 M HCl in dioxane (1.25 mL, 5.0
mmol). The reaction mixture was stirred at room temperature
overnight. Et.sub.2O (10 mL) was added to the reaction mixture. The
solid product was collected by filtration and further washed with
ether (2 mL.times.2). After drying under vacuum for 2 hours, 334 mg
(85%) of
1-(4-bromo-2-fluorophenyl)-6-oxo-4-(piperidin-4-yloxy)-1,6-dihydropyridaz-
ine-3-carbonitrile HCl salt was obtained as an off-white solid. MS
(ESI) 393 (M+H).
Step B. Example 54
[0454] Example 54 was prepared in 91% yield according to procedures
described in Example 47 (Step B) substituting
1-(4-(methylsulfonyl)phenyl)-6-oxo-4-(piperidin-4-yloxy)-1,6-dihydropyrid-
azine-3-carbonitrile HCl for
1-(4-bromo-2-fluorophenyl)-6-oxo-4-(piperidin-4-yloxy)-1,6-dihydropyridaz-
ine-3-carbonitrile HCl salt. .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. ppm 1.79-2.20 (m, 4H) 3.72-3.95 (m, 2H) 3.95-4.20 (m, 2H)
4.48-4.90 (m, 1H) 6.31 (s, 1H) 7.26-7.31 (m, 1H) 7.44 (d, J=9.23
Hz, 2H) 8.24 (s, 2H). MS (ESI) 507 (M+H).
Example 55
tert-Butyl
4-(1-(4-cyano-3-fluorophenyl)-3-(hydroxymethyl)-6-oxo-1,6-dihyd-
ropyridazin-4-yloxy)piperidine-1-carboxylate
##STR00076##
[0456] To a stirring solution of methyl
4-(1-(tert-butoxycarbonyl)piperidin-4-yloxy)-1-(4-cyano-3-fluorophenyl)-6-
-oxo-1,6-dihydropyridazine-3-carboxylate (27.2 mg, 0.1 mmol) in
THF/MeOH (1:1) (3 mL) at room temperature under argon was added
NaBH.sub.4 (18.9 mg, 0.5 mmol) at 0.degree. C. in an ice bath under
argon carefully. The reaction mixture was allowed to warm to room
temperature gradually and stirred overnight. EtOAc (20 mL) and
water (20 mL) were added to the reaction mixture. Layers were
separated. Organic layer were washed with water (15 mL), and brine
(15 mL). Organic phase was dried (MgSO.sub.4), filtered and
concentrated. The crude product was dissolved in a small amount of
DCM (.about.2 ml) and loaded onto a 40 g ISCO silica gel column
which was eluted with a 20 min gradient from 20% to 100%
EtOAc/Hexanes. 37 mg (82%) of tert-butyl
4-(1-(4-cyano-3-fluorophenyl)-3-(hydroxymethyl)-6-oxo-1,6-dihydropyridazi-
n-4-yloxy)piperidine-1-carboxylate was obtained as a white solid.
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. ppm 1.39-1.53 (m, 9H)
1.68-1.88 (m, 2H) 1.88-2.09 (m, 2H) 2.51 (t, J=5.93 Hz, 1H)
3.20-3.49 (m, 2H) 3.54-3.76 (m, 2H) 4.43-4.63 (m, 1H) 4.69 (d,
J=5.71 Hz, 2H) 6.23 (s, 1H) 7.53-7.85 (m, 3H). MS (ESI) 389
(M+H-tBu).
Example 56
tert-Butyl
4-(3-cyano-1-(4-nitrophenyl)-6-oxo-1,6-dihydropyridazin-4-yloxy-
)piperidine-1-carboxylate
##STR00077##
[0457] Step A. Preparation of 4-nitrobenzenediazonium
[0458] 4-Nitrobenzenediazonium was prepared in 100% yield according
to procedures described in Example 18 (Step A) substituting
4-(methylsulfonyl) aniline for 4-nitroaniline. The reaction mixture
was used directly to next step.
Step B. Preparation of (E)-dimethyl
2-(2-(4-nitrophenyl)hydrazono)-3-oxopentanedioate
[0459] (E)-Dimethyl
2-(2-(4-nitrophenyl)hydrazono)-3-oxopentanedioate was prepared in
94% yield according to procedures described in Example 18 (Step B)
substituting 4-(methylsulfonyl)benzenediazonium for
4-Nitrobenzenediazonium. MS (ESI) 324 (M+H).
Step C. Preparation of methyl
4-hydroxy-1-(4-nitrophenyl)-6-oxo-1,6-dihydropyridazine-3-carboxylate
[0460] Methyl
4-hydroxy-1-(4-nitrophenyl)-6-oxo-1,6-dihydropyridazine-3-carboxylate
was prepared in 48% yield according to procedures described in
Example 18 (Step C) substituting (E)-dimethyl
2-(2-(4-(methylsulfonyl)phenyl)hydrazono)-3-oxopentanedioate for
(E)-Dimethyl 2-(2-(4-nitrophenyl)hydrazono)-3-oxopentanedioate. MS
(ESI) 292 (M+H).
Step D. Preparation of methyl
4-(1-(tert-butoxycarbonyl)piperidin-4-yloxy)-1-(4-nitrophenyl)-6-oxo-1,6--
dihydropyridazine-3-carboxylate
[0461] Methyl
4-(1-(tert-butoxycarbonyl)piperidin-4-yloxy)-1-(4-nitrophenyl)-6-oxo-1,6--
dihydropyridazine-3-carboxylate was prepared in 67% yield according
to procedures described in Example 14 substituting methyl
1-(3,4-dichlorophenyl)-4-hydroxy-6-oxo-1,6-dihydropyridazine-3-carboxylat-
e for Methyl
4-hydroxy-1-(4-nitrophenyl)-6-oxo-1,6-dihydropyridazine-3-carboxylate
with MS (4A) in the reaction mixture. .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. ppm 1.39-1.52 (m, 9H) 1.75-2.21 (m, 4H) 3.55
(d, J=3.30 Hz, 4H) 3.94 (s, 3H) 4.38-4.94 (m, 1H) 6.28 (s, 1H) 7.88
(d, J=8.79 Hz, 2H) 8.32 (d, J=8.79 Hz, 2H). MS (ESI) 419
(M+H-tBu).
Step E. Preparation of tert-butyl
4-(3-carbamoyl-1-(4-nitrophenyl)-6-oxo-1,6-dihydropyridazin-4-yloxy)piper-
idine-1-carboxylate
[0462] tert-Butyl
4-(3-carbamoyl-1-(4-nitrophenyl)-6-oxo-1,6-dihydropyridazin-4-yloxy)piper-
idine-1-carboxylate was prepared in 100% yield according to
procedures described in Example 31 (Step A) substituting methyl
4-(1-(tert-butoxycarbonyl)piperidin-4-yloxy)-1-(4-(methylsulfonyl)phenyl)-
-6-oxo-1,6-dihydropyridazine-3-carboxylate for Methyl
4-(1-(tert-butoxycarbonyl)piperidin-4-yloxy)-1-(4-nitrophenyl)-6-oxo-1,6--
dihydropyridazine-3-carboxylate. MS (ESI) 404 (M+H).
Step F. Example 56
[0463] Example 56 was prepared in 93% yield according to procedures
described in Example 31 (Step B) substituting tert-butyl
4-(3-carbamoyl-1-(4-(methylsulfonyl)phenyl)-6-oxo-1,6-dihydropyridazin-4--
yloxy)piperidine-1-carboxylate for tert-Butyl
4-(3-carbamoyl-1-(4-nitrophenyl)-6-oxo-1,6-dihydropyridazin-4-yloxy)piper-
idine-1-carboxylate. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. ppm
1.44-1.50 (m, 9H) 1.76-1.94 (m, 2H) 1.94-2.18 (m, 2H) 3.28-3.55 (m,
2H) 3.58-3.95 (m, 2H) 4.36-4.89 (m, 1H) 6.29 (s, 1H) 7.84 (d,
J=9.34 Hz, 2H) 8.35 (d, J=8.79 Hz, 2H). MS (ESI) 386 (M+H-tBu).
Example 57
4-(1-(5-(Difluoromethoxy)pyrimidin-2-yl)piperidin-4-yloxy)-1-(4-(methylsul-
fonyl)phenyl)-6-oxo-1,6-dihydropyridazine-3-carbonitrile
##STR00078##
[0464] Step A. Preparation of 2-(methylthio)-5-(4,
4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine
[0465] To a stirring solution of 5-bromo-2-(methylthio)pyrimidine
(950 mg, 4.63 mmol) in DMF (5 mL) at room temperature under argon
was added
4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (1.77
g, 6.95 mmol), potassium acetate (1.36 g, 13.90 mmol), and
diacetoxypalladium (104 mg, 0.463 mol). The resulting suspension
was degassed with argon for 15 min and heated at 85.degree. C.
overnight. The reaction was cooled to room temperature. EtOAc (10
mL) was added to the reaction mixture, which was washed with brine
(15 mL.times.3). Organic phase was dried (MgSO.sub.4), filtered and
concentrated. The crude product was used directly to next step.
Step B. Preparation of 2-(methylthio)pyrimidin-5-ol
[0466] To a stirring solution of 2-(methylthio)-5-(4,
4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine (from step A)
(1.167 g, 4.63 mmol) in THF/H.sub.2O (20 mL 1:1) at room
temperature under argon was added sodium perborate tetrahydrate
(2.137 g, 13.9 mmol). The reaction mixture was stirred at room
temperature overnight. The reaction was cooled to room temperature.
EtOAc (10 mL) was added to the reaction mixture, which was washed
with brine (15 mL.times.3). Organic phase was dried (MgSO.sub.4),
filtered and concentrated. The crude product was very insoluble,
therefore it was used directly to next step. MS (ESI) 143
(M+H).
Step C. Preparation of
5-(difluoromethoxy)-2-(methylthio)pyrimidine
[0467] To a stirring solution of 2-(methylthio)pyrimidin-5-ol (from
step B) (71 mg, 0.50 mmol) in CH.sub.3CN (2.5 mL) and water (2.5
mL) at room temperature under argon was added K.sub.2CO.sub.3 (0.69
g, 5.0 mmol) and followed by 2-chloro-2,2-difluoro-1-phenylethanone
(286 mg, 1.5 mmol). The reaction tube was sealed and heated at
80.degree. C. for 5 hours. The reaction was cooled to room
temperature. EtOAc (10 mL) was added to the reaction mixture, which
was washed with brine (15 mL.times.3). Organic phase was dried
(MgSO.sub.4), filtered and concentrated. The crude product was
dissolved in a small amount of DCM (.about.2 ml) and loaded onto a
40 g ISCO silica gel column which was eluted with a 20 min gradient
from 0% to 100% EtOAc/Hexanes. 23 mg (23% for three steps) of
5-(difluoromethoxy)-2-(methylthio) pyrimidine was obtained as an
off white solid. MS (ESI) 193 (M+H).
Step D. Preparation of
5-(difluoromethoxy)-2-(methylsulfonyl)pyrimidine
[0468] To a stirring solution of 5-(difluoromethoxy)-2-(methylthio)
pyrimidine (19 mg, 0.10 mmol) in DCM (3 mL) at room temperature
under argon was added MCPBA (74 mg, 0.30 mmol). The reaction
mixture was stirred at room temperature for 1 hour. Solvent was
removed in vacuo under reduced pressure and crude product was used
directly to next step. MS (ESI) 225 (M+H).
Step E. Example 57
[0469] To a stirring solution of
1-(4-(methylsulfonyl)phenyl)-6-oxo-4-(piperidin-4-yloxy)-1,6-dihydropyrid-
azine-3-carbonitrile HCl (example 47 step A) (41 mg, 0.10 mmol) in
NMP (3 mL) at room temperature under argon was added DIPEA (38.8
mg, 0.30 mmol) and 5-(difluoromethoxy)-2-(methylsulfonyl)pyrimidine
(22.4 mg, 0.1.0 mmol). The resulting reaction mixture was heated at
100.degree. C. under argon overnight. After cooling to room
temperature, 15 mL of EtOAc was added to the reaction mixture. The
reaction mixture was washed with water (15 mL), and brine (15 mL).
Organic phase was dried (MgSO.sub.4), filtered and concentrated.
The crude product was dissolved in a small amount of DCM (.about.3
ml) and loaded onto a 24 g ISCO silica gel column which was eluted
with a 20 min gradient from 20% to 100% EtOAc/Hexanes. 8 mg (15%
for two steps) of
4-(1-(5-(difluoromethoxy)pyrimidin-2-yl)piperidin-4-yloxy)-1-(4-(methylsu-
lfonyl)phenyl)-6-oxo-1,6-dihydropyridazine-3-carbonitrile was
obtained as a tan solid .sup.1H NMR (400 MHz, CDCl.sub.3) .delta.
ppm 1.75-2.27 (m, 4H) 3.08 (s, 3H) 3.66-3.97 (m, 2H) 3.97-4.24 (m,
2H) 4.54-4.95 (m, 1H) 6.34 (s, 1H) 7.84 (d, J=8.79 Hz, 2H) 8.07 (d,
J=8.79 Hz, 2H) 8.24 (s, 2H). MS (ESI) 519 (M+H).
Example 58
Isopropyl
4-(3-cyano-1-(4-cyano-3-fluorophenyl)-6-oxo-1,6-dihydropyridazin-
-4-yloxy)piperidine-1-carboxylate
##STR00079##
[0471] To a stirring solution of
1-(4-cyano-3-fluorophenyl)-6-oxo-4-(piperidin-4-yloxy)-1,6-dihydropyridaz-
ine-3-carbonitrile HCl salt (Example 36, step A) (19 mg, 0.05 mmol)
in DCM (3 mL) at room temperature under argon was added TEA (0.014
mL, 0.10 mmol) and isopropyl carbonochloridate (12 mg, 0.10 mmol).
The reaction mixture was stirred at room temperature overnight.
Solvent was removed in vacuo and the crude product was dissolved in
a small amount of DCM (.about.2 ml) and loaded onto a 40 g ISCO
silica gel column which was eluted with a 20 min gradient from 0%
to 100% EtOAc/Hexanes. 15 mg (43%) of isopropyl
4-(3-cyano-1-(4-cyano-3-fluorophenyl)-6-oxo-1,6-dihydropyridazin-4-yloxy)-
piperidine-1-carboxylate was obtained as white solid. .sup.1H NMR
(400 MHz, CDCl.sub.3) .delta. ppm 7.72-7.81 (1H, m), 7.56-7.72 (2H,
m), 6.30 (1H, s), 4.82-5.04 (1H, m, J=6.6, 6.3, 6.2, 6.2 Hz), 4.65
(1H, ddd, J=7.0, 3.4, 3.3 Hz), 3.65-3.84 (2H, m), 3.37-3.61 (2H,
m), 1.96-2.12 (2H, m), 1.81-1.96 (2H, m), 1.13-1.33 (6H, m). MS
(ESI) 426 (M+H).
Example 59
Isopropyl
4-(3-cyano-1-(4-(methylsulfonyl)phenyl)-6-oxo-1,6-dihydropyridaz-
in-4-yloxy)piperidine-1-carboxylate
##STR00080##
[0473] Example 59 was prepared in 47% yield according to procedures
described in Example 50 (Step C) substituting
1-(4-cyano-3-fluorophenyl)-6-oxo-4-(piperidin-4-yloxy)-1,6-dihydropyridaz-
ine-3-carbonitrile HCl salt for
1-(4-(methylsulfonyl)phenyl)-6-oxo-4-(piperidin-4-yloxy)-1,6-dihydropyrid-
azine-3-carbonitrile HCl (example 47 step A). .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. ppm 8.09 (2H, d, J=8.8 Hz), 7.85 (2H, d, J=8.8
Hz), 6.32 (1H, s), 4.96 (1H, t, J=6.3 Hz), 4.49-4.78 (1H, m),
3.60-3.93 (2H, m), 3.40-3.64 (2H, m), 3.10 (3H, s), 1.77-2.12 (4H,
m), 1.28 (6H, d, J=6.0 Hz). MS (ESI) 461 (M+H).
Example 60
Preparation of trans-tert-butyl
4-(5-chloro-1-(4-cyano-3-fluorophenyl)-2-oxo-1,2-dihydropyridin-4-yloxy)--
3-methylpiperidine-1-carboxylate
##STR00081##
[0474] Step A. Preparation of
4-(5-chloro-4-hydroxy-2-oxopyridin-1(2H)-yl)-2-fluorobenzonitrile
[0475] A mixture of 2-fluoro-4-iodobenzonitrile (4000 mg, 16.19
mmol), 5-chloro-4-hydroxypyridin-2(1H)-one (2357 mg, 16.19 mmol),
4,7-dimethoxy-1,10-phenanthroline (778 mg, 3.24 mmol), copper(I)
iodide (617 mg, 3.24 mmol) and potassium carbonate (4476 mg, 32.4
mmol) in DMSO (40 mL) was stirred at 140.degree. C. under N.sub.2
for 3 hrs. After cooling to room temperature, the reaction mixture
was diluted with H.sub.2O (50 mL) and 1N HCl was added to adjust
the pH to .about.2 (pH paper). The resulting mixture was extracted
with EtOAc (400 mL, 2.times.). The combined extracts were dried
(Na.sub.2SO.sub.4) and evaporated under reduced pressure to give
black oil. The residue was purified by flash chromatography on
silica gel (0-7% MeOH/CH.sub.2Cl.sub.2) to give brown oil (3.2 g,
43.3%). MS (ESI) 265 (M+H).
Step B. Example 60
[0476] To a mixture of
4-(5-chloro-4-hydroxy-2-oxopyridin-1(2H)-yl)-2-fluorobenzonitrile
(193 mg, 0.729 mmol), tert-butyl
4-hydroxy-3-methylpiperidine-1-carboxylate (173 mg, 0.802 mmol) and
triphenylphosphine (230 mg, 0.875 mmol) in THF (2.0 mL) was added
DEAD (0.129 mL, 0.875 mmol). The resulting mixture was stirred at
room temperature overnight and then evaporated under reduced
pressure. The residue was purified by flash chromatography on
silica gel (0-100% EtOAc/hexane) to yield trans-tert-butyl
4-(5-chloro-1-(4-cyano-3-fluorophenyl)-2-oxo-1,2-dihydropyridin-4-yloxy)--
3-methylpiperidine-1-carboxylate (183.5 mg, 50.1%) as an orange
solid. .sup.1H NMR (400 MHz, DMSO): 6 ppm 7.99-8.15 (m, 2H), 7.80
(dd, J=10.55, 1.76 Hz, 1H), 7.55 (dd, J=8.35, 1.76 Hz, 1H), 6.21
(s, 1H), 4.67-4.84 (m, 1H), 3.52 (app br s, 2H), 3.18 (app br s,
2H), 1.99 (app br s, 1H), 1.82 (app br s, 1H), 1.62-1.73 (m, 1H),
1.40 (s, 9H), 0.90 (d, J=7.03 Hz, 3H). MS (ESI) 406 (M-56+H).
Example 61
Preparation of cis- and trans-isomers of
4-(5-chloro-4-(1-(5-cyclopropylpyrimidin-2-yl)-3-methylpiperidin-4-yloxy)-
-2-oxopyridin-1(2H)-yl)-2-fluorobenzonitrile
##STR00082##
[0477] Step A. Preparation of
4-(5-chloro-4-(3-methylpiperidin-4-yloxy)-2-oxopyridin-1(2H)-yl)-2-fluoro-
benzonitrile hydrochloride
[0478] To a solution of trans-tert-butyl
4-(5-chloro-1-(4-cyano-3-fluorophenyl)-2-oxo-1,2-dihydropyridin-4-yloxy)--
3-methylpiperidine-1-carboxylate (200 mg, 0.433 mmol) in MeOH (1.0
mL) at room temperature was added hydrochloric acid (2.5 mL, 10.00
mmol, 4.0 M in dioxane). The reaction mixture was stirred for 30
min and then evaporated under reduced pressure. The residue was
co-evaporated with ethanol (2.times.) to give 198 mg of the title
compound as an orange solid. This material was used in the next
step without further purification. MS (ESI) 362 (M+H).
Step B. Example 61
[0479] A mixture of
4-(5-chloro-4-(3-methylpiperidin-4-yloxy)-2-oxopyridin-1(2H)-yl)-2-fluoro-
benzonitrile hydrochloride (159 mg, 0.399 mmol),
2-chloro-5-cyclopropylpyrimidine (67.9 mg, 0.439 mmol) and
potassium carbonate (221 mg, 1.597 mmol) in DMSO (1.5 mL) was
heated at 90-110.degree. C. for 40 hrs and then additional
potassium carbonate (110 mg, 0.788 mmol) was added. The resulting
mixture was continuously heated at 100.degree. C. overnight and
then partitioned between EtOAc and water. The aqueous layer was
extracted further with EtOAc (3.times.). The combined organic
extracts were washed with water and brine, dried (Na.sub.2SO.sub.4)
and evaporated under reduced pressure. The residue was purified by
flash chromatography on silica gel (0-100% EtOAc/hexane) to yield
cis-4-(5-chloro-4-(1-(5-cyclopropylpyrimidin-2-yl)-3-methylpiperidi-
n-4-yloxy)-2-oxopyridin-1(2H)-yl)-2-fluorobenzonitrile (10.2 mg,
5%, top spot on TLC plate) as a light yellow solid and to yield
trans-4-(5-chloro-4-(1-(5-cyclopropylpyrimidin-2-yl)-3-methylpiperidin-4--
yloxy)-2-oxopyridin-1(2H)-yl)-2-fluorobenzonitrile (34.4 mg, 15%,
bottom spot on TLC plate) as a light yellow solid. Cis-isomers:
.sup.1H NMR (500 MHz, CDCl.sub.3) .delta. ppm 8.13 (s, 2H), 7.76
(t, J=7.42 Hz, 1H), 7.36-7.41 (m, 2H), 7.33 (d, J=8.25 Hz, 1H),
6.04 (s, 1H), 4.48-4.62 (m, 2H), 4.16 (td, J=8.80, 3.85 Hz, 1H),
3.19-3.29 (m, 1H), 2.98 (dd, J=13.75, 9.90 Hz, 1H), 2.18-2.30 (m,
1H), 2.01-2.12 (m, 1H), 1.63-1.77 (m, 2H), 1.08 (d, J=6.60 Hz, 3H),
0.89-0.95 (m, 2H), 0.57-0.62 (m, 2H). MS (ESI) 480 (M+H).
Trans-isomers: .sup.1H NMR (500 MHz, CDCl.sub.3) .delta. ppm 8.13
(s, 2 H), 7.76 (t, J=7.42 Hz, 1H), 7.36-7.43 (m, 2H), 7.33 (d,
J=8.25 Hz, 1H), 6.03 (s, 1H), 4.58 (app br s, 1H), 4.29-4.42 (m,
2H), 3.28-3.40 (m, 2H), 2.01-2.17 (m, 2H), 1.77-1.89 (m, 1H),
1.68-1.77 (m, 1H), 0.99-1.12 (m, 3H), 0.85-0.97 (m, 2H), 0.51-0.63
(m, 2H). MS (ESI) 480 (M+H).
Assay(s) for GPR119G Protein-Coupled Receptor Activity
[0480] The in vitro modulation of recombinant human GPR119 was
determined as follows.
HIT-T15 cAMP Assay
[0481] A HIT-T15 hamster insulinoma cell line was purchased from
ATCC and grown in the medium recommended by ATCC (i.e., Growth
Medium: F12K Medium (Invitrogen 21127-022; 10% D-horse Serum; and
2.5% FBS).
[0482] To conduct the cAMP assay, cells expressing a GPR119
receptor are plated on 96 well plates (e.g., BD Falcon: REF 353948,
black side, clear bottom, TC surface) at a density of about
4.5.times.10.sup.4 cells per well in growth medium and incubated
overnight. Following incubation, the growth medium is removed from
the wells followed by a single rinse with the assay buffer from the
HITHUNTER.RTM. cAMP kit (100 .mu.l/well). Following the rinse, 20
.mu.l of assay buffer is added to each well followed by addition of
10 .mu.l of a 3.times. concentration of compound working solution.
The solution is then mixed well. The final concentration range of
compound is from about 10.sup.-5 M to about 10.sup.-11 M. The
reaction is incubated at 37.degree. C., in a 5% CO.sub.2 for 1
hour. Following incubation, the cAMP concentration is determined
using the HITHUNTER.RTM. cAMP kit according to the manufacturer's
protocol.
Human Tet-Inducible cAMP Assay
[0483] Cell lines expressing GPR119 are generated using the Flp-In
T-REx 293 tetracycline inducible gene expression system are
cultured in culture medium comprising the following components:
DMEM#11965, 10% FBS, 2 mM L-glutamine, 200 ug/ml Hygromycin B, and
15 ug/ml blasticidin.
[0484] For cAMP assays, cells are plated on 96 well plates (e.g.,
BD Falcon: REF 353948, black side, clear bottom, TC surface) at a
density of about 4.5.times.10.sup.4 cells per well in growth medium
containing 1.0 ug/ml tetracycline (1.0 mg/ml stock). The cells are
then incubated for 48 hours at 37.degree. C.
[0485] Following the incubation, the growth medium is removed from
the wells and the wells rinsed (once) with the assay buffer
included in the HITHUNTER.RTM. cAMP kit (100 .mu.l/well). Following
the wash, 20 .mu.l of assay buffer is added to each well, followed
by addition of 10 .mu.l of a 3.times. concentration compound
working solution. The solution is then mixed. The final
concentration range of compound is from about 10.sup.-5M to about
10.sup.-11 M. The reagents are then incubated at 37.degree. C. at
5% CO.sub.2 for 1 hour.
[0486] The manufacturer's protocol may be followed for cAMP
determination. The HITHUNTER.RTM. cAMP kit protocol is outlined for
the HIT-T15 cAMP assays described above.
[0487] Compounds of the present invention were tested in the Human
Tet-inducible cAMP assay described immediately above and the
results shown in Table 1 below were obtained.
TABLE-US-00001 TABLE 1 Example hGPR119 EC.sub.50 (nM) 11 4603 16
3392 18 4010 26 5 31 83 34 3 38 8 42 107 45 95
Luciferase Assay
[0488] HEK 293 cells may be plated on poly-D-lysine treated 96-well
BD black side/clear bottom plates at a density of about
3.times.10.sup.4 cells/well in growth medium. The growth medium may
comprise the following: D-MEM (Cat #12430) with high glucose and
10% fetal bovine serum.
[0489] Cells may be transfected with vectors comprising native or
non-native GPR119 sequences using commercially available vectors
(e.g., Stratagene) and transfection reagents. The standard
manufacturer's protocols may be followed to transfect the cells.
Following transfection, the transfection medium may be removed and
assay medium added to the wells of the assay plates.
[0490] Once the assay plates are prepared, compound dilution plates
may be made. To do so, make a first compound dilution plate using
10 mM of the compound of interest diluted to about 1 mM in DMSO.
Then make 12 point half-log dilutions of the compounds (in DMSO)
using an automated liquid handler. Next, make a second dilution
plate by diluting the wells in the first plate ten fold (10.times.)
using assay medium. Once the plates are complete, the highest dose
is about 10 .mu.M and the lowest dose is about 0.03 nM.
[0491] Once the dilution plates are complete, one can add about 10
.mu.l of the 10.times. compound dilution to the assay plate
containing the assay medium transiently transfected cells. Tap the
plate to mix the reagents and incubate the plate overnight at
37.degree. C., 95% O.sub.2, and 5% CO.sub.2 in an incubator.
[0492] Following incubation, a luciferase assay system may be used
(e.g., STEADY-GLO.RTM. Luciferase Assay System from Promega)
according to the manufacturer's instructions. Following completion
of the reaction, immediately measure the readout of the assay using
a top count luminometer.
Mouse Oral Glucose Tolerance Test
[0493] Twenty four (24) male C57BL/6J mice (8-10 weeks old, average
weight 28 g) were randomized into 4 groups (1 mouse/cage) of 6 mice
per group based on fed plasma glucose and body weight. Prior to
initiating the study, mice were fasted overnight and the next
morning they were weighed and placed in the experimental lab. After
30 min in the environment, the mice were bled via tail tip at -30
min and immediately given their first oral administration of
vehicle (0.5% Methocel, 0.1% Tween 80 in water) or compound
solutions (5 ml/kg). At time 0 the mice were bled and given 50%
glucose (2 g/kg) to initiate the oral glucose tolerance test
(oGTT). The mice were bled 30, 60 and 120 min after the glucose
load. Blood samples were drawn into potassium EDTA, placed on ice
during the study and subsequently centrifuged for 10 min at 3000
rpm at 4.degree. C. Plasma samples were diluted 11-fold for glucose
analysis in the COBAS MIRA.RTM. System (Roche Diagnostics). Area
under the curve was calculated from the plasma glucose time course
data using the trapezoid rule with fasting plasma glucose as the
baseline (GraphPad Prism Software). The statistical significance of
the changes in the glucose AUCs resulting from the different
treatments was determined by one-way ANOVA followed by Dunnett's
test using the vehicle group as the control (JMP software, release
5.1.2).
Utilities and Combinations
A. Utilities
[0494] The compounds of the present invention possess activity as
agonists of the GPR119 receptor, and, therefore, may be used in the
treatment of diseases associated with GPR119 receptor activity. Via
the activation of GPR119 receptor, the compounds of the present
invention may preferably be employed to increase insulin production
or increase GLP-1 secretion or both.
[0495] Accordingly, the compounds of the present invention can be
administered to mammals, preferably humans, for the treatment of a
variety of conditions and disorders, including, but not limited to,
treating, preventing, or slowing the progression of diabetes and
related conditions, microvascular complications associated with
diabetes, macrovascular complications associated with diabetes,
cardiovascular diseases, Metabolic Syndrome and its component
conditions, inflammatory diseases and other maladies. Consequently,
it is believed that the compounds of the present invention may be
used in preventing, inhibiting, or treating diabetes,
hyperglycemia, impaired glucose tolerance, insulin resistance,
hyperinsulinemia, retinopathy, neuropathy, nephropathy, wound
healing, atherosclerosis and its sequelae (acute coronary syndrome,
myocardial infarction, angina pectoris, peripheral vascular
disease, intermittent claudication, myocardial ischemia, stroke,
heart failure), Metabolic Syndrome, hypertension, obesity,
dyslipidemia, hyperlipidemia, hypertriglyceridemia,
hypercholesterolemia, low HDL, high LDL, vascular restenosis,
peripheral arterial disease, lipid disorders, bone disease
(including osteoporosis), PCOS, HIV protease associated
lipodystrophy, glaucoma and inflammatory diseases, such as,
psoriasis, rheumatoid arthritis and osteoarthritis, and treatment
of side-effects related to diabetes, lipodystrophy and osteoporosis
from corticosteroid treatment.
[0496] Metabolic Syndrome or "Syndrome X" is described in Ford et
al., J. Am. Med. Assoc., 287:356-359 (2002) and Arbeeny et al.,
Curr. Med. Chem.-Imm., Endoc. & Metab. Agents, 1:1-24
(2001).
B. Combinations
[0497] The present invention includes within its scope
pharmaceutical compositions comprising, as an active ingredient, a
therapeutically effective amount of at least one of the compounds
of Formula I, alone or in combination with a pharmaceutical carrier
or diluent. Optionally, compounds of the present invention can be
used alone, in combination with other compounds of the invention,
or in combination with one or more other therapeutic agent(s),
e.g., an antidiabetic agent or other pharmaceutically active
material.
[0498] The compounds of the present invention may be employed in
combination with other GPR119 receptor agonists or one or more
other suitable therapeutic agents useful in the treatment of the
aforementioned disorders including: anti-diabetic agents,
anti-hyperglycemic agents, anti-hyperinsulinemic agents,
anti-retinopathic agents, anti-neuropathic agents,
anti-nephropathic agents, anti-atherosclerotic agents,
anti-ischemic agents, anti-hypertensive agents, anti-obesity
agents, anti-dyslipidemic agents, anti-dyslipidemic agents,
anti-hyperlipidemic agents, anti-hypertriglyceridemic agents,
anti-hypercholesterolemic agents, anti-restenotic agents,
anti-pancreatic agents, lipid lowering agents, appetite
suppressants, treatments for heart failure, treatments for
peripheral arterial disease and anti-inflammatory agents.
[0499] Examples of suitable anti-diabetic agents for use in
combination with the compounds of the present invention include
insulin and insulin analogs (e.g., LysPro insulin, inhaled
formulations comprising insulin); glucagon-like peptides;
sulfonylureas and analogs (e.g., chlorpropamide, glibenclamide,
tolbutamide, tolazamide, acetohexamide, glypizide, glyburide,
glimepiride, repaglinide, meglitinide); biguanides (e.g.,
metformin, phenformin, buformin); alpha2-antagonists and
imidazolines (e.g., midaglizole, isaglidole, deriglidole, idazoxan,
efaroxan, fluparoxan); other insulin secretagogues (e.g.,
linogliride, insulinotropin,
exendin-4,N,N-dimethyl-N'-[2-(4-morpholinyl)phenyl]guanidine
(E)-2-butenedioate salt (BTS-675820),
(-)-N-(trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine
(A-4166)); thiazolidinediones and PPAR-gamma agonists (e.g.,
ciglitazone, pioglitazone, troglitazone, rosiglitazone); PPAR-alpha
agonists e.g., fenofibrate, gemfibrozil); PPAR alpha/gamma dual
agonists (e.g., muraglitazar, peliglitazar); SGLT2 inhibitors
(e.g.,
3-(benzo[b]furan-5-yl)-2',6'-dihydroxy-4'-methylpropiophenone-2'-O-(6-O-m-
ethoxycarbonyl)-.beta.-d-glucopyranoside (T-1095 Tanabe Seiyaku),
phlorizin, TS-033 (Taisho), dapagliflozin (BMS), sergiflozin
(Kissei), AVE 2268 (Sanofi-Aventis)); 11-beta-hydroxysteriod
dehydrogenase type I inhibitors (e.g., AMG221, INCB13739);
dipeptidyl peptidase-IV (DPP4) inhibitors (e.g., saxagliptin,
sitagliptin, vildagliptin, and denagliptin); glucagon-like
peptide-1 (GLP-1) receptor agonists (e.g., Exenatide (Byetta),
NN2211 (Liraglutide, Novo Nordisk), AVE0010 (Sanofi-Aventis), R1583
(Roche/Ipsen), SUN E7001 (Daiichi/Santory), GSK-716155 (GSK/Human
Genome Sciences) and Exendin-4 (PC-DACTM); aldose reductase
inhibitors (e.g., those disclosed in WO 99/26659); RXR agonists
(e.g., reglitazar (JTT-501),
5-[[6-[(2-fluorophenyl)methoxy]-2-naphthalenyl]methyl]-2,4-thiazolidinedi-
one (MCC-555),
5-[[3-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)-4-(triflu-
oromethoxy)-phenyl]methylene]-2,4-thiazolidinedione (MX-6054),
DRF2593, farglitazar,
(.+-.)-5-[(2,4-dioxothiazolidin-5-yl)methyl]-2-methoxy-N-[[(4-trifluorome-
thyl)phenyl]-methyl]benzamide (KRP-297),
6-[1-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)cyclopropyl-
]-3-pyridinecarboxylic acid (LG100268)); fatty acid oxidation
inhibitors (e.g., clomoxir, etomoxir; .alpha.-glucosidase
inhibitors: precose, acarbose, miglitol, emiglitate, voglibose,
2,6-dideoxy-2,6-imino-7-O-.beta.-D-glucopyranosyl-D-glycero-L-gulo-heptit-
ol (MDL-25,637), camiglibose); beta-agonists (e.g., methyl
ester[4-[(2R)-2-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]phe-
noxy]-acetic acid (BRL 35135),
2-[4-[(2S)-2-[[(2S)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]phenox-
y]-acetic acid (BRL 37344),
4-[(3R)-3-[bis[(2R)-2-hydroxy-2-phenylethyl]amino]butyl]-benzamide
(Ro 16-8714),
2-[4-[2-[[(2S)-2-hydroxy-3-phenoxypropyl]amino]ethoxy]phenoxy]--
N-(2-methoxyethyl)-acetamide (ICI D7114),
5-[(2R)-2-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]-3-benzod-
ioxole-2,2-dicarboxylic acid, disodium salt (CL 316,243), TAK-667,
AZ40140); phosphodiesterase inhibitors, both cAMP and cGMP type
(e.g., sildenafil,
9-((1S,2R)-2-fluoro-1-methylpropyl)-2-methoxy-6-(1-piperazinyl)purine
hydrochloride (L-686398), L-386,398); amylin agonists (e.g.,
pramlintide); lipoxygenase inhibitors (e.g., masoprocal);
somatostatin analogs (e.g., lanreotide, seglitide, octreotide);
glucagon antagonists (e.g., BAY 276-9955); insulin signaling
agonists, insulin mimetics, PTP1B inhibitors (e.g.,
2-[2-(1,1-dimethyl-2-propenyl)-1H-indol-3-yl]-3,6-dihydroxy-5-[7-(3-methy-
l-2-butenyl)-1H-indol-3-yl]-2,5-cyclohexadiene-1,4-dione
(L-783281), TER17411, TER17529); gluconeogenesis inhibitors (e.g.,
GP3034); somatostatin analogs and antagonists; antilipolytic agents
(e.g., nicotinic acid, acipimox, N-cyclohexyl-2'-O-methyl-adenosine
(WAG 994)); glucose transport stimulating agents (e.g.,
4-chloro-a-[(4-methylphenyl)sulfonyl]-benzeneheptanoic acid
(BM-130795)); glucose synthase kinase inhibitors (e.g., lithium
chloride, CT98014, CT98023); galanin receptor agonists; Chemokine
receptor antagonist CCR2/5 (e.g., NCB3284, MK-0812, INCB8696,
maraviroc (Pfizer) and vicriviroc); thyroid receptor agonists
(e.g., KB-2115 (KaroBio)); glucokinase activators (e.g.,
RO-27-4375, RO-28-1675 (Roche),
6-[[3-[(1S)-2-methoxy-1-methylethoxy]-5-[(1S)-1-methyl-2-phenylethoxy]ben-
zoyl]amino]-3-pyridinecarboxylic acid (GKA-50 AstraZeneca)); GPR119
agonists (e.g., 1,1-dimethylethyl ester
4-[[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]methoxy]-1-piperidinecarboxylic
acid (PSN-632408 OSI Prosidion)); GDIR agonists (e.g., APD668
(Arena)); GPR40 modulators(e.g.,
(S)-4-(dimethylamino)-3-(4-((4-methyl-2-p-tolylthiazol-5-yl)methoxy)pheny-
l)-4-oxobutanoic acid,
6-chloro-2-(4-chlorobenzylthio)-1-(4-(methoxymethoxy)phenyl)-1H-benzo[d]i-
midazole).
[0500] Examples of suitable lipid lowering agents and
anti-atherosclerotic agents for use in combination with the
compounds of the present invention include one or more MTP/ApoB
secretion inhibitors (e.g., dirlopatide,
N-(2,2,2-trifluoroethyl)-9-[4-[4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-
-yl]carbonyl-]amino]-1-piperidinyl]butyl]-9H-fluorene-9-carboxamide,
methanesulfonate, CP-741952 (Pfizer), SLx-4090 (Surface Logix));
HMG CoA reductase inhibitors (e.g., atorvastatin, rosuvastatin,
simvastatin, pravastatin, lovastatin, fluvastatin); squalene
synthetase inhibitors, PPAR alpha agonists and fibric acid
derivatives (e.g., fenofibrate, gemfibrozil); ACAT inhibitors;
lipoxygenase inhibitors; cholesterol absorption inhibitors (e.g.,
ezetimibe); thyroid receptor agonists (e.g., as set forth above);
Ileal Na+/bile acid cotransporter inhibitors (e.g., compounds as
disclosed in Drugs of the Future, 24:425-430 (1999); upregulators
of LDL receptor activity (e.g.,
(3R)-3-[(13R)-.beta.-hydroxy-10-oxotetradecyl]-5,7-dimethoxy-1(3H)-isoben-
zofuranone (Taisho Pharmaceutical Co. Ltd.) and
(3.alpha.,4.alpha.,5.alpha.)-4-(2-propenyl)-cholestan-3-ol (Eli
Lilly); bile acid sequestrants (e.g., WELCHOL.RTM., COLESTID.RTM.,
LoCholest and QUESTRAN.RTM.; and fibric acid derivatives, such as
Atromid, LOPID.RTM. and Tricot); cholesterol ester transfer protein
inhibitors (e.g., torcetrapib and
(2R)-3-{[3-(4-chloro-3-ethyl-phenoxy)-phenyl]-[[3-(1,1,2,2-tetrafluoroeth-
oxy)phenyl]methyl]amino}-1,1,1-trifluoro-2-propanol); nicotinic
acid and derivatives thereof (e.g., niacin, acipimox); PCSK9
inhibitors; LXR agonists (e.g., those disclosed in U.S. Patent
Application Publication Nos. 2003/01814206, 2005/0080111, and
2005/0245515); lipoxygenase inhibitors (e.g., such as benzimidazole
derivatives, as disclosed in WO 97/12615, 15-LO inhibitors, as
disclosed in WO 97/12613, isothiazolones, as disclosed in WO
96/38144, and 15-LO inhibitors, as disclosed by Sendobry et al.,
"Attenuation of diet-induced atherosclerosis in rabbits with a
highly selective 15-lipoxygenase inhibitor lacking significant
antioxidant properties", Brit. J. Pharmacology, 120:1199-1206
(1997), and Cornicelli et al., "15-Lipoxygenase and its Inhibition:
A Novel Therapeutic Target for Vascular Disease", Current
Pharmaceutical Design, 5:11-20 (1999)).
[0501] Preferred hypolipidemic agents are pravastatin, lovastatin,
simvastatin, atorvastatin, fluvastatin, cerivastatin, atavastatin,
and rosuvastatin.
[0502] Examples of suitable anti-hypertensive agents for use in
combination with the compounds of the present invention include
beta adrenergic blockers, calcium channel blockers (L-type and
T-type; e.g., diltiazem, verapamil, nifedipine, amlodipine and
mybefradil), diuretics (e.g., chlorothiazide, hydrochlorothiazide,
flumethiazide, hydroflumethiazide, bendroflumethiazide,
methylchlorothiazide, trichloromethiazide, polythiazide,
benzthiazide, ethacrynic acid tricrynafen, chlorthalidone,
furosemide, musolimine, bumetanide, triamtrenene, amiloride,
spironolactone), renin inhibitors (e.g., aliskiren), ACE inhibitors
(e.g., captopril, zofenopril, fosinopril, enalapril, ceranopril,
cilazopril, delapril, pentopril, quinapril, ramipril, lisinopril),
AT-1 receptor antagonists (e.g., losartan, irbesartan, valsartan),
ET receptor antagonists (e.g., sitaxsentan, atrsentan, and
compounds disclosed in U.S. Pat. Nos. 5,612,359 and 6,043,265),
Dual ET/AII antagonist (e.g., compounds disclosed in WO 00/01389),
neutral endopeptidase (NEP) inhibitors, vasopeptidase inhibitors
(dual NEP-ACE inhibitors) (e.g., omapatrilat and gemopatrilat),
nitrates, central alpha agonists (e.g., clonidine), alpha1 blockers
(e.g., prazosine), arterial vasodilators (e.g., minoxidil),
sympatolytics (e.g., resperine), renin inhibitors (e.g., Aliskiren
(Novartis)).
[0503] Examples of suitable anti-obesity agents for use in
combination with the compounds of the present invention include a
cannabinoid receptor 1 antagonist or inverse agonist (e.g.,
rimonabant,
(45)-3-(4-chlorophenyl)-N-[(4-chlorophenyl)sulfonyl]-4,5-dihydro-N'-methy-
l-4-phenyl-1H-pyrazole-1-carboximidamide (SLV 319), CP-945598
(Pfizer), Surinabant (SR-147778, Sanofi-Aventis),
N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl--
2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (Merck) and
those discussed in Hertzog, D. L., Expert Opin. Ther. Patents,
14:1435-1452 (2004)); a beta 3 adrenergic agonist (e.g., rafabegron
(AJ9677, Takeda/Dainippon),
N-[4-[2-[[(2S)-3-[(6-amino-3-pyridinyl)oxy]-2-hydroxypropyl]amino]ethyl]p-
henyl]-4-(1-methylethyl)-benzenesulfonamide (L750355, Merck), or
CP331648 (Pfizer,) or other known beta .delta. agonists, as
disclosed in U.S. Pat. Nos. 5,541,204, 5,770,615, 5,491,134,
5,776,983, and 5,488,064, with rafabegron,
N-[4-[2-[[(2S)-3-[(6-amino-3-pyridinyl)oxy]-2-hydroxypropyl]amino]ethyl]p-
henyl]-4-(1-methylethyl)-benzenesulfonamide, and CP331648 being
preferred); a lipase inhibitor (e.g., orlistat or cetilistat, with
orlistat being preferred); a serotonin and norepinephrine reuptake
inhibitor (e.g., sibutramine, Abbott and tesofensine, Neurosearch)
with sibutramine being preferred; a dopamine reuptake inhibitor
(e.g., buproprion, GSK); or 5-HT.sub.2C agonist, (e.g., lorcaserin
hydrochloride (Arena), WAY-163909
[(7bR,10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino-
[6,7,1hi]indole], with lorcaserin hydrochloride being preferred);
5-HT6 receptor antagonists (Suven, Biovitrum, Epix),
anti-epileptics topiramate (Johnson & Johnson) and zonisamide,
a ciliary neurotrophic factor agonist (e.g., AXOKINE.RTM.
(Regeneron); brain-derived neurotrophic factor (BDNF), orexin
antagonists, histamine receptor-3 (H3) modulators,
melanin-concentrating hormone receptor (MCHR) antagonists (e.g.,
GSK-856464 (GlaxoSmithKline), T-0910792 (Amgen)); diacylglycerol
acyltransferase (DGAT) inhibitors (e.g., BAY-74-4113 (Bayer));
acetyl-CoA carboxylase (ACC) inhibitors (e.g.,
N-(4-(4-(4-isopropoxyphenoxy)phenyl)but-3-yn-2-yl)acetamide
(A-80040, Abbott),
(R)-anthracen-9-yl(3-(morpholine-4-carbonyl)-1,4'-bipiperidin-1'-
-yl)methanone (CP-640186, Pfizer)), SCD-1 inhibitors as described
by Jiang et al., Diabetes, 53 (2004), (abs 653-p); amylin receptor
agonists (e.g., compounds disclosed in WO 2005/025504); thyroid
receptor agonists (e.g., as set forth above); growth hormone
secretagogue receptor (GHSR) antagonists (e.g., A-778193 (Abbott),
leptin and leptin mimetics (e.g., OB-3 (Aegis/Albany Medical
College), leptin analogs A-100 and A-200 (Amgen), CBT-001452
(Cambridge Biotechnology), ML-22952 (Millennium)), PYY receptor
agonist (e.g., AC-162352 (Amylin), PYY-3-36 (Emishere),
PYY(3-36)NH2 (Unigene)), NPY-Y4 agonists (7.TM. Pharma WO
2005/089786(A2,A3)-1), NPY-5 antagonists (e.g., NPY5RA-972
(AstraZeneca), GW-594884A (GlaxoSmithKline), J-104870 (Banyu));
MTP/apoB secretion inhibitors (as set forth above), and/or an
anorectic agent.
[0504] The anorectic agent which may be optionally employed in
combination with compounds of the present invention include
dexamphetamine, phentermine, phenylpropanolamine, or mazindol, with
dexamphetamine being preferred.
[0505] Other compounds that can be used in combination with the
compounds of the present invention include CCK receptor agonists
(e.g., SR-27895B); galanin receptor antagonists; MCR-4 antagonists
(e.g.,
N-acetyl-L-norleucyl-L-glutaminyl-L-histidyl-D-phenylalanyl-L-arginyl-D-t-
ryptophyl-glycinamide, (HP-228); urocortin mimetics, CRF
antagonists, and CRF binding proteins (e.g., mifepristone (RU-486),
urocortin).
[0506] Further, the compounds of the present invention may be used
in combination with HIV protease inhibitors, including but not
limited to REYATAZ.RTM. and KALETRA.RTM..
[0507] Examples of suitable memory enhancing agents, anti-dementia
agents, or cognition promoting agents for use in combination with
the compounds of the present invention include, but are not limited
to ARICEPT.RTM., razadyne, donepezil, rivastigmine, galantamine,
memantine, tacrine, metrifonate, muscarine, xanomelline, deprenyl
and physostigmine.
[0508] Examples of suitable anti-inflammatory agents for use in
combination with the compounds of the present invention include,
but are not limited to, NSAIDS, prednisone, acetaminophen, aspirin,
codeine, fentanyl, ibuprofen, indomethacin, ketorolac, morphine,
naproxen, phenacetin, piroxicam, sufentanyl, sunlindac, interferon
alpha, prednisolone, methylprednisolone, dexamethazone,
flucatisone, betamethasone, hydrocortisone, beclomethasone,
REMICADE.RTM., ORENCIA.RTM., and ENBREL.RTM..
[0509] The aforementioned patents and patent applications are
incorporated herein by reference.
[0510] The above other therapeutic agents, when employed in
combination with the compounds of the present invention may be
used, for example, in those amounts indicated in the Physicians'
Desk Reference, as in the patents set out above, or as otherwise
determined by one of ordinary skill in the art.
[0511] The compounds of Formula I can be administered for any of
the uses described herein by any suitable means, for example,
orally, such as in the form of tablets, capsules, granules or
powders; sublingually; bucally; parenterally, such as by
subcutaneous, intravenous, intramuscular, or intrasternal
injection, or infusion techniques (e.g., as sterile injectable
aqueous or non-aqueous solutions or suspensions); nasally,
including administration to the nasal membranes, such as by
inhalation spray; topically, such as in the form of a cream or
ointment; or rectally such as in the form of suppositories; in
dosage unit formulations containing non-toxic, pharmaceutically
acceptable vehicles or diluents.
[0512] In carrying out the method of the invention for treating
diabetes and related diseases, a pharmaceutical composition will be
employed containing the compounds of Formula I, with or without
other antidiabetic agent(s) and/or antihyperlipidemic agent(s)
and/or other type therapeutic agents in association with a
pharmaceutical vehicle or diluent. The pharmaceutical composition
can be formulated employing conventional solid or liquid vehicles
or diluents and pharmaceutical additives of a type appropriate to
the mode of desired administration, such as pharmaceutically
acceptable carriers, excipients, binders, and the like. The
compounds can be administered to a mammalian patient, including
humans, monkeys, dogs, etc. by an oral route, for example, in the
form of tablets, capsules, beads, granules or powders. The dose for
adults is preferably between 1 and 2,000 mg per day, which can be
administered in a single dose or in the form of individual doses
from 1-4 times per day.
[0513] A typical capsule for oral administration contains compounds
of Formula I (250 mg), lactose (75 mg), and magnesium stearate (15
mg). The mixture is passed through a 60 mesh sieve and packed into
a No. 1 gelatin capsule.
[0514] A typical injectable preparation is produced by aseptically
placing 250 mg of compounds of Formula I into a vial, aseptically
freeze-drying and sealing. For use, the contents of the vial are
mixed with 2 mL of physiological saline, to produce an injectable
preparation.
* * * * *